[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 1 of 111 Title Page  
Protocol Title:  
Immunogenicity and Safety of SARS- CoV- 2 Recombinant Protein Vaccine Formulations (with or 
without adjuvant) in Healthy Adults 18 Years of Age and Older 
Study Code: VAT00001 
Protocol Version Number:  5.0 
Amendment Number : Amendment 1 
Compound: 
SARS -CoV2 prefusion Spi[INVESTIGATOR_603408] ( CoV2 preS dTM ): antigen Formulation 1 (low -dose 
[5 µg] or Formulation 2 (high-dose [15 µg] ) 
AF03: CoV2 preS dTM-AF03, Squalene-based adjuvant 2.5% 
AS03: CoV2 preS dTM-AS03, Squalene-based adjuvant 2.1% Study Phase: Phase I/II  
Short Title:  
Study of Recombinant Protein Vaccine Formulations against COVID-19 in Healthy Adults 
18 Years of Age and Older 
Sponsor Name [CONTACT_29560]:  
[COMPANY_011] Pasteur Inc. 
Discovery Drive, Swiftwater, PA [ZIP_CODE], [LOCATION_003] 
Manufacturer:   
CoV2 preS dTM and AF03 adjuvant: Same as Sponsor 
AS03 adjuvant: GlaxoSmithKline (Vaccines) 
Regulatory Agency Identifier Numbers:  
BB-IND: [ZIP_CODE] 
WHO UTN: U1111 -1250-4757 
Approval Date :  [ADDRESS_1103052] Information are provided in the Operating Guidelines. 
The study centers, the Investigators at each center, and the Coordinating Investigator(s) are listed 
in a separate document. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 1 of 112[STUDY_ID_REMOVED]
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page [ADDRESS_1103053] version used in the 
study  
 
Overall Rationale for Amendment 1: 
The protocol was amended from v4.[ADDRESS_1103054] 2020 for a  study design change that allows 
participants, if they are eligible, to receive one of the COVID -19 vaccines currently available via 
emergency use authorization. In addition, t he 4-month interim analysis will not be conducted as 
efficacy analysis is moved to the 6-month interim analysis. 
 
Major revisions between Version 4.0 and Version 5.0 
Revision  Rationale  
Table  1.1 and Table  1.2: Collection of concomitant 
medications  
Revised to include participants can receive an 
approved/authorized COVID -[ADDRESS_1103055] received 
emergency use authorization by [CONTACT_799697] 7.1.2:  language added to contraindications 
paragraph regarding subjects who receive an 
approved/authorized COVID -[ADDRESS_1103056] received 
emergency use aut horization by [CONTACT_799697] 9.5: removed the sentence, “Another interim 
analysis will be performed on efficacy data obtained up to 4-month follow up for assessment of early efficacy (Visit 
5 for participants in each cohort )”  Efficacy analysis moved to the 6 -month 
interim analysis; 4- month analysis not 
needed  
 
  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 2 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page [ADDRESS_1103057] of Figures  .................................................................................................................................. 8  
1 Protocol Summary ............................................................................................................. 9  
1.1 Synopsis ............................................................................................................................ 9  
1.2 Schema  ............................................................................................................................ 15  
1.3 Schedule of Activities (SoA) .......................................................................................... 16  
2 Introduction ..................................................................................................................... 28  
2.1 Study Rationale ............................................................................................................... 30  
2.2 Background ..................................................................................................................... 30  
2.3 Benefit/Risk Assessment  ................................................................................................ 30  
2.3.1  Risks from Study Participation ..................................................................................... 32  
2.3.2  Benefits from Study Participation  ................................................................................ 34  
2.3.3  Overall Benefit -Risk Conclusion .................................................................................. 35  
3 Objectives and Endpoints  ............................................................................................... 35  
4 Study Design .................................................................................................................... 37  
4.1 Overall Design  ................................................................................................................ 37  
4.2 Scientific Rationale for Study Design  ............................................................................. 40  
4.3 Justification for Protein Dose Levels  .............................................................................. 44  
4.4 End of Study Definition .................................................................................................. 45  
5 Study Population  ............................................................................................................. 45  
5.1 Inclusion Criteria  ............................................................................................................ 45  
5.2 Exclusion Criteria  ........................................................................................................... 45  
5.3 Lifestyle Considerations  ................................................................................................. 47  
5.4 Screen Failures  ................................................................................................................ 48  
6 Study Intervention  ........................................................................................................... 48  
6.1 Study Interventions Administered  .................................................................................. 48  
6.2 Preparation/Handling/Storage/Accountability  ................................................................ 50  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 3 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 4 of 111 6.3 Measures to Minimize Bias: Randomization and Blinding  ............................................ 51  
6.3.1  Randomization and Allocation Procedures .................................................................. 51  
6.3.2  Blinding and Code-breaking Procedures ...................................................................... 52  
6.4 Study Intervention Compliance ...................................................................................... 53  
6.5 Concomitant Therapy ...................................................................................................... 53  
6.5.1  Rescue Medicine  ........................................................................................................... 54  
6.6 Dose Modification  .......................................................................................................... 54  
6.7 Intervention After the End of the Study .......................................................................... 54  
7 Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal  .......................................................................................... 54  
7.1 Discontinuation of Study Intervention ............................................................................ 54  
7.1.1  Temporary Contraindications ....................................................................................... 54  
7.1.2  Definitive Contraindications  ......................................................................................... 55  
7.2 Participant Discontinuation/Withdrawal from the Study  ................................................ [ADDRESS_1103058] to Follow-up ............................................................................................................ 56  
8 Study Assessments and Procedures  ............................................................................... 56  
8.1 Baseline Screening for SARS -CoV-2 antibodies ........................................................... 59  
8.2 Efficacy and Immunogenicity Assessments  ................................................................... 59  
8.2.1  Immunogenicity Assessments ...................................................................................... 59  
[IP_ADDRESS]  SARS -CoV-2 Neutralizing Antibody Assessment ..................................................... 59  
[IP_ADDRESS]  SARS -CoV-2 Spi[INVESTIGATOR_799667] ........................................ 59  
[IP_ADDRESS]  Cellular- Mediated Immunity (using whole blood)  ..................................................... 60  
8.2.2  Efficacy Assessments ................................................................................................... 60  
[IP_ADDRESS]  Definitions  .................................................................................................................. 60  
[IP_ADDRESS]  COVID-19- like Illness Surveillance  .......................................................................... 62  
[IP_ADDRESS]  SARS -CoV-2 Nucleoprotein Antibody Serum IgG ELISA ....................................... 62  
[IP_ADDRESS]  Nucleic Acid Amplification Test (NAAT) for COVID -19 Case Detection  ............... 63  
8.3 Safety Assessments ......................................................................................................... 63  
8.3.1  Medical History  ............................................................................................................ 63  
8.3.2  Physical Examinations .................................................................................................. 63  
8.3.3  Vital Signs  .................................................................................................................... 63  
8.3.4  Clinical Safety Laboratory Assessments  ...................................................................... 63  
8.4 Adverse Events and Serious Adverse Events ................................................................. 64  
8.4.1  Time Period and Frequency for Collecting AE and SAE Information ......................... 66  
8.4.2  Method of Detecting AEs and SAEs ............................................................................ 67  
8.4.3  Follow-up of AEs and SAEs ........................................................................................ 68  
8.4.4  Regulatory Reporting Requirements for SAEs ............................................................ 68  
8.4.5  Pregnancy ..................................................................................................................... 68  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 4 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page [ADDRESS_1103059]  ............................................................................... 69  
8.4.7  Medically Attended Adverse Events  ............................................................................ 69  
8.5 Treatment of Overdose ................................................................................................... 69  
8.6 Pharmacokinetics ............................................................................................................ 69  
8.7 Pharmaco dynamics ......................................................................................................... 69  
8.8 Genetics  ........................................................................................................................... 70  
8.9 Biomarkers  ...................................................................................................................... 70  
8.10  Immunogenicity Assessments ......................................................................................... 70  
8.11  Medical Resource Utilization and Health Economics .................................................... 70  
9 Statistical Considerations  ............................................................................................... 70  
9.1 Statistical Hypotheses  ..................................................................................................... 70  
9.2 Sample Size Determination  ............................................................................................. 70  
9.3 Populations for Analyses  ................................................................................................ 71  
9.4 Statistical Analyses  ......................................................................................................... 72  
9.4.1  General Considerations  ................................................................................................. 72  
9.4.2  Primary Endpoints ........................................................................................................ 72  
[IP_ADDRESS]  Immunogenicity ......................................................................................................... 72  
[IP_ADDRESS]  Safety .......................................................................................................................... 72  
9.4.3  Secondary Endpoints .................................................................................................... 73  
[IP_ADDRESS]  Immunogenicity ......................................................................................................... 73  
[IP_ADDRESS]  Efficacy  ...................................................................................................................... 73  
9.4.4  Exploratory Endpoint  ................................................................................................... 73  
[IP_ADDRESS]  Immunogenicity ......................................................................................................... 73  
9.5 Interim Analyses  ............................................................................................................. 74  
9.6 Data Monitoring Committee (DMC) .............................................................................. 74  
10 Supporting Documentation and Operational Considerations  .................................... 75  
10.1  Appendix: Regulatory, Ethical, and Study Oversight Considerations  ............................ 75  
10.1.1  Regulatory and Ethical Considerations  ........................................................................ 75  
10.1.2  Financial Disclosure  ..................................................................................................... 75  
10.1.3  Informed Consent Process ............................................................................................ 76  
10.1.4  Data Protection and Future Use of Stored Samples ..................................................... 76  
10.1.5  Committees Structure  ................................................................................................... 78  
10.1.6  Dissemination of Clinical Study Data .......................................................................... 78  
10.1.7  Data Quality Assurance  ................................................................................................ 78  
10.1.8  Source Documents ........................................................................................................ 79  
10.1.9  Study and Site Start and Closure .................................................................................. 79  
10.1.10  Publication Policy  ......................................................................................................... 80  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 5 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 6 of 111 10.2  Appendix: Clinical Laboratory Tests .............................................................................. 80  
10.3  Appendix: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow-up, and Reporting ............................................................................ 82  
10.3.1  Definition of AE  ........................................................................................................... 82  
10.3.2  Definition of SAE  ......................................................................................................... 84  
10.3.3  Recording and Follow-Up of AE and/or SAE .............................................................. 86  
10.3.4  Reporting of SAEs ........................................................................................................ 88  
10.3.5  Assessment of Intensity  ................................................................................................ 89  
[IP_ADDRESS]  Tables for Clinical Abnormalities  .............................................................................. 89  
[IP_ADDRESS].1  Solicited AR Intensity Grading Scale  ...................................................................... 89  
[IP_ADDRESS].2  Unsolicited AE Intensity Grading Scale  .................................................................. 94  
[IP_ADDRESS]  Tables for Laboratory Abnormalities  ......................................................................... 94  
10.4  Appendix: Collection of Pregnancy Information ............................................................ 97  
10.5  Appendix: AESIs  ............................................................................................................ 99  
10.6  Appendix: Risk- based Approach .................................................................................. 102  
10.7  Appendix: Abbreviations .............................................................................................. 103  
10.8  Appendix: Protocol Amendment/Update History  ......................................................... 105  
11 References  ...................................................................................................................... 108  
12 Sponsor Signature [CONTACT_3490]  ................................................................................................ 111  
 
  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 6 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page [ADDRESS_1103060] of Tables  
Table  1.1: Schedule of activities 1 (Cohort 1) ............................................................................... 17  
Table  1.2: Schedule of activities 2 (Cohort 2) ............................................................................... 22  
Table  1.3: Schedule of activities 3: Follow- up of COVID-19- like illness  .................................... 27  
Table  2.1: Potential risks o f clinical significance and risk management  ...................................... 33  
Table  3.1: Objectives and endpoints ............................................................................................. 35  
Table  4.1: Overall design .............................................................................................................. 37  
Table  4.2: Planned sample size  ..................................................................................................... 39  
Table  6.1: Identity of study interventions ...................................................................................... 48  
Table  8.1: Blood sampling per visit .............................................................................................. 58  
Table  8.2: COVID-19- like illness symptoms: CRF and Diary Card / Memory Aid terms ........... 61  
Table  10.1: Protocol -required safety laboratory assessments ....................................................... 81  
Table  10.2: Solicited injection site reactions: terminology, definitions, and intensity scales ....... 90  
Table  10.3: Solicited systemic reactions: terminology, definitions, and intensity scales ............. 92  
Table  10.4: Intensity thresholds for laboratories abnormalities  .................................................... 95  
Table  10.5: List of potential immune- mediated diseases  ............................................................ 100  
 
  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 7 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page [ADDRESS_1103061] of Figures  
Figure 1.1: Graphical study design (Cohort 1) .............................................................................. 15  
Figure 1.2: Graphical study design (Cohort 2) .............................................................................. 16  
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 8 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 9 of 111 1 Protocol Summary 
1.1 Synopsis 
Protocol Title:  
Immunogenicity and Safety of SARS- CoV- 2 Recombinant Protein Vaccine Formulations (with or 
without adjuvant) in Healthy Adults 18 Years of Age and Older 
Short Title:  
Study of Recombinant Protein Vaccine Formulations against COVID-19 in Healthy Adults 
18 Years of Age and Older 
Rationale: 
An outbreak of severe respi[INVESTIGATOR_603411], Hubei Province, China in December 
2019 heralded the appearance of a novel coronavirus, severe acute respi[INVESTIGATOR_6507] 2 (SARS -CoV-2), in the human population. The rapid escalation of the outbreak led 
to a declaration by [CONTACT_603484] 20 January 2020 of a P ublic Health 
Emergency of International Concern , followed by [CONTACT_799698] 11 March 2020 of a pandemic 
(1). As of [ADDRESS_1103062] 2020, the virus ha s been detected in 188 countries/regions and infected over 
23.7 million individuals  (2). 
The clinical profile of COVID -19, the illness caused by [CONTACT_7544]- CoV- 2, is variable (3). In the 
majority of cases, the manifestations are mild, or individuals may be asymptomatic. Among those with symptoms, typi[INVESTIGATOR_603412], cough, and shortness of breath. More severe manifestations include acute hypoxemic respi[INVESTIGATOR_712421] a nd mechanical 
ventilation, in some cases resulting in death. Based on early data, adults over 50 years of age and individuals with chronic medical conditions are at a higher risk of severe outcomes and death. At present, no licensed vaccine exists for this  strain nor any other coronaviruses.  
To address the urgent medical need caused by [CONTACT_603486], [COMPANY_011] Pasteur is developi[INVESTIGATOR_007] a candidate vaccine consisting of a stabilized prefusion trimer of the SARS -CoV-2 Spi[INVESTIGATOR_2531] (S) protein  
based on the work by [CONTACT_799699]  (4). [COMPANY_011] Pasteur will a pply the manufacturing technology that 
is used to produce commercialized recombinant hemagglutinin (HA) vaccine, Flub lok
®. It is 
anticipated that the recombinant protein vaccine will require an adjuvant to optimize the immune response and for dose-sparing potential. While [COMPANY_011] Pasteur ’s proprietary AF03 adjuvant will be 
utilized for this vaccine development, it is anticipated that the demand for a protective vaccine will likely exceed the supply capacity for any single adjuvant; thus, a second adjuvant supplied by 
[CONTACT_35316] , AS03 , will also be evaluated.  
The current first- in-human study will evaluate the immunogenicity and safety of the candidate 
vaccine with the goal of selecting a formulation, or formulations, and an injection schedule to proceed to efficacy evaluation as rapi[INVESTIGATOR_2595].
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 9 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 10 of 111 Objectives and Endpoints:  
Objectives  Endpoints  
Primary   
Immunogenicity  
To describe the neutralizing antibody profile at 
Day (D) 01, D22, and D36 of each study 
intervention group.  Immunogenicity  
Neutralizing antibody titers will be measured with the neutralization assay.  
• Antibody titer at D01, D22, and D36  
• Fold-rise (fold -rise in serum antibody 
neutralization titer post-vaccination relative to 
D01) at D22,  and D36  
• 2-fold and 4-fold rise in serum neutralization 
titer (post/pre ) relative to D01 at D22, and 
D36) 
• Occurrence of neutralizing antibody seroconversion,  defined as baseline values 
below lower limit of quantification ( LLOQ ) 
with detectable neutralization titer above assay LLOQ  at D22 and D36
 
Safety  
To describe the safety profile of all participants in 
each age group and each study intervention group up to [ADDRESS_1103063] injection.  Safety  
• Presence of unsolicited systemic adverse 
events ( AEs) reported in the 30 minutes after 
each injection 
• Presence of solicited (pre -listed in the 
participant’s diary card and Case Report Form [CRF]) injection site reactions and systemic 
reactions occurring up to 7  days after each 
injection  
• Presence of unsolicited AEs reported up to 21 days after each injection. 
• Presence of medically attended adverse event  
(MAAEs) throughout the study   
• Presence of serious adverse events (SAEs ) and 
adverse events of special interest ( AESIs ) 
throughout the study 
• Presence of out -of-range biological test results 
up to [ADDRESS_1103064] injection (ie, up to D09 
for Cohort 1 and up to D30 for Cohort  2) 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 10 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 11 of 111 Secondary   
Immunogenicity  
1) To describe binding antibody profile at D 01, 
D22, D36, D181 (Cohort 1) or D202 (Cohort 
2), and D366 (Cohort 1) or D387 (Cohort 2)  of 
each study intervention group. 
2) To describe the neutralizing antibody profile at 
D181 (Cohort 1) or D202 (Cohort 2)  and D366 
(Cohort 1) and D387 (Cohort 2)  of each study 
intervention group. Immunogenicity  
Binding antibody titers to full-length SARS-CoV-2 
S protein will be measured for each study 
intervention group with the enzyme-linked 
immunosorbent assay (ELISA) method.  
• Individual anti -S antibody concentration at 
D01, D22, D36, D181 (Cohort  1) or D202 
(Cohort 2), and D366 (Cohort 1) or D387 
(Cohort 2)   
• Individual anti -S antibody concentration ratio 
(fold-rise in serum ELISA concentration post -
vaccination relative to D0 1) at D22, D36, 
D181 (Cohort 1) or D202 (Cohort 2) , and 
D366 (Cohort 1) or D387 (Cohort 2)   
• Fold-rise in anti -S antibody  concentration 
(post/pre ) ≥ 2 and ≥  4 at D22, D36, D181 
(Cohort 1) or D202 (Cohort 2), and D366 (Cohort 1) or D387 (Cohort 2)  
Neutralizing antibody titers will be measured with 
the neutralization assay.  
• Antibody titer at  D181 (Cohort 1) or D202 
(Cohort 2) and D366 (Cohort 1) or D387 
(Cohort 2)  
• Fold-rise (fold -rise in serum neutralization 
titer post-vaccination relative to D01) at D181 
(Cohort 1) or D202 (Cohort 2) and D366 (Cohort 1) or D387 (Cohort 2)  
• 2-fold and 4-fold rise in serum neutralization titer (post/pre ) relative to D01 at D181 
(Cohort  1) or D202 (Cohort 2)  and D366 
(Cohort 1) or D387 (Cohort 2)  
• Occurrence of neutralizing antibody seroconversion, defined as values below LLOQ at baseline with d etectable 
neutralization titer above assay LLOQ  at D181 
(Cohort 1) or D202 (Cohort 2) and D366 
(Cohort 1) or D387 (Cohort 2)  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 11 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 12 of 111 Efficacy 
1) To describe the occurrence of virologically -
confirmed COVID-19-like  illness and 
serologically -confirmed SARS -CoV-2 
infection . 
2) To evaluate the correlation  / association  
between antibody responses to SARS -CoV -2 
Recombinant Protein and the risk of 
virologically -confirmed COVID-19-like  
illness and/or serologically -confirmed SARS -
CoV-2 infection . Efficacy 
• Virologically-conf irmed COVID-19-like  
illness as defined by [CONTACT_799700]  
• Serologically-confirmed SARS -CoV-2 
infection is defined by [CONTACT_7544]-CoV-2-specific antibody detection in a non -S ELISA 
• Correlates of risk / protection based on 
antibody responses to SARS -CoV-2 as 
evaluated using virus neutralization or ELISA , 
considering virologically -confirmed  COVID-
19-like illness  and/or serologically -confirmed 
SARS -CoV-[ADDRESS_1103065]-in -human, dose -ranging, 
multi-center study  with a Sentinel Safety Cohort 
and Early Safety Data Review  (ESDR)  
Phase  I/II 
Control method  Placebo -controlled  
Study population  Healthy , seronegative adults 18 years of age and 
older  
Countries  [LOCATION_002]  
Level and method of blinding  • Blinding for vaccine group assignment 
(formulation and adjuvant): participant s, 
outcome assessors, Investigators, laboratory personnel, Sponsor study staff (except those involved in ESDR, and for concerned participants  only)  
• No blinding for injection schedule  
• No blinding for vaccine group assignment: 
those preparing/administering the study 
interventions  
Study intervention assignment method Randomization for study intervention and assigned 
stratification by [CONTACT_799701]/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 12 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 13 of 111 Disclosure Statement : 
This is a parallel group prevention study, stratified into  2 age groups based on age 
at enrollment: the younger adult age group (18-49 years) will be randomly assigned 
to one of 11 arms; the older adult age group (≥ 50  years) will be randomly assigned 
to one of 10 arms. Participants, outcome assessor s, Investigators , laboratory 
personnel, and the majority of sponsor study staff (except those involved in the ESDR and for concerned participants only) will be blinded to vaccine assignment group (formulation and adjuvant); injection schedule will be unblinded; and those preparing/administering  the study interventions will be unblinded to vaccine group 
assignment .  
Number of Participants:  
Approximately 440 participants 18 years of age and older (300 adults 18 through 49 years of age and 140 adults 50 years of age  and older) are planned to be randomized.  
As a precautionary step, a Sentinel Safety Cohort of 6 participants (younger adults only) within 
each dosing group from Cohort [ADDRESS_1103066] will be performed, including evaluation of safety data and laboratory measures to D09 in Cohort 1 among younger adults 18-49 years of age. Upon acceptable safety  demonstrated from unblinded data review by [CONTACT_799702] ( Responsible Medical Officer [RMO] , Study Biostatistician 
and Programmer, Pharmacovigilance Scienc e Expert, and Global Safety Officer) , the remaining 
participants in Cohort  1 and all participants in Cohort 2 will be enrolled. 
Intervention Groups and Duration:  
A total of 440 participants are planned to be enrolled as shown below: 
Participants 18 -49 years of age  
Cohort  Group Dose Level * Adjuvant  N 
Sentinel 
Safety † 
(N=3 0) Total  
(N=300)  
Cohort 1:  
1 injection  1 5 µg AF03 6 20 
2 5 µg AS03  6 20 
3 15 µg  AF03 6 20 
4 15 µg  AS03  6 20 
5 Placebo  None  6 20 
Cohort 2:  
2 injections  6 5 µg AF03 N/A 20 
7 5 µg AS03  N/A 60 
8 15 µg  AF03 N/A 20 
9 15 µg  AS03  N/A 60 
10 15 µg  None  N/A 20 
11 Placebo  None  N/A 20 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 13 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 14 of 111 Participants 50  years of age and older  
Cohort  Group Dose Level * Adjuvant  N 
(N=140)  
Cohort 1:  
1 injection  1 5 µg AF03 10 
2 5 µg AS03  10 
3 15 µg  AF03 10 
4 15 µg  AS03  10 
5 Placebo  None  10 
Cohort 2:  
2 injections  6 5 µg AF03 10 
7 5 µg AS03  30 
8 15 µg  AF03 10 
9 15 µg  AS03  30 
10 15 µg None  N/A‡ 
11 Placebo  None  10 
*Antigen Formulation naming for each dose level: CoV2 preS dTM antigen: Formulation 1 (low -dose [5 µg]); 
Formulation 2 ( high-dose [15  µg]) 
† Sentinel Safety Cohort: 6 participants within each dosing group from Cohort 1 (18-49 years of age only) will be 
included in the Sentinel Safety Cohort.  
‡ As part of risk mitigation for enhanced COVID- 19, the older age stratification (≥ 50 years) will not be allocated 
to this study arm.  
Note: A subset of 87 participants in Cohort 2 (60 participants 18 -49 years of age [18 per group in AS03 -adjuvanted 
vaccines; 6 per group in all other study groups]) and 27 participants ≥  50 years of age [9 per group in 
AS03 -adjuvanted groups; 3 per group in all other study groups, with the exception of the unadjuvanted group for 
which there will be no older adults]), will be randomly assigned to a  cellular -mediated immune (CMI) subset.   
All participants will receive 1  injection of either one of the investigational study vaccine 
formulations or the placebo control at D01 (Vaccination [VAC] 1). Participants in Cohort 2 will 
receive a second injection of study vaccine formulation or placebo at D22 (VAC2).  
If a COVID- 19 vaccine becomes available from a company other than [COMPANY_011] Pasteur, then 
participants are free to receive that vaccine. Participants who receive a COVID -19 vaccine will 
still b e followed for safety until the end of the study but will be discontinued from study 
intervention administration thereafter.  
Enrolled participants who seek vaccination of an authorized/approved vaccine outside of the study will be encouraged to discuss thi s intention proactively with the study investigator and will be 
permitted to receive the authorized vaccine at any time. As efficacy has not been demonstrated for any of the investigational formulations under evaluation in the current study, it is not required to unblind participants to the VAT00001 study assignment prior to administration of an authorized COVID- 19 vaccine.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 14 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 15 of 111 If the participant receives the authorized/approved vaccine, this information would be collected 
and the participant’s data up to the point of receipt of authorized/approved vaccine will be included in the primary analysis for immunogenicity and safety. Participants will continue to be followed for the duration of the study as per scheduled visits and procedures. Participants will be 
invited to a visit prior to receiving the vaccine and invited to provide a blood sample for immunological assessment.  
The duration of each participant’s participation in the study will be approximately [ADDRESS_1103067] injection : 
• Cohort 1: approximately 365 days duration total 
• Cohort 2: approximately 386 days duration total 
Data Monitoring Committee: No  
1.2 Schema  
The graphical design of VAT00001 study is as presented in Figure 1.1 (Cohort 1) and Figure 1.2 
(Cohort 2).  
Figure  1.1: Graphical study design (Cohort 1)  
Ab, antibody; BL, blood sample; TC, telephone call; V, visit; VAC, vaccination 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 15 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 16 of 111 Figure  1.2: Graphical study design (Cohort 2)  
Ab, antibody; BL, blood sample; CMI, cellular -mediated immunity; MC, mononuclear cell; TC, telephone 
call; V, visit; VAC, vaccination; WB, whole blood  
1.3 Schedule of Activities (SoA)  
Visits and procedures are detailed in the Operating Guidelines.   
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 16 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 17 of 111 Table  1.1: Schedule of activities  1 (Cohort 1) 
Phase I /II Study, 7 Visits, 1 Telephone Call, 1 Injection , 6 Blood Sample Time -points, Approximately 12 Months’ Duration Per Participant  
Visit (V) / Contact  [CONTACT_603518]  V01 V02 V03 V04 Telephone  
Call V05 V06  V07 or Safety 
Follow -up 
Call§§§§  
Study timelines (Day [D])   D01 D09 D22 D36 D43 D113 D181 D366 
Time Interval (days)    V01 + 8 
days V01 + 21 
days V01 + 35 
days V01 + 42 
days V01 +112 
days V01 + 180 
days V01 + 365 days  
Time windows (days)   N/A [+2 days]  [+7 days]  [+7 days]  [+2 days]  [+7 days]  [+14 days]  [+14 days]  
Visit procedures:           
Informed consent  X X        
Point -of-care SARS -CoV -[ADDRESS_1103068]   X        
Inclusion/exclusion criteria  X X        
Collection of demographic data  X X        
Collection of medical history  X 
Significant 
Medical 
History  X      
  
Physical examination*  X        
Pre-vaccination temperature   X        
Urine pregnancy test (if applicable) †   X        
Contact [CONTACT_167504], 
participant number, and unique dose 
number allocation.  X X    
  
  
Respi[INVESTIGATOR_799668](s)  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 17 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 18 of 111 Visit (V) / Contact  [CONTACT_603518]  V01 V02 V03 V04 Telephone  
Call V05 V06  V07 or Safety 
Follow -up 
Call§§§§  
Study timelines (Day [D])   D01 D09 D22 D36 D43 D113 D181 D366 
Time Interval (days)    V01 + 8 
days V01 + 21 
days V01 + 35 
days V01 + 42 
days V01 +112 
days V01 + 180 
days V01 + 365 days  
Time windows (days)   N/A [+2 days]  [+7 days]  [+7 days]  [+2 days]  [+7 days]  [+14 days]  [+14 days]  
Visit procedures:           
Clinical safety laboratory assessments ‡ 
(10 mL) 
    (All participants)  X X§ X     
  
Serum samples for Ab assays (30  mL) 
    (All participants)  X BL0001§  BL0002 BL0003  BL0004 BL0005 BL0006 
Vaccination ( VAC ) X X        
Immediate surveillance (30 min utes) X X        
Diary Card provided   DC1**   DC2§§  DC3***   DC4†††  DC5‡‡‡   
Diary Card reviewed    DC1††    DC3 ††    
Diary Card collected     DC1‡‡  DC2‡‡   DC3‡‡  DC4‡‡  DC5‡‡  
Collection of solicited injection site & 
systemic reactions  X D01-D08       
Collection of unsolicited AEs  X D01-D22      
Collection of concomitant medications  X 
Reportable 
concomitant 
medication  All reportable concomitant 
medications  
(including influenza vaccination)  Influenza and COVID -19 vaccination s only 
Telephone call  X     X‡‡‡‡    X§§§§  
Passive surveillance  X  Participants will be instructed to contact [CONTACT_799703] a COVID -19-like illness at 
any time during the study.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 18 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 19 of 111 Visit (V) / Contact  [CONTACT_603518]  V01 V02 V03 V04 Telephone  
Call V05 V06  V07 or Safety 
Follow -up 
Call§§§§  
Study timelines (Day [D])   D01 D09 D22 D36 D43 D113 D181 D366 
Time Interval (days)   V01 + 8 
days V01 + 21 
days V01 + 35 
days V01 + 42 
days V01 +112 
days V01 + 180 
days V01 + 365 days  
Time windows (days)   N/A [+2 days]  [+7 days]  [+7 days]  [+2 days]  [+7 days]  [+14 days]  [+14 days]  
Visit procedures:           
Active surveillance calls X     TC to occur every [ADDRESS_1103069] until D181§§§   
(See also Schedule of Activities  Table  1.3 
for follow -up)  
Collection of SAEs, AESIs ****, and 
MAAEs  X To be reported at any time during the study  
Collection of pregnancies  X 
End of phase participation record††††  X     X X X  
End of active phase participation record  X        X 
[ADDRESS_1103070] 
(only for those discontinued early) §§§§  X        X 
Abbreviations: Ab, Antibody; AE, adverse event; AESI, adverse event of special interest; BL, blood sample (#); CRF, Case Report Form; DC, Diary Card; IRT, interactive 
response technology; MAAE, medically attended adverse event ; S, Spi[INVESTIGATOR_2531]; SAE, serious adver se event ; SARS -CoV -2, severe acute respi[INVESTIGATOR_6507] 2; V, visit; 
VAC, vaccination   
*Targeted physical examination based on the participant’s medical history and the examiner’s medical judgment will be performed at V01.  
† Urine pregnancy test is applicable to childbearing potential female participant (to be considered of non -childbearing potential, a female must be post -menopausal for at least 1 
year or surgically sterile ). Urine pregnancy test is to be performed before vaccination.  
‡ Safety  laboratory assessments will include: Serum Chemistries (liver enzymes / Chem 7, lipase, and amylase); hematology ( complete blood count  with differential ); Urinalysis; 
Microscopy. In cases of abnormal safety laboratory results, unscheduled visits may occur, based on Investigator’s judgment.  
§ BL0001 and the first safety laboratory assessment sample will be collected at pre -vaccination (baseline).  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 19 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 20 of 111 Visit (V) / Contact  [CONTACT_603518]  V01 V02 V03 V04 Telephone  
Call V05 V06  V07 or Safety 
Follow -up 
Call§§§§  
Study timelines (Day [D])   D01 D09 D22 D36 D43 D113 D181 D366 
Time Interval (days)    V01 + 8 
days V01 + 21 
days V01 + 35 
days V01 + 42 
days V01 +112 
days V01 + 180 
days V01 + 365 days  
Time windows (days)   N/A [+2 days]  [+7 days]  [+7 days]  [+2 days]  [+7 days]  [+14 days]  [+14 days]  
Visit procedures:           
** Participants will use this DC1  to record information about solicited reactions, unsolicited AEs, SAEs, and AESIs from D01 to D08 after vaccination and will continue to record 
information about unsolicited AEs, SAEs, and AESIs from D09 to V03.  
†† The Investigator or an authorized design ee will remind the participants to bring back the DC at the next visit and will answer any questions.  
‡‡ The Investigator or an authorized designee will interview the participants to collect the information recorded in the DC and will attempt to clarify anything that is incomplete or 
unclear.  
§§ Participants will use this DC2 for SAE s, AESIs , and COVID -19-like illness follow -up from V03 to V04.  
*** Participants will use this DC3 for SAE s, AESIs , and COVID- 19-like illness follow -up from V04 to V05.  
††† Participants will use this DC4 for SAE s, AESIs , and COVID- 19-like illness follow -up from V05 to V06.  
‡‡‡ Participants will use this DC5 for SAE s, AESIs , and COVID- 19-like illness follow -up from V06 to V07.  
§§§ Prior to these specified time -points, active s urveillance will still occur during the established contacts (phone calls and visits).  
**** AESIs (serious and non- serious) will be collected throughout the study as SAEs to ensure that events are communicated to the Sponsor in an expedited manner and foll owed -
up until the end of the follow -up period or resolution, as per the assigned causal relationship . These include: Anaphylactic reactions, Generalized convulsion, 
Thrombocytopenia, Lacrimal and salivary disorders (tearing, dry mouth, dry eyes), any new-o nset chronic medical conditions, and potential immune -mediated diseases.  
†††† In case of participant discontinuation at a visit, the entire visit will be completed  
‡‡‡‡  During the D43 telephone call, staff will review the DC3 pertaining to SAE, AESI, and COVID- 19-like illness between V04 and the call and will remind the participant to 
bring back the DC3 for V05.  This telephone call will NOT be collected in the CRF.  
§§§§  All participants will be scheduled to attend V07 for blood sampling and 12 -Month Safety Follow -up. However, if any participants discontinue the study early, they are still to 
be followed for safety and are to be contact[CONTACT_213229] a 12- Month Safety Follow- up call to identify the occurrence of any SAEs and AESIs that had not yet been reported. If 
discontinuation occurs at a scheduled visit, the participant will be provided a Memory Aid instead of a DC for SAE follow -up (including AESIs) until the 12 -Month 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 20 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 21 of 111 Visit (V) / Contact  [CONTACT_603518]  V01 V02 V03 V04 Telephone  
Call V05 V06  V07 or Safety 
Follow -up 
Call§§§§  
Study timelines (Day [D])   D01 D09 D22 D36 D43 D113 D181 D366 
Time Interval (days)    V01 + 8 
days V01 + 21 
days V01 + 35 
days V01 + 42 
days V01 +112 
days V01 + 180 
days V01 + 365 days  
Time windows (days)   N/A [+2 days]  [+7 days]  [+7 days]  [+2 days]  [+7 days]  [+14 days]  [+14 days]  
Visit procedures:           
Safety Follow -up call. If a participant discontinues between visits (with no Memory Aid provid ed yet), the participant will use the last DC received to collect information 
for the 12 -Month Safety Follow -up call.  
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 21 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 22 of 111 Table  1.2: Schedule of activities 2 (Cohort 2) 
Phase I/II Study, 7 Visits, 2 Telephone Call s, 2 Injections, 6 Blood Sample Time -points, Approximately 13 Months’ Duration Per Participant  
Visit (V) / Contact  [CONTACT_799704] F V01 Telephone 
Call 1 V02 V03 V04 Telephone 
Call 2 V05 V06 V07 or  
Safety 
Follow -up 
Call*****  
Study timelines (Day [D])   D01 D09 D22 D 30 D36 D43 D134 D202 D387 
Time Interval (days)    V01 + 8 
days V01 + 21 
days V02 + 8 
days V02 + 14 
days V02 + 21 
days V02 + 112 
days V02 + 
180 days  V02 + 365 
days 
Time windows (days)   N/A [+2 days]  [+7 days]  [+2 days]  [+7 days]  [+2 days]  [+7 days]  [+14 
days]  [+14 days]  
Visit procedures:            
Informed consent  X X         
Point -of-care SARS -CoV -[ADDRESS_1103071]  X         
Inclusion/exclusion criteria  X X         
Collection of demographic data  X X         
Collection of medical history  X 
Significant 
Medical 
History  X       
  
Physical examination*  X         
Pre-vaccination temperature   X  X       
Urine pregnancy test (if applicable)  †  X  X       
Contact [CONTACT_603519], participant number, 
and unique dose number allocation.  X X     
  
  
Contact [CONTACT_799705].  X   X       
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 22 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 23 of 111 Visit (V) / Contact  [CONTACT_799704] F V01 Telephone 
Call 1 V02 V03 V04 Telephone 
Call 2 V05 V06 V07 or  
Safety 
Follow -up 
Call*****  
Study timelines (Day [D])   D01 D09 D22 D 30 D36 D43 D134 D202 D387 
Time Interval (days)    V01 + 8 
days V01 + 21 
days V02 + 8 
days V02 + 14 
days V02 + 21 
days V02 + 112 
days V02 + 
180 days  V02 + 365 
days 
Time windows (days)   N/A [+2 days]  [+7 days]  [+2 days]  [+7 days]  [+2 days]  [+7 days]  [+14 
days]  [+14 days]  
Visit procedures:            
Temporary and definitive 
contraindications  X   X       
Respi[INVESTIGATOR_799668](s)  
Clinical safety laboratory 
assessments ‡ (10 mL) 
(All participants)  X X§   X    
  
Serum samples for Ab assays  
(30 mL) 
(All participants)  X BL0001 §  BL0002 §  BL0003  BL0004 BL0005 BL0006 
 
Cellular-mediated Immunity  (40 mL) 
(Subset of 87 participants  in 
Cohort  2) X MC0001§  MC0002§  MC0003     
TruCulture (4  mL) 
(Subset of 87 participants  in 
Cohort  2) X WB0001§  WB0002§  WB0003     
Vaccination ( VAC ) X X  X       
Immediate surveillance (30 min utes) X X  X       
Diary Card provided   DC1**   DC2§§  DC3 ***  DC4 ††† DC5‡‡‡   
Diary Card reviewed    DC1††   DC2††   DC3 ††    
Diary Card collected     DC1‡‡  DC2‡‡  DC3‡‡ DC4‡‡ DC5‡‡ 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 23 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 24 of 111 Visit (V) / Contact  [CONTACT_799704] F V01 Telephone 
Call 1 V02 V03 V04 Telephone 
Call 2 V05 V06 V07 or  
Safety 
Follow -up 
Call*****  
Study timelines (Day [D])   D01 D09 D22 D 30 D36 D43 D134 D202 D387 
Time Interval (days)   V01 + 8 
days V01 + 21 
days V02 + 8 
days V02 + 14 
days V02 + 21 
days V02 + 112 
days V02 + 
180 days  V02 + 365 
days 
Time windows (days)   N/A [+2 days]  [+7 days]  [+2 days]  [+7 days]  [+2 days]  [+7 days]  [+14 
days]  [+14 days]  
Visit procedures:            
Collection of solicited injection site 
& systemic reactions X D01-D08 
(up to [ADDRESS_1103072]-
VAC1)  D01-D08 (up to [ADDRESS_1103073]-VAC2)     
  
Collection of unsolicited AEs   X D01-D22 
(up to [ADDRESS_1103074] -VAC1)        
  D01-D22 
(up to [ADDRESS_1103075] -VAC2)     
Collection of concomitant 
medications  X 
Reportable 
concomitant 
medication  All reportable concomitant medications  
(including influenza vaccination) Influenza  and COVID -19 vaccination s 
only 
Telephone call  X  X§§§    X§§§§    X*****  
Passive surveillance  X Participants will be instructed to contact [CONTACT_799703] a COVID -19-like illness at any time during  
the study.  
Active surveillance  calls X      TC to occur every [ADDRESS_1103076] until D202 **** 
(See also Schedule of Activities Table  1.3 
for follow -up)  
Collection of SAEs , AESIs †††† , 
and MAAEs  X To be reported at any time during the study  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 24 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 25 of 111 Visit (V) / Contact  [CONTACT_799704] F V01 Telephone 
Call 1 V02 V03 V04 Telephone 
Call 2 V05 V06 V07 or  
Safety 
Follow -up 
Call*****  
Study timelines (Day [D])   D01 D09 D22 D 30 D36 D43 D134 D202 D387 
Time Interval (days)    V01 + 8 
days V01 + 21 
days V02 + 8 
days V02 + 14 
days V02 + 21 
days V02 + 112 
days V02 + 
180 days  V02 + 365 
days 
Time windows (days)   N/A [+2 days]  [+7 days]  [+2 days]  [+7 days]  [+2 days]  [+7 days]  [+14 
days]  [+14 days]  
Visit procedures:            
Collection of pregnancies  X 
End of phase participation 
record ‡‡‡‡  X      X X X  
End of active phase participation 
record  X         X 
[ADDRESS_1103077] (only for those 
discontinued early)  *****  X         X 
Abbreviations: Ab, Antibody; AE, adverse event; AESI, adverse event of special interest; BL, blood sample (#); CRF, Case Report Form ; DC, Diary Card; IRT, interactive response 
technology; MAAE, medically attended adverse event ; MC, mononuclear cell ; S, Spi[INVESTIGATOR_2531]; SAE, serious adverse event; SARS -CoV -2, severe acute respi[INVESTIGATOR_6507] 2; 
V, visit; VAC, Vaccination; WB, whole blood   
*Targeted physical examination based on the participant’s medical history and the examiner’s medical judgment will be performed at V01.  
† Urine pregnancy test is applicable to childbearing potential female participant (to be considered of non -childbearing potential, a female must be post -menopausal for at least 1 year  
or surgically sterile). Urine pregnancy test is to be performed before vaccinati on. 
‡ Safety laboratory assessments will include: Serum Chemistries (liver enzymes / Chem 7, lipase, and amylase); hematology ( complete blood count with differential ); Urinalysis ; 
Microscopy . In cases of abnormal safety laboratory results, unscheduled visi ts may occur, based on Investigator’s judgment.  
§ BL0001, MC0001,  WB0001 and the first safety laboratory assessment sample will be collected at pre-VAC1  (baseline); and BL0002 , MC0002 , and WB0002 samples will be 
collected at pre-VAC2 . 
** Participants will  use this  DC1  to record information about solicited reactions, unsolicited AEs, SAEs, and AESIs from D01 to D08 after vaccination and will continue to record 
information about unsolicited AEs, SAEs, and AESIs from D09 to V02.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 25 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 26 of 111 †† The Investigator or an authorized designee will remind the participants to bring back the DC at the next visit and will answer any questions.  
‡‡ The Investigator or an authorized designee will interview the participants to collect the information recorded in the DC and will attempt to clarify anything that is incomplete or 
unclear.  
§§ Participants will use this DC2 to record solicited reactions, unsolicited AEs, SAEs, and AESIs (from V02 to V03) and will continue to collect unsolicited AEs, SAEs, and AESIs 
(from V03 to V04).  
*** Part icipants will use this DC3 for unsolicited AEs follow -up until D43 and SAE s, AESIs , and COVID -19-like illness follow -up from V04 to V05.  
††† Participants will use this DC4 for SAE s, AESIs , and COVID- 19-like illness follow -up from V05 to V06.  
‡‡‡ Participants will use this DC5  for SAE s, AESIs , and COVID- 19-like illness follow -up from V06 to  V07. 
§§§ During the D09 telephone call, staff will review the DC1 for solicited reactions from D01 to D08 after vaccination, inqui re whether the participant experiences any SAE or AESI 
not yet reported, and remind the participant to bring back DC1 for V02. This telephone call will NOT be documented in the CRF.  
****  Prior to these specified time -points, active surveillance will still occur during the established contacts (phone calls and visits).  
††††  AESIs (serious and non- serious) will be collected throughout the study as SAEs to ensure that events are communicated to the Sponsor in an expedited manner and followed -up 
until the end of the follow -up period or resolution, as per the assigned causal relationship . These include: Anaphylactic reactions, Generalized convulsion, 
Thrombocytopenia, Lacrimal and salivary disorders (tearing, dry mouth, dry eyes), any new -onset chronic medical conditions , and potential im mune -mediated diseases .  
‡‡‡‡  In case of participant discontinuation at a visit, the entire visit will be completed.  
§§§§  During the D43 telephone call, staff will review the DC3 pertaining to unsolicited AEs , SAE, AESI, and COVID -19-like illness between V04 and the call and will remind the 
participant to bring back the DC3 for V05 . This telephone call will NOT be documented in the CRF.  
***** All participants will be scheduled to attend V07 for blood sampling and 12 -Month (post -VAC2) Safety Follow -up. Howe ver, if any participants discontinue the study early, 
they are still to be followed for safety and are to be contact[CONTACT_213229] a Safety Follow -up call to identify the occurrence of any SAEs and AESIs that had not yet been reported. If 
discontinuation occurs a t a scheduled visit, the participant will be provided a Memory Aid instead of a DC for SAE follow -up (including AESIs) until the Safety Follow -up call. If a 
participant discontinues between visits (with no Memory Aid provided yet), the participant will use  the last DC received to collect information for the Safety Follow -up call. 
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 26 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 27 of 111 Table  1.3: Schedule of activities 3: Follow- up of COVID-19- like illness  
Contact [CONTACT_799706] * Visit  Follow -up Telephone Call † 
Verify information on COVID -19-like illnesses and schedule appointment for 
collection of respi[INVESTIGATOR_799669] ‡ X  
 
Remind participant to complete Memory Aid or Diary Card  X   
Collection of respi[INVESTIGATOR_799670] §  
Collection of disease burden and health care information  X X X 
Collection of treatments received during COVID -19-like illness   X X X 
Collection of information on respi[INVESTIGATOR_387148]  X X X 
* Initial illness identification phone call  
† Follow -up telephone call approximately 30 days after illness  
‡ Start of first clinical manifestation of COVID -19-like illnes s 
§ “X” indicates that the nasopharyngeal swab number will be unique to each site. Further details are provided in the Operating Guidelines.  
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 27 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 28 of 111 2 Introduction 
[COMPANY_011] Pasteur’s Recombinant severe acute respi[INVESTIGATOR_6507] 2 ( SARS -CoV-2) 
protein vaccine is being developed in the setting of a pandemic for the active immunization for the 
prevention of SARS- CoV-2 infection and/or COVID-19 disease. The initial intended use of the 
vaccine is for adults, 18 years of age and older. It is planned that studies to support use of the vaccine in children 6 months to 17 years of age will be conducted after the initial data from studies in adults are available.   
The candidate antigen is a stabilized prefusion trimer of the SARS -CoV-2 S protein. The 
coronavirus Spi[INVESTIGATOR_2531] (S) protein is the major viral envelope glycoprotein and mediates attachment and entry into host cells. The S protein precursor is cleaved to form non- covalently associated 
subunits, S1 and S2 (5) . The S protein appears on the surface of the virus as a mushroom -like 
structure, containing a cap of three S1 subunits and a stem of three S2 subunits. The S1 subunit contains the receptor binding domain (RBD), which attaches to the host cellular receptor. In the case of SARS -CoV-2, the receptor is Angiotensin Converting Enzyme- Related Peptidase 2, a 
membrane- bound carboxypeptidase localized to vascular endothelial as well as epi[INVESTIGATOR_603426] 
(6). The RBD is a major antigenic target for immune responses. The S2 domain contains the 
fusion peptide and transmembrane regions. Upon binding to the cellular receptor, S1 is cleaved from the virus and the S2 subunit undergoes a conformational change to mediate viral membrane fusion with the host cell membrane.  
Prior r esearch with Middle East Respi[INVESTIGATOR_23223]  (MERS) -CoV identified that the 
introduction of double proline substitutions (2P) at the beginning of the central helix of the S2 
subunit could stabilize the structure and prevent conformational changes in the S trimer  (7). When 
used to immunize mice, the MERS -CoV 2P construct was associated with improved breadth and 
potency of neutralizing responses compared to monomeric MERS- CoV S1 or wild -type S. This 
strategy was identified as bein g of general relevance to betacoronaviruses, which include HCoV-
NL63, MERS- CoV, and SARS -CoV-1, and by [CONTACT_799707]- CoV-2 (4) . The pre-fusion 
stabilized SARS -CoV- [ADDRESS_1103078] to be evaluated in the current study is based on this 
research.  
The antigen will be manufactured using the same technology as is used to manufacture Flublok vaccine, which is a recombinant hemagglutinin ( HA) vaccine licensed for the prevention of 
influenza in adults 18 years of age and older (8) . In this system, the gene of interest is cloned into 
a baculovirus transfer vector, which is used to form recombinant baculoviruses. The viral stock is 
used to infect an insect cell line (ExpresSF+ ). The recombinant protein is expressed in t he infected 
insect cells. After incubation, the recombinant protein is purified. This process is adaptable to a variety of antigens. Millions of doses of Flublok vaccine have been administered since its 
approval for human use corresponding to HA s of differ ent influenza strains ( H1, H3, and B) 
covering multiple influenza seasons. Additionally, the process has previously been applied to the development of candidate SARS- CoV-1 vaccines. Following the SARS outbreak, Protein 
Sciences developed candidate S protei n vaccines, including a full- length S protein and a 
transmembrane- deleted ectodomain antigen. These were tested in a variety of preclinical models 
and found to induce neutralizing antibody responses and to be partially protective in a ferret challenge mode l. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 28 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 29 of 111 It is anticipated that, owing to the need to mobilize naïve B and T cell responses, the magnitude 
and quality of the immune response to the candidate antigen will be enhanced through delivery 
with an adjuvant. This may allow for titration of the amount of antigen used; and, thus, be antigen-sparing and potentially increase the available supply of antigen. In addition, the adjuvant may influence the quality of the immune response. Prior mouse experiments with candidate 
SARS -CoV- 1 vaccines had identified t hat recombinant S protein candidates were immunogenic 
and that adjuvantation with alum could improve the titer of neutralizing antibodies (9) . However, 
in these experiments it was observed that mice receiving the alum -adjuvanted, recombinant S 
protein vaccine displayed immunopathology in t he lungs that was suggestive of a T-helper ( Th)2-
type response. Therefore, in this program to develop a SARS -CoV-2 vaccine with recombinant 
protein ( SARS CoV2  prefusion Spi[INVESTIGATOR_603408] [SARS CoV2 preS dTM ]), the adjuvants AS03 
and AF03, that may promote a more balanced Th1/Th2 response (10)  (11), are being  investigated.   
AS03 and AF03 are both oil- in-water emulsions containing squalene. Both have been evaluated in 
the context of pandemic or pre- pandemic influenza vaccines. Safety of AS03 -adjuvanted products 
has been extensively evaluated and found to be generally well tolerated w ith an acceptable safety 
profile  (12) . AS03 was evaluated with pandemic H7 HA manufactured by [CONTACT_799708], demonstrating robust neutralizing antibody responses and hemagglutination inhibition, 
together with an acceptable safety p rofile. As has been the case for several  pandemic agents, 
unadjuvanted H7 HA-containing influenza vaccines were  poorly immunogenic (13)  (14). 
AF03 has been administered to over 1,500 humans in the setting of clinic al trials and was 
approved for use in Europe as a component of Humenza
®, an H1N1 pandemic influenza vaccine 
(15). In a more recent study, AF03 was demonstrated to have strong effects on the magnitude and 
breadth of neutralizing responses to influenza in mice (16) . A pr eclinical study in macaques 
demonstrated a higher level of protection following AF03-adjuvanted vaccination from 
pneumonia and decrease severity of lung disease on challenge with the homologous H5N1 
influenza strain than alum -adjuvanted or unadjuvanted com parators. The protection was correlated 
with the level of neutralizing antibodies  (17) . Recent human clinical experience has included use 
of AF03 in combination with quadrivalent inactivated influenza antigens (n=40, 15 µg  of HA per 
strain, total of 60  µg of protein) and quadrivalent baculovirus recombinant influenza antigens 
(n=40, 45 µg  of HA per strain, total of 180 µg  of protein manufactured by [CONTACT_799709]) in a 
Phase I trial ([STUDY_ID_REMOVED]) ; the formulations were found to be generally well tolerated , and 
review by [CONTACT_799710]. 
A potential safety issue with coronavirus vaccines is the ability to potentiate immunopathology in 
vaccinees upon exposure to w ild-type virus (18). The molecular mechanism for this phenomenon, 
sometimes termed Antibody Dependent Enhancement , Vaccine- Associated Enhanced Respi[INVESTIGATOR_799671],  or Immune Enhancement of viral infection, is also not fully understood. In the context of 
coronavirus infections, various factors have been suggested as potentially contributing to the phenomenon. These include the epi[INVESTIGATOR_603427], the method of delivery of the antigen, the magnitude of the immune responses, the balance between binding and functional antibodies, the elicitation of antibodies with functional characteristics such as binding to particular Fc receptors, and the nature of the Th  cell response (9)  (19)  (20). It is anticipated that the design of the 
candidate SARS- CoV-[ADDRESS_1103079] 
neutralizing antibodies  over binding antibodies, based on data generated with other coronavirus 
vaccine antigens (4)  (7). The inclusion of adjuvanted formulations is anticipated to further 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 29 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 30 of 111 enhance the magnitude of neutralizing antibody responses and induce a balanced Th1/Th -2 cell 
responses (10) (11) . Taken together, these strategies mitigate by [CONTACT_799711]. 
2.[ADDRESS_1103080]- in-human study will evaluate the immunogenicity and safety of the candidate 
vaccine with the goal of selecting a formulation, or formulations, and a dosing schedule to 
proceed to efficacy evaluation as rapi[INVESTIGATOR_2595].  
2.2 Background 
SARS -CoV-2 is a novel coronavirus that emerged in the human population and has led to a 
pandemic of acute respi[INVESTIGATOR_603429] -19. Coronaviruses are a fam ily of large, 
enveloped, positive-sense, single-stranded ribonucleic acid (RNA) viruses that infect a wide 
variety of mammalian and avian species. The viral genome is packed into a capsid comprised of the viral nucleocapsid protein, which is in turn surrounded by [CONTACT_603528]. Viral proteins associated with the envelope include the S protein, which mediates viral attachment and entry into cells.  
The burden of SARS- CoV- [ADDRESS_1103081] emerging in December 2019 among over 23.7 million confirmed cases (as of [ADDRESS_1103082] 2020) (2) . In many locations, the rapid emergence of COVID-[ADDRESS_1103083] has had economic consequences. A safe and effective vaccine would be a vital tool to address the significant medical an d societal burden caused by [CONTACT_47098]. 
The CoV2 preS dTM  recombinant protein vaccine belongs to the pharmacotherapeutic group of 
“Other viral vaccines”. The vaccine contains recombinant S protein , stabilized to maintain native 
prefusion trimer configura tion as present on the viral envelope. 
Further details of the chemistry, pharmacology, and safety of the CoV2 preS dTM recombinant protein vaccine are provided in the Investigator’s Brochure (IB) . 
2.3 Benefit/Risk Assessment 
The novel coronavirus outbreak started in December [ADDRESS_1103084] 2020, the 
virus has been detected in 188 countries/regions, infected over 23.[ADDRESS_1103085] died from C OVID-19 (2) . 
The investigational recombinant protein vaccine  consists of a stabilized prefusion trimer of the 
SARS -CoV-2 S protein. The coronavirus S protein precursor is cleaved to form non-covalently 
associated subunits, S1 and S2  (5). The S1 subunit contains the RBD, which attaches to the viral 
receptor; the RBD is the major antigenic target for immune responses. The S2 domain contains 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 30 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page [ADDRESS_1103086] cell. The S1 and S2 subunits combine as a trimer of each subunit.  
It is anticipated that owing to the need to mobilize naïve B and T cell responses, the magnitude of 
the immune response to the candidate antigen will be enhanced through delivery with an adjuvant. This may allow for titration of the amount of antigen used; and, thus, be antigen-sparing and potentially increase the available supply of antigen. In addition, the adjuvant may influence the character of the im mune response. Prior mouse experiments with candidate SARS- CoV-1 
vaccines had identified that recombinant S protein candidates were immunogenic and that adjuvantation with alum could improve the titer of neutralizing antibodies (9). However, in these 
experiments it was observed that mice receiving the alum -adjuvanted, recombinant S protein 
vaccine displayed immunopathology in the lungs that was suggestive of a Th2-type response. Therefore, the adjuvants AS03 and AF03, that may promote a more balanced Th1/Th2 response (10) (11) , will be investigated.  
A potential safety issue with coronavirus vaccines is the ability to potentiate immunopathology in 
vaccinees upon exposure to wild-type virus (18). The potential for a coronavirus vaccine to 
exacerbate disease is a theoretical concern that has not been documented to date, but that will be 
explain ed as a theoretical risk in the Informed Consent document. 
AF03 is a squalene emulsion -based adjuvant similar to MF59 and AS03 adjuvants bu t utilizes an 
alternative manufacturing process that involves phase inversion temperature emulsification and 
incorporates 2 non- ionic surfactants (15) . During the 2009 H1N1 pandemic, [COMPANY_011] Pasteur 
developed an AF03 adjuvanted A/H1N1 pandemic influenza vaccine ( Humenza) and performed 
clinical studies to support the licensure of the vaccine. Clinical trials using AF03 with A/H5N1 
and A/H1N1 pandemic influenza antigen have been performed in adults (21); elderly; and 
children, including infants (22) . Taken together, the data from these studies showed that AF03 
enhanced the magnitude of antibody response, proportion of participants  with seroprotective titers 
and durability of antibody responses. With regards to safety, the addition of AF03 was associat ed 
with a higher frequency of solicited injection site reactions as expected with any adjuvanted vaccine, while solicited systemic reactions and unsolicited adverse events (AEs) varied in each 
age group. Overall, AF03 appears to be safe and well tolerated when administered as half - or full -
dose (6.2 mg or 12.5 mg of squalene per vaccine dose) and in any age group. No safety signals were detected with AF03 adjuvanted pandemic influenza vaccines in any of the populations included in the clinical studies.  
Like AF03 adjuvant, AS03 is an oil- in-water emulsion containing squalene. To support the 
licensing of A/H1N1 pandemic influenza vaccines in elderly people, Pandemrix
® and Arepanrix®, 
2 large clinical studies were carried out in participants aged 61 years and above (23) . Additional 
clinical studies were conducted in adults ≥ 18 years of age, children from 6 months to 18 years, 
and older adults ≥ [ADDRESS_1103087] -licensure safety studies (12). All these studies 
but 2 were conducted with vaccine antigen of H1N1 strain. The 2 other clinical studies assessed 
the vaccines antigens H7N1 and H9N2 (24) . Q-Pan®, an Influenza A (H5N1) Virus Monovalent 
Vaccine adjuvanted with AS03 is licensed by [CONTACT_55257] . AS03 was also assessed in the 
development of an adjuvanted trivalent influenza vaccine (TIV) . A Phase III efficacy trial 
evaluat ed efficacy of AS03 -adjuvanted TIV compared to unadjuvanted TIV among 43,695 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 31 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page [ADDRESS_1103088] -licensure data showed 
that AS03 enhanced antibody and T cell responses with an acceptable safety profile.   
Of note, based on the theoretical concern that vaccination with an adjuvanted vaccine containing 
potent immunostimulants may interfere with immunological self -tolerance, pI[INVESTIGATOR_159170] (potential 
Immune -Mediated Diseases) are adverse events of special interest  (AESIs)  undergoing special 
safety monitoring for vaccines containing Adjuvant Systems. pI[INVESTIGATOR_163510] a subset of AEs that 
include autoimmune diseases and other inflammatory and/or neurological disorders of interest which may or may not have an autoimmune etiology (see Table  10.[ADDRESS_1103089]). 
The efficacy of the candidate vaccine formulations has not been established. CoV2 preS dTM Recombinant Protein Candidate Vaccine Benefit/Risk Profile is expected to be positive based on available evidence. Study participation and study conduct is considered fundamental from the 
societal perspective towards the goal of finding a vaccine to help control the pandemic and decrease individual and public health burden of COVID-[ADDRESS_1103090] SARS -CoV-2 infection 
and/or COVID-19 disease and its complications with a clinical benefit of reduction of the associated burden of disease in population over 18 years of age. 
More detailed information about the known and expected benefits and risks, reasonably expected 
AEs, the potential risks, and uncertainties of CoV2 preS dTM  vaccine may be found in the 
CoV2  preS dTM  vaccine IB. 
In addition, information related to the AF03 adjuvant may be found in the AF03 IB. 
Also, more detailed information related to  the AS03 adjuvant will be made available by 
[CONTACT_35316] ([COMPANY_004]). 
2.3.1 Risks from Study Participation  
The potential risks of clinical significance and risk management are summarized in  Table  2.1. 
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 32 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 33 of 111 Table  2.1: Potential risks of clinical significance and risk management 
Potential Risk of Clinical 
Significance  Summary of Data/Rationale for Risk  Risk Management  
Investigated Vaccine: CoV2 preS dTM (AF03 or AS03)  
Anaphylactic reactions  Class -effect for all vaccines (even not 
adjuvanted)  Observation period after vaccination 
for early detection and treatment  
Risk management will also be based on Exclusion criterion  E08 (see  
Section  5.2). 
Enhanced COVID -19 A potential safety issue with coronavirus vaccines is the ability to potentiate 
immunopathology in vaccinees upon 
exposure to wild- type virus  (18). The 
molecular mechanism for this 
phenomenon, sometimes termed 
Antibody Dependent Enhancement , 
Vaccine -Associated Enhanced 
Resp iratory Disease,  or Immune 
Enhancement of viral infection, is also not fully understood. In the context of 
coronavirus infections, various factors 
have been suggested as potentially contributing to the phenomenon. These 
include the epi[INVESTIGATOR_603427], the me thod 
of delivery of the antigen, the magnitude of the immune responses, the balance 
between binding and functional antibodies, the elicitation of antibodies 
with functional characteristics such as 
binding to particular Fc receptors, and the nature of the T -helper cell response 
(9) (19) (20) (25) COVID -19-like illness will be part 
of the efficacy objective with active 
and passive surveillance.  
It is anticipated that the design of the candidate SARS -CoV -[ADDRESS_1103091] neutralizing 
antibodies over binding antibodies, 
based on data generated with other coronavirus vaccine antigens  (4) 
(7).  
The inclusion of adjuvanted formulations is anticipated to further 
enhance the magnitude of 
neutralizing antibody responses and 
induce a balanced Th1/Th -2 cell 
responses  (10) (11).  
Taken together, these strategies mitigate by [CONTACT_799712].  
Individuals with chronic comorbid conditions considered to be associated with an increased risk of 
severe COVID -19 will be excluded 
(26). 
Number of study participants of 
older age group will be minimized to balance the theoretical risks and 
the ability to determine the 
consistency of the immune responses compared to younger 
adults.  
In addition, no older age group 
study participants are included in the antigen -only group (without 
adjuvant).  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 33 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 34 of 111 Potential Risk of Clinical 
Significance  Summary of Data/Rationale for Risk  Risk Management  
Potential Immune -Mediated 
Diseases  Based on the theoretical concern that 
vaccination with an adjuvanted vaccine 
containing potent immunostimulants may interfere with immunological self -
tolerance, pI[INVESTIGATOR_799672]. pI[INVESTIGATOR_799673] a subset of AEs that include 
autoimmune diseases and other inflammatory and/or neurological 
disorders of interest which may or may 
not have an autoimmune etiology.  During the informed consent process, the participants enrolling in 
the study will be informed of this 
potential risk and the need to attend 
the clinic if they are unwell. pI[INVESTIGATOR_799674]. The occurrence of 
pI[INVESTIGATOR_752058].  
Refer to IB s’ Section 5 and 
Section 6 for more 
informa tion regarding 
potential risks.  Refer to the IB Section 5 and Section 6 for more information regarding the data from previous experience with the 
adjuvants in the investigated vaccine.   
Study Procedures  
Vasovagal reactions ( near -
syncope or syncope), or 
psychogenic reactions to 
needle (vaccine injection or 
blood sampling)  Anxiety -related reactions can occur 
following, or even before, any vaccination as a psychogenic response to 
the needle injection or blood draw, and 
may be accompanied by [CONTACT_799713], paresthesia or 
seizure -like activity  Observation period after vaccination for early detection and treatment  
Theoretical risk that 
participant  can be exposed to 
other SARS -CoV- [ADDRESS_1103092] with other individuals when visiting study site (study site to set up system) should  
be minimized  
Protective material ( eg, masks for 
participants , clothing, goggles) to  be 
used in sites . 
Home visit option for completion of study procedures in the setting of 
containment measures to minimize 
exposure.  
2.3.[ADDRESS_1103093] is considered fundamental from the societal perspective towards the goal of finding a vaccine to help control the pandemic and decrease individual and public health burden of COVID-19 illness  and SARS -CoV-2 infection.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 34 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 35 of 111 2.3.3 Overall Benefit -Risk Conclusion  
Considering the significant medical need, scale of the pandemic, urgent requirement for measures 
to address the pandemic, together with actions taken to minimize risk to participants enrolled in the study, there is no unreasonable and significant risk of illness or injury for the participants. 
3 Objectives and Endpoints  
The study objectives and the corresponding endpoints are described in Table  3.1. 
Table  3.1: Objectives and endpoints  
Objectives  Endpoints  
Primary   
Immunogenicity 
To describe the neutralizing antibody profile 
at D01, D22, and D36 of each study 
intervention group.  Immunogenicity  
Neutralizing antibody titers will be measured with the 
neutralization assay.  
• Antibody titer at D01, D22, and D36  
• Fold-rise (fold -rise in serum antibody neutralization titer 
post-vaccination relative to D01) at D22, and D36  
• 2-fold and 4 -fold rise in serum neutralization titer (post/pre ) 
relative to D01 at D22, and D36 
• Occurrence of neutralizing antibody seroconversion, defined 
as baseline values below lower limit of quantification 
(LLOQ ) with detectable neutralization titer above assay 
LLOQ at D22 and D36 
Safety  
To describe the safety profile of all 
participants in each age group and each study 
intervention group up to [ADDRESS_1103094] 
dose.  Safety  
• Presence of unsolicited systemic AEs reported in the 
30 minutes after each injection  
• Presence of solicited (pre -listed in the participant’s diary card 
and Case Report Form [CRF ]) injection site reactions and 
systemic reactions occurring up to 7  days after each injection  
• Presence of unsolicited AEs reported up to 21  days after each 
injection  
• Presence of medically  attended adverse events ( MAAEs ) 
throughout the study  
• Presence of serious adverse events ( SAEs ) and adverse 
events of special interest ( AESIs ) throughout the study  
• Presence of out- of-range biological test results up to [ADDRESS_1103095] dose (ie, up to D09 for Cohort 1 and up to D30 for 
Cohort 2) 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 35 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 36 of 111 Secondary   
Immunogenicity  
1) To describe binding antibody profile at 
D01, D22, D36 , D181 ( Cohort 1) or D202 
(Cohort 2), and D366 (Cohort 1) or D387 (Cohort 2)  of each study intervention 
group .  
2) To describe the neutralizing antibody profile at D181 (Cohort 1) or D202 (Cohort 2)  and D366 (Cohort 1) or D387 
(Cohort 2)  of each study intervention 
group . Immunogenicity  
Binding antibody titers to full -length SARS -CoV -2 Spi[INVESTIGATOR_799675]- linked immunosorbent assay  (ELISA) method.  
• Individual anti -S antibody concentration at D01, D22, D36 , 
D181 (Cohort 1) or D202 (Cohort 2) , and D366 (Cohort 1) or 
D387 (Cohort 2)  
• Individual anti -S antibody concentration ratio (fold -rise in 
serum ELISA concentration post -vaccination  relative to D 01) 
at D22, D36, D181 (Cohort 1) or D202 (Cohort 2) , and D366 
(Cohort 1) or D387 (Cohort 2)  
• Fold-rise in anti -S antibody concentration (post/pre ) ≥ 2 and 
≥ 4 at D22, D36, D181 (Cohort 1) or D202 ( Cohort  2), and 
D366 (Cohort 1) or D387 (Cohor t 2) 
Neutralizing antibody titers will be measured with the 
neutralization assay.  
• Antibody titer at D181 (Cohort 1) or D202 (Cohort 2)  and 
D366 (Cohort 1) or D387 (Cohort 2)   
• Fold-rise (fold -rise in serum neutralization titer post -
vaccination relative to D01) at D181 (Cohort 1) or D202 
(Cohort 2)  and D366 (Cohort 1) or D387 (Cohort 2)   
• 2-fold and 4 -fold rise in serum neutralization titer [post/pre] 
relative to D01 at D181 (Cohort 1) or D202 (Cohort 2)  and 
D366 (Cohort 1) or D387 (Cohort 2) 
• Occurrence of neutralizing antibody seroconversion, defined 
as values below LLOQ at baseline with detectable neutralization titer above assay LLOQ at D181 (Cohort 1) or 
D202 (Cohort 2) and D366 (Cohort 1) or D387 (Cohort 2)  
Efficacy  
1) To describe the occurrence of 
virologi cally -confirmed COVID -19-like 
illness and serologically -confirmed 
SARS -CoV -2 infection . 
2) To evaluate the correlation  / association  
between antibody responses to SARS -
CoV -2 Recombinant Protein and the risk 
of virologically -confirmed  
COVID -19-like illness and/or 
serologically -confirmed SARS- CoV -2 
infection . Efficacy  
• Virologically -confirmed COVID -19-like illness as defined 
by [CONTACT_799714]  
• Serologically -confirmed SARS- CoV -2 infection as defined 
by [CONTACT_7544] -CoV -2-specific antibody detection in a non- S 
ELISA  
• Correlates of risk / protection based on antibody responses to 
SARS -CoV -2 as evaluated using virus neutralization or 
ELISA , considering virologically-confirmed  COVID -19-like 
illness  and/or serologically -confirmed SARS -CoV -2 
infection as defined above  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 36 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 37 of 111 Exploratory   
Immunogenicity 
1) To describe cellular immune response 
profile at D01, D22 , and D36 for each 
study intervention group in a subset of  
Cohort 2 . 
2) To describe the ratio between neutralizing antibodies and binding antibodies . Immunogenicity 
• T-helper cell (Th) 1 and Th2 cytokines will be measured in 
whole blood following stimulation with full-length S protein 
and/or pools of S-antigen peptides  
• Ratio between binding antibody (ELISA) concentration and 
neutralizing antibody titer  
Other  
To evaluate other emerging biomarkers as 
effect modifiers or as correlates of risk  / 
protection . Biomarker measurement at baseline and/or post -vaccination visits 
(D22, D36, D113 [Cohort 1] or D134 [Cohort 2], D181 [Cohort1] 
or D202 [Cohort 2]) , and D366 [ Cohort 1] or D387 [ Cohort 2 ]) 
4 Study Design  
4.1 Overall Design 
The design of the study is summarized i n Table  4.1. 
Table  4.1: Overall design  
Type of design Parallel group, first-in-human, placebo- controlled, dose -
ranging, multi- center study  with a Sentinel Safety Cohort 
and Early Safety Data Review  (ESDR)  
Phase  I/II 
Control method  Placebo- controlled  
Study population Healthy , seronegative adults 18 years of age and older  
Level and method of blinding  • Blinding for vaccine group assignment (formulation 
and adjuvant): participants, outcome assessors, Investigators, laboratory personnel, Sponsor study staff (except those involved in ESDR, and for concerned participants only)  
• No blinding for injection schedule  
• No blinding for vaccine group assignment: those 
preparing/administering the study interventions  
Study intervention assignment method  Enrollment will be stratified by [CONTACT_654]: 300 participants 18- 49 
years of age and 140 partici pant ≥ 50 years of age. All 
440 participants will be randomized to receive either 1 
injection (Cohort 1) or 2  injections (Cohort 2) of the study 
intervention to which they are randomized.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 37 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 38 of 111 Number of participants  Approximately 440 participants 18 years of age and older 
(300 adults 18 through 49 years of age and 140 adults 
≥ 50 years of  age) are planned to be randomized  
Intervention groups  Within each cohort:  
• participants aged 18- 49 years :  
• will be randomized to 6 groups to receive 
Antigen Formulation 1 (low -dose [5 µg]) with 
either AF03 or AS03 adjuvant; Formulation 
2 (high- dose [15 µg]) with either AF03, AS03, or 
no adjuvant; or placebo (Note: unadjuvanted arm 
included in Cohort 2 only)  
• N = 20 participants in each  group, except for 
AS03 -adjuvanted groups in Cohort 2 with 
60 participants in each group  
• participants aged ≥ 50 years:  
• will be randomized to 5 groups to receive 
Antigen Formulation 1 (low-dose [5  µg]) or 
Formulation 2 ( high-dose [15 µg]) each with 
either AF03 or AS03; or placebo 
• N = [ADDRESS_1103096] dose:  
• Cohort 1: approximately 365 days duration total  
• Cohort  2: approximately 386 days duration total  
Countries  [LOCATION_002]  
Use of an Independent Data Monitoring 
Committee, Dose Escalation Committee, or 
similar review group  NO 
 
A total of 440 participants are planned to be enrolled. At the time of inclusion, participants will be 
screened for SARS -CoV -2 seropositivity status and stratified according to age. Those who are 
seronegative will be randomized as shown in  Table  4.2. 
As a precautionary step, a Sentinel Safety Cohort of 6 participants (younger adults only) within 
each dosing group from Cohort 1 will be enrolled. An Early Safety Data Review (ESDR) will be 
performed, including evaluation of safety data and laboratory measures to D09 in Cohort 1 among younger adults 18-49 years of age. Upon acceptable safety  demonstrated from unblinded data 
review by [CONTACT_799715] (RMO, Biostatistician and Pr ogrammer, 
Pharmacovigilance Science Expert, and Global Safety Officer ), the remaining participants in 
Cohort 1 and all participants in Cohort 2 will be enrolled.  Further details are provided in 
Section  8.4. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 38 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 39 of 111 Table  4.2: Planned sample size  
Participants 18 -49 years of age  
Cohort Group Dose Level*  Adjuvant  N 
Sentinel Safety † 
(N=3 0) Total 
(N=300)  
Cohort 1:  
1 injection  1 5 µg AF03  6 20 
2 5 µg AS03  6 20 
3 15 µg  AF03  6 20 
4 15 µg AS03  6 20 
5 Placebo  None  6 20 
Cohort 2:  
2 injections  6 5 µg AF03  N/A 20 
7 5 µg AS03  N/A 60 
8 15 µg  AF03  N/A 20 
9 15 µg AS03  N/A 60 
10 15 µg  None  N/A 20 
11 Placebo  None  N/A 20 
Participants 50 years of age and older  
Cohort Group Dose Level * Adjuvant  N 
(N=140) 
Cohort 1:  
1 injection  1 5 µg AF03  10 
2 5 µg AS03  10 
3 15 µg  AF03  10 
4 15 µg AS03  10 
5 Placebo  None  10 
Cohort 2:  
2 injections  6 5 µg AF03  10 
7 5 µg AS03  30 
8 15 µg  AF03  10 
9 15 µg AS03  30 
10 15 µg  None  N/A‡  
11 Placebo  None  10 
*Antigen Formulation naming for each dose level: CoV2 preS dTM antigen: Formulation 1 (low-dose [5 µg]); Formulation 2 
(high-dose [15  µg]) 
† Sentinel Safety Cohort: 6 participants within each dosing group from Cohort 1 (18-49 years of age only) will be included in 
the Sentinel Safety Cohort.  
‡ As part of risk mitigation for enhanced COVID -19, the older age stratification (≥  50 years) will not be allocated to this study 
arm. 
Note : A subset of 87 participants in Cohort 2 (60 participants 18-49 years of age [18 per group in AS03-adjuvanted vaccines; 6 
per group in all other study groups]) and 27 participants ≥ 50 years of age [9 per group in AS03-adjuvanted groups; 3 per group 
in all other study groups, with the exception of the unadjuvanted group for which there will be no older adults]), will be randomly assigned to a cellular- mediated immune (CMI) subset.   
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 39 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 40 of 111 All participants will receive 1  injection of either one of the investigational  study vaccine 
formulations or the placebo control at Day (D)01 (Vaccination [VAC] 1). Participants in Cohort 2 
will receive a second injection  (of the same intervention as received at D01) of study vaccine 
formulation or placebo at D22 (VAC2). 
If a COVID- [ADDRESS_1103097] dose targeted in the present study (quadrivalent Flublok vaccine contains a total of 180 µg  of HA protein; the highest 
dose of this CoV2 preS dTM  vaccine is 15 µg  in the study). While clinical and post-marketing 
experience with proteins manufactured with the baculovirus manufacturing system is specific for influenza proteins, it is relevant to point out that these include different proteins (H1, H3, B 
Yamagata, B Victoria HAs), with each one changed over time to support the recommended 
compositions of seasonal influenza vaccines. This provides reassurance about the safety of the protein manufacturing platform, at protein doses higher than planned in this study, and for a variety of different protein constructs.  
AF03 was administered to more than 1500 individuals as part of the clinical development of 
adjuvanted influenza vaccines. This included exposure of children and adults, including elderly adults; more than 200 older adults received inactivated influenza vaccine in combination with AF03. No safety concerns were identified in these studies, and AF03 adjuvanted vaccines were safe and well  tolerated. The clinical development of AF03-adjuvanted H1N1 influenza vaccine led 
to regulatory approval of the Humenza vaccine by [CONTACT_3558] (EMA) .  
AS03 has been administered to thousands of individuals (adults and elderly) as part of clinical 
trials of influenza vaccines as well as other vaccines (27) . Notably, more than 20,000 older adults 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 40 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 41 of 111 received AS03-adjuvanted influenza vaccine in a large, multi- country efficacy trial  (24). 
Furthermore, hundreds of millions of doses of AS03- adjuvanted H1N1 vaccines were 
administered post-licensure in the context of H1N1 pandemic control. The vaccines were found to 
be well  tolerated. Of note, an increased risk of narcolepsy was observed in some individuals after 
the vaccination campaign with Pandemrix in 2009-2010. A similar risk of narcolepsy was not identified with other non-adjuvanted influenza vaccines or other AS03 -adjuvanted vaccines, like 
Arepanrix  (28) (29) . Current data suggest that cases of narcolepsy seen immediately following the 
2009/2010 pandemic were the result of an immune cascade, triggered by [CONTACT_398]4 T cell cross-reactivity to HA proteins from the H1N1 virus itself and hypocretin. This conclusion is consistent with the position reached by [CONTACT_470699] 2016 when it concluded that: “ Based on the  evidence 
generated so far, a hypothesis that takes into account the potential role of  antigen is more likely to 
explain the increased risk of narcolepsy observed with  Pandemrix than hypotheses that are based 
on a direct role for the AS03 adjuvant ” (30) .  
Recombinant proteins produced in the baculovirus manufacturing platform by [CONTACT_799716]03 and AS03. AF03 was administered to 40 adults 18 through 45  years of age in a Phase I trial ([STUDY_ID_REMOVED]) as the adjuvant of a quadrivalent 
recombinant influenza vaccine (total of 180 µg  of HA protein, 4 different HA proteins at 45 µg  
each). The study is ongoing, and more than [ADDRESS_1103098] been completed; and Independent D ata and Monitoring C ommittee (IDMC) has evaluated the safety data and has not 
raised any safety concerns. AS03 was administered to 184 adults 18 through 49 years of age with an H7 recombinant influenza vaccine in study BP-I-17-002 ([STUDY_ID_REMOVED]) sponsored by [CONTACT_799717] (BARDA). The AS03 adjuvanted H7 
recombinant protein vaccine was found to be safe and well tolerated and led to robust immune 
responses.  
As a precautionary step, a Sentinel Safety Cohort of 6 participants (younger adul ts only) within 
each dosing group from Cohort [ADDRESS_1103099] will be performed, including 
evaluation of safety data and laboratory measures to D09 in Cohort 1 among younger adults 18-49 years of age. Upon acceptable safety  demonstrated from unblinded review by [CONTACT_799702] (RMO , Biostatistician and Programmer, Pharmacovigilance 
Science Expert, and Global Safety Officer ), the remaining participants in Cohort [ADDRESS_1103100] likely that 2 injections may be necessary.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 41 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 42 of 111 A separation of 2 1 days for the 2-injection schedule is proposed for this program, mirroring the 
schedule that was evaluated and approved for pandemic influenza vaccines to address the 2009 
H1N1 influenza pandemic (AS03 adjuvanted vaccines Pandemrix™, Arepanrix™; and AF03 
adjuvanted Humen za vaccine ). This schedule results in a second injection  of the vaccine being 
administered earlier than with other common vaccines with  longer separations between injections  
(ie, 28 days), thus aiming at earlier generation of potentially protective immune responses. This may be of particular interest in an ongoing pandemic setting .  
In addition to antibody response [ADDRESS_1103101] injection, durability after a single injection 
also needs to be taken into account for schedule selection decisions , as peak immune responses 
after 1 injection  may be adequate but could (at least theoretically) wane rapi[INVESTIGATOR_375], potentially 
leaving vaccinees at risk in the event of ongoing circulation of the novel coronavirus. A further 
consideration is allowing sufficient time for contraction of innate immune responses and expansion of the adaptive immune response after dosing, which would be underestimated if evaluated too soon after the dose. In this regard, at le ast fourteen days after a second dose is 
deemed sufficient, based on experience with other vaccines ( 27) (31)  (32).Therefore, antibody 
titers at D2 2 ([ADDRESS_1103102] injection ) and D36 (14 days after a second injection ) after a 
single injection or after [ADDRESS_1103103] identified that the presence of pre-challenge neutralizing antibodies were predictive of protection from infection or symptoms 
following challenge (33)  (34). For this reason, neutralizing responses are expected to provide the 
most relevant functional evaluation of immune responses for this vaccine candidate. 
Rationale for Study Population 
The study will enroll participants with no history of COVID-[ADDRESS_1103104] consistently indicated a higher risk of severe complications 
and death in older adults (35)  (36) . Therefore, it is considered of great relevance to generate data 
in the older adult population to inform schedule and formulation selection that will serve the general adult population, including those at particular risk of poor outcomes. A Sentinel Safety 
Cohort among younger adults is included to provide preliminary short- term safety data prior to 
enrollment of older adult participants. The study incorporates several measures to mitigate the theoretical risk of vaccine- associated ERD . The se include a higher representation of the younger 
adult strata for the same reason, given that adults over [ADDRESS_1103105] also been 
overrepresented in studies describing critical illness and death, although to a lesser degree than those older than 75 years  (35) . Therefore, the proposed design aims at generating data that will 
allow selection of the relevant formulations and injection schedule accounting for potential age 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 42 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 43 of 111 effects. Data for each formulation will be generated in both younger adults and older adults, 
allowing the evaluation of the consistency in the patterns of immune response for each formulation between the 2 age strata; additionally, aggregated “main” effects by [CONTACT_799718] (n=120 across vaccine formulations) and pooled younger adult data (n=240 across vaccine formulations with corresponding data in the older strata).   
Evidence to date indicates that individuals with chronic medical conditions are at increased risk of severe outcomes associated wi th COVID-19 (37) . The e xclusion of individuals with chronic 
underlying conditions is considered  an additional risk mitigation measure to address the 
theoretical phenomenon of immune enhancement. Clinical and epi[INVESTIGATOR_799676] n of older adults among those with critical or fatal COVID- 19 illness is 
meaningfully ameliorated when stratified/controlled for the presence of chronic medical conditions (26) . Exclusion of individuals with chronic medical conditions f rom this trial mitigates 
the potential (theoretical) risk of exacerbating the occurrence of critical or fatal outcomes as a 
result of study  participation. 
Rationale for Active  Arms 
The study aims at selecting schedule and formulation to progress to further clinical development. 
The importance of the schedule evaluation has been stated above, and it is the justification for 
inclusion of Cohort 1 and Cohort 2 in each age strata in the study. Within each cohort, the study design allows the evaluation of the candidate vaccine protein dose level (2 different dose levels) 
adjuvanted with AS03 or AF03. A range of dose level evaluation is of particular interest in the setting of a pandemic: if adequate responses are observed with lower doses of antigen, higher number of doses of vaccine could be supplied to address the anticipated large demand that will be needed to end the pandemic. 
Within Cohort 2, the study includes an arm with the higher dose level of protein antigen alone 
(unadjuvanted). This arm allow s the evaluation and demonstration of the expected adjuvant 
effects (magnitude and quality of the immune response and dose- sparing effect). While it is 
anticipated that an adjuvanted formulation will be optimal, this  study design will allow the 
generation of empi[INVESTIGATOR_799677] . The unadjuvanted arm is restricted to 
the younger adult stratum, as a risk mitigation measure: previous studies with SARS- CoV-1 
inactivated  and protein- based vaccines suggested the possibility of vaccine -induced 
immunopathology upon viral infection when used alone or with a Th2-based adjuvant (alum) (9) . 
AS03 and AF03 adjuvants have been generally associated with a balanced Th1/Th2 immune 
response (10) (11) . Exclusion of unadjuvanted arms  from the older adult stratum  mitigates the 
potential (theoretical) risk of vaccine -induced immunopathology occurring in those who are 
already at higher risk of more severe COVID -[ADDRESS_1103106]-marketing experience with AS03, in addition to its readiness for large -scale supply and the extensive and multi-national regulatory experience, hi gher priority will 
be given to AS03 adjuvanted formulations for advancement into Phase III development. Nevertheless, generating meaningful Phase I/II clinical data with AF03 adjuvanted formulations is still of interest for several reasons: 1) AF03 can ser ve as an alternative adjuvant system, should 
any issues arise during development with AS03; 2) the AF03 adjuvant may still allow to increase 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 43 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page [ADDRESS_1103107] ess the pandemic; 3) the AF03 adjuvant may be of interest in the future if 
COVID-19 becomes seasonal, in which case a co -formulated vaccine would be attractive; in such 
circumstances, co -formulation with AF03 will be more feasible than with AS03 as both protein 
and adjuvant are proprietary to [COMPANY_011] Pasteur. The higher priority given to AS03 adjuvanted formulations and the higher likelihood of robust immune responses with a 2- injection schedule 
provides rationale to generate more precise data for AS03 formu lations in Cohort 2 of this 
Phase I/II study; this is the justification for a sample size of [ADDRESS_1103108] a size of 30 total, except for the un-adjuvanted arm which would only comprise 20 younger adults. 
Rationale for Blinding  
This is an observer -blind study for formulation and adjuvant. Owing to the need for mixing of 
study formulations from separately supplied antigen, adjuvants, and / or diluent, the person 
preparing and administering the vaccine will be unblinded to vaccine group assignment. Blinding of all “observers” will minimize the risk of bias arising from the possibility of consciously or unconsciously influencing the reporting of study outcome measures due and knowledge of the formulation administered. 
Rationale for Placebo 
Placebo, rather than a benefit licensed vaccine, will be used for comparison to vaccine to allow 
safety comparisons between vaccine and placebo as there are no other licensed COVID-19 
vaccin es on the market. The inclusion of placebo groups will also maintain the blind, allow ing the 
unbiased evaluation of clinical outcomes related to COVID -19-like illness and SARS- CoV-2 
infection by [CONTACT_1570] (secondary efficacy objective). 
4.3 Justification  for Protein Dose Levels 
Dose levels are based on data from previous studies with AF03 for [COMPANY_011] Pasteur’s  Influenza 
vaccine products , a study done with [COMPANY_011] Pasteur-manufactured monovalent H7N9 influenza 
vaccine adjuvanted with AS03 or MF59 (38) , and on studies done with Panblok H7 adjuvanted 
with AS03 and MF59. Additionally, formulations of SARS candidates and recently reported data from candidate SARS -CoV- 2 vaccines that were developed and tested preclinically informed the 
range of antigen dosing that was considered. 
• For [COMPANY_011] Pasteur’s pandemic influenza vaccine projects, the main doses evaluated with H1 
and H5 antigens adjuvanted with AF03 were 3.8 µg, 7.5 µg, and 15 µg.  
• For monovalent H7N9 influenza vaccine, 2 doses of 3.75 µg, 7.5 µg or 15 µg of H7 antigen 
adjuvanted with AS03 were compared to a variety of other formulations and vaccine combinations, including 2 doses of 45 µg of H7 antigen alone. 
• For Panblok H7, the doses evaluated in Study BP-I-17-002 with MF59 and AS03 were: 3.75 µg, 7.5 µg, and 15 µg.  
• For Protein Sciences’ SARS -CoV dTM S protein vaccine, the doses evaluated with or without 
Alhydrogel® were 5 µg, 15 µg, and 45 µg.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 44 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 45 of 111 • A recombinant prefusion stabilized SARS- CoV-2 S protein vaccine manufactured in 
baculovirus expression system  was tested in non -human primates at doses of 1  µg, 5 µg, and 
25 µg, delivered with a proprietary adjuvant  (39).  
• An inactivate whole virus SARS -CoV-2 candidate vaccine adjuvant with Alum was tested in 
non-human primates at doses of 2  µg and 8 µg per dose (40) . 
It is unknown how immunogenic the  CoV2 preS dTM  vaccine will be compared to recombinant 
influenza antigens. Assuming conservatively that it will be weakly  immunogenic, the responses 
following administration of  H7 Panblok with MF59 and AS03 are informative . H7 (in common 
with H5) is weakly  immunogenic ( 13) (14)  and could frame dosing expectations under this 
conservative assumption.  
The homologous and heterologous seroprotection ( hemagglutination inhibition [ HAI] titer ≥  1:40) 
rate responses at D50  to H7 with MF59 were generally lower than H7 with AS 03. With AS03, 
homologous and heterologous HAI seroprotection rates above 95% were seen with the 7.5 µg and 
the 15 µg dose groups, and homologous seroprotection responses of 94.6% were seen with the 
3.[ADDRESS_1103109] 
dose (15 µg) were lower than the heterologous HAI seroprotection observed with the lowest dose 
of AS03 (3.75 µg). These findings highlight that even for immunogens considered poorly immunogenic, robust immune responses can be generated with lower antigen doses when delivered in a 2- dose series with a suitable adjuvant.   
4.[ADDRESS_1103110] completed the study if he/she has completed the last contact [CONTACT_211268]. 
The end of the study is defined as the date of the last contact [CONTACT_139111].  
However, for periodic safety reports, the study is considered completed when the Clinical Study 
Report is finalized.  
5 Study Population  
Prospective approval of protocol de viations to recruitment and enrollment criteria, also known as 
protocol waivers or exemptions, is not permitted. 
5.1 Inclusion Criteria  
Participants are eligible for the study only if all of the following criteria are met:  
I01: Aged 18 years of age or older on the day of inclusion 
I02: Informed consent form has been signed and dated 
I03: Able to attend all scheduled visits and to comply with all study procedures 
5.2 Exclusion Criteria  
Participants are not eligible for the study if any of the following criteria are met: 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 45 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 46 of 111 E01: Participant is pregnant, or lactating, or of childbearing potential and not using an 
effective method of contraception or abstinence from at least [ADDRESS_1103111] 1 year or surgically sterile.  
E02: Participation at the time of study enrollment (or in the [ADDRESS_1103112] study vaccination) or planned participation during the present study period in another clinical trial investigating a vaccine, drug, medical device, or medical procedure  
E03: Receipt of any vaccine in the [ADDRESS_1103113] 2 weeks before and a minimum of 2 weeks after study vaccines.
a  
E04: Prior administration o f a coronavirus vaccine (severe acute respi[INVESTIGATOR_18960] 2 [SARS -CoV-2], SARS-CoV, Middle East Respi[INVESTIGATOR_23223] 
[MERS -CoV])  
E05: Receipt of immune globulins, blood or blood-derived products in the past 3 months 
E06: Known or suspected congenital or acquired immunodeficiency; or receipt of immunosuppressive therapy, such as anti-cancer chemotherapy or radiation therapy, within the preceding 6 months; or long- term systemic corticosteroid therapy 
(prednisone or equivalent for more than [ADDRESS_1103114] 
3 months) 
E07: History of SARS -CoV- 2 infection, confirmed either clinically, serologically
b, or 
microbiologically  
E08: Known systemic hypersensitivity to any of the vaccine components, or history of a life-threatening reaction to a vaccine contai ning any of the same substances
c 
E09: Self-reported thrombocytopenia, contraindicating intramuscular (IM) vaccination 
based on I nvestigator’s judgment 
E10: Bleeding disorder, or receipt of anticoagulants in the 3 weeks preceding inclusion, contraindicating IM  vaccination based on Investigator’s judgment 
                                                 
 
a While receipt of any vaccine as listed in this criterion is exclusionary for this study,  enrolled participants are free to 
receive an authorized/approved COVID -19 vaccine during the follow -up period. As efficacy has not been 
demonstrated for any of the investigational formulations under evaluation in the current study, it is not required to 
unblind participants to the VAT00001 study assignment prior to administration of an authorized COVID- 19 
vaccine.  If the participant receives the authorized/approved vaccine, this information would be collected and the 
participant’s data up to the point of receipt of authorized/approved vaccine will be included in the primary analysis for immunogenicity and safety.  Participants will continue to be followed for the duration of the trial as 
per scheduled visits and procedures. (see Section 7.1.2 : Definitive Contraindications).  
b Potential study participants will need to have a negative SARS -CoV -[ADDRESS_1103115] at time of enrollment.  
c The components of SARS -CoV -2 Recombinant Protein vaccine are listed  in Section 6.1 and in the SARS -CoV -2 
Recombinan t Protein Investigator’s Brochure.  In addition, information for the AF03 adjuvant are listed in the 
AF03 Investigator’s Brochure.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 46 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 47 of 111 E11: Deprived of freedom by [CONTACT_29511], or in an emergency setting, 
or hospi[INVESTIGATOR_29476] 
E12: Current alcohol abuse or drug addiction  
E13: Chronic illness or condition considered to potentially increase the risk for severe 
COVID illnessa (26) or that, in the opi[INVESTIGATOR_689] , is at a stage where it 
might interfere with study conduct or completionb 
E14: Moderate or severe acute illness/infection (according to Investigator judgment) on the 
day of vaccination or febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]). A prospective participant should not be included in the study until the condition has resolved or the febrile event has subsided  
E15: Receipt of any therapy known to have in- vitro antiviral activity against SARS -CoV-[ADDRESS_1103116] blood draw  
E16: Identified as an Investigator or employee of the Investigator or study center with direct involvement in the proposed study, or identified as an immediate family member (ie, parent, spouse, natural or adopted child) of the Investigator or employee with direct involvement in the proposed study 
E17: Residence in a nursing home or long- term care facility  
E18: Health care workers providing direct patient care for COVID -19 patients 
E19: Participa nts with active or prior documented autoimmune disorder (such as potential 
immune -mediated diseases [pI[INVESTIGATOR_159170]] ) 
If the participant has a primary physician who is not the Investigator, the site should contact [CONTACT_29512]’s consent to inform him / her of the participant’s participation in the study. In addition, the site should ask this primary physician to verify exclusion criteria relating to previous therapi[INVESTIGATOR_014], such as receipt of blood products or previous vaccines. 
5.3 Lifestyle Considera tions  
No other restrictions than the ones listed in the exclusion criteria or in the contraindications for subsequent vaccinations are required. 
                                                 
 
a Factors that may increase the risk of severe COVID illness include: autoimmune disease (see also Appendix 10.[ADDRESS_1103117] of potential immune -mediated medical conditions); cerebrovascular disease; chronic pulmonary disease 
(including asthma, chronic obstructive pulmonary  disease, emphysema , cystic fibrosis, pulmonary fibrosis) ; 
current smoking or former smoking;  current vapi[INVESTIGATOR_007]; diabetes mellitus; cardiovascular disease  (including 
hypertension) ; chronic renal disease; chronic liver disease; immunocompromised condition; neu rologic disorder  
(including dementia); obesity (body mass index ≥  30); sickle cell disease; thalassemia.  
b Chronic illness may include, but is not limited to, psychiatric disorders.  
c Therapy/ treatment including, but not limited to, favipir avir, lopi[INVESTIGATOR_054]/ ritonavir, remdesivir, arbidol, c hloroquine, 
hydrox ychloroquine.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 47 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 48 of 111 5.4 Screen Failures  
Screen failures are defined as participants who consent to participate in the clinical study but are 
not subsequently randomly assigned to study intervention. Screening information is recorded in the source documents. 
6 Study Intervention  
Study intervention is defined as any investigational intervention(s), marketed product(s), placebo, or medical device(s) intended to be administered to a study participant according to the study 
protocol. 
6.1 Study Interventions Administered  
Study interventions are described in Table  6.1. 
Table  6.1: Identity of study interventions  
CoV2 preS dTM -AF03  
Intervention 
Name  [CONTACT_799742]2 preS dTM -AF03  
(low-dose) CoV2 preS dTM -AF03  
(high-dose)  
Study Groups  1 and 6  3 and 8  
Use Experimental  
Type  Vaccine  
Dose Formulation  Liquid, mix at bedside pre-injection according to dose preparation protocol  
Unit Dose 
Strengths  Each 0.5 mL dose of Study Intervention will contain the following:  
• preS-deltaTM monovalent: 
prefusion S delta TM COVID19 
antigen, low -dose (5  µg) • preS-deltaTM monovalent: 
prefusion S delta TM COVID19 
antigen, high-dose (15  µg) 
Excipi[INVESTIGATOR_840]/Diluent  Each mono-dose vial of squalene -based AF03 adjuvant 2.5% contains:  
• Diluent: Phosphate -buffered saline (PBS)   
• Sorbitan monooleate (Dehymuls SMO™)    (1.85 mg)  
• POE (12) Cetostearyl ether (Kolliphor CS12™)   (2.38 mg)  
• Mannitol        (2.31 mg)  
Dosage Level  0.5 mL per dose  
Number of Doses / 
Dosing Interval  Cohort 1  : 1 injection / Cohort 2  : 2 injections, 21  days apart  
Route of 
Administration  IM injection  
Site of 
Administration  Deltoid muscle in the upper arm  
Sourcing  Provided by [CONTACT_799719]  (antigen and 
adjuvant  will be kitted together in a 2 -vial box). Each study intervention ( vial) will 
bear one fixed label and each box will bear detachable label (s) and one fixed label 
containing the dose number. All will be labeled as required per US requirement.  
Batch Number  TBD  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 48 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 49 of 111 CoV 2 preS dTM -AS03  
Intervention 
Name  [CONTACT_799742]2 preS dTM -AS03  
(low-dose) CoV2 preS dTM -AS03  
(high-dose)  
Study Groups  2 and 7  4 and 9  
Use Experimental  
Type  Vaccine  
Dose Formulation  Liquid, mix at bedside pre-injection according to dose preparation  protocol  
Unit Dose 
Strengths  Each 0.5 mL dose of Study Intervention will contain the following:  
• preS-deltaTM monovalent: 
prefusion S delta TM COVID19 
antigen, low -dose (5  µg) • preS-deltaTM monovalent: 
prefusion S delta TM COVID19 
antigen, high -dose (15  µg) 
Excipi[INVESTIGATOR_840]/Diluent  Each multi -dose vial of squalene -based AS03 adjuvant 2.1% contains:  
• Diluent: PBS     
• Tocopherol (antioxidant)     (11.86 mg)  
• Polysorbate 80 (Tween®80)     (4.86 mg)  
Dosage Level  0.5 mL per dose  
Number of Doses / 
Dosing Interval  Cohort 1 : 1 injection / Cohort 2  : 2 injections, 21  days apart  
Route of 
Administration  IM injection  
Site of 
Administration  Deltoid muscle in the upper arm  
Sourcing  CoV preS dTM  : Provided by [CONTACT_603557]03: Provided by [CONTACT_799720]  (antigen and 
adjuvant  will be kitted together in a 2-vial box) . Each study intervention (vial) will 
bear one fixed label and each box will bear detachable label(s) and one fixed label 
containing the dose number. All will be labeled as required per US requirement.  
Batch Number  TBD  
CoV2 preS dTM  
Intervention Name  [CONTACT_799742]2 preS dTM  
(high -dose)  
Study Groups  10  
(18-49 years of age in Cohort 2 only)  
Use Experimental  
Type  Vaccine  
Dose Formulation  Liquid, mix at bedside pre-injection according to dose preparation protocol  
Unit Dose 
Strengths  Each 0.5 mL dose of CoV2 preS dTM  antigen (high -dose) will contain the 
following:  
• preS-deltaTM monovalent: prefusion S delta TM COVID19 antigen, 
high-dose (15  µg) 
Excipi[INVESTIGATOR_840]/Diluents  Diluent  : PBS  
Dosage Level  0.5 mL per dose  
Number of Doses / 
Dosing Interval  Cohort 1  : 1 injection / Cohort 2  : 2 injections, 21  days apart  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 49 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 50 of 111 Route of 
Administration  IM injection  
Site of 
Administration  Deltoid muscle in the upper arm  
Sourcing  Provided by [CONTACT_799719]  (antigen and 
diluent will be kitted together in a 2-vial box) . Each study intervention (vial) will 
bear one fixed label and each box will bear detachable label(s) and one fixed 
label containing the dose number. All will be labeled as required per US 
requirement.  
Batch Number  TBD  
Placebo  
Intervention Name  [CONTACT_799743]  5 and 11 
Use Placebo - comparator  
Type  Vaccine  
Dose Formulation  Liquid, in a single -vial presentation  
Unit Dose 
Strengths  0.9% normal saline   
Dosage Level  0.5 mL per dose  
Number of Doses / 
Dosing Interval  Cohort 1  : 1 injection / Cohort  2 : 2 injections, 21  days apart  
Route of 
Administration  IM injection  
Site of 
Administration  Deltoid muscle in the upper arm  
Sourcing  Provided by [CONTACT_799721] t o the kits 
used for other study interventions. Each study intervention (vial) will bear one 
fixed label and each box will bear detachable label(s) and one fixed label 
containing the dose number. All will be labeled as required per US requirement.  
Batch Number  TBD  
 
6.2 Preparation/Handling/Storage/Accountability  
Detailed guidance and information are provided in the Operating Guidelines. 
1) The Investigator or designee must confirm appropriate temperature conditions have been 
maintained during transit for all study intervention received and any discrepancies are 
reported and resolved before use of the study intervention. 
2) Only participants enrolled in the study may receive study intervention and only authorized site staff may supply or administer study intervention. All study intervention must be stored in a secure, environmentally controlled, and monitored (manual or automated) area in accordance with the labeled storage conditions with access limited to the Investigator and 
authorized site staff.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 50 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 51 of 111 3) The CoV2 preS dTM antigen will be mixed with the mon o-dose vial of AF03 adjuvant, multi-
dose vial of AS03  adjuvant, or PBS at the site prior to administration . Vaccine formulations 
will be prepared in the CoV2 preS dTM antigen vials by [CONTACT_799722] 
(AF03 or AS03) or PBS. 
4) The Investigator, institution, or the head of the medical institution (where applicable) is 
responsible for study intervention accountability, reconciliation, and record maintenance (ie, receipt, reconciliation, and final disposition records).  
5) Further guidance and information for the final disposition of unused study interventions are provided in the Operating Guidelines. 
6.3 Measures to Minimize Bias: Randomization and Blinding  
6.3.1 Randomization and Allocation Procedures  
On the day of enrollment, participants who meet the eli gibility  criteria and sign the Informed 
Consent Form (ICF) will be stratified by 2 age groups (18- 49 year s and ≥ 50 years) and then be 
randomly assigned to receive 1 injection (Cohort 1) or 2 injections (Cohort 2) of CoV2  preS DTM  
investigational study vaccine or placebo. As shown in Table  4.2, within each cohort:  
• participants aged 18 -49 years :  
• will be randomized to 6 groups to receive Antigen Formulation 1 (low-dose [5 µg]) with either AF03 or AS03 adjuvant; Formulation 2 (high-dose [15 µg]) with either AF03, AS03, or no adjuvant; or placebo (Note: unadjuvanted arm included in Cohort 2 only)  
• N = 20 participants in each group, except for AS03-adjuvanted groups in Cohort 2 with 60 participants in each group 
• participants aged ≥ 50 years :  
• will be randomized to 5  groups to receive Antigen Formulation 1 (low -dose [5  µg]) or 
Formulation 2 (high-dose [15 µg]) each with either AF03 or AS03; or placebo 
• N = 10 participants in each group, except for AS03-adjuvanted groups in Cohort 2 with 30 participants in each group 
The study will initially enroll 30 participants (6 within each dosing group from Cohort 1) 
18-49 years of age, who will comprise the Sentinel Safety Cohort . Participants in this cohort will 
receive 1 injection of study intervention to which they were randomized, and safety and laboratory parameters up to D09 will be evaluated. Upon demonstration of acceptable safety, the remain ing 
participants in Cohort 1 and all participants in Cohort 2 will be enrolled and randomized. 
A subset of 87 participants  in Cohort 2 (60 participants 18- 49 years of age [18 per group in AS03-
adjuvanted vaccines; 6 per group in all other study groups] ) and 27 participants ≥ 50 years of age 
[9 per group in AS03-adjuvanted groups; 3 per group in all other study groups, with the exception 
of the unadjuvanted group for which there will be no older adults]), will be randomly assigned to a cellular -mediated immu ne (CMI) subset . 
Site staff will connect to the Interactive Response Technology ( IRT), enter the identification, 
security information, and confirm a minimal amount of data in response to IRT prompts. The IRT will then provide the group assignment and have the site staff confirm it. The full detailed 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 51 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page [ADDRESS_1103118] of a 12 -digit string (a 3 -digit country 
identifier, a 4 -digit study center identifier, and a 5- digit participant identifier). For example, 
Participant 840000100005 is the fifth participant enrolled in Center Number 1 in the US (840 being the US country code).  
Participant numbers should not be reassigned for any reason. The randomization codes will be 
kept securely in the IRT system.  
6.3.2 Blinding and Code -breaking Procedures  
The study will be performed in a modified double-blind (observer-blind) fashion: 
• Investigators and study staff who conduct the safety assessment and the participant will not 
know which vaccine is administered in order to decrease the risk of potential bias  
• Only the study site staff who prepare and administer the vaccine and are not involved with the 
safety and efficacy evaluation will know which vaccine is administered  
• Testing laboratories will be blinded  
The code may be broken in the event of an AE only when the identification of the vaccine 
received could influence the treatment of the participant. Code-breaking should be limited to the participant(s) experiencing the AE. 
The blind of individual participants can be broken by [CONTACT_29517] a delegate through the 
IRT system, as explained in the code-breaking procedures described in the Operating Guidelines. 
Once the emergency has been addressed by [CONTACT_779], the Investigator or a delegate must notify the 
[COMPANY_011] Pasteur RMO if a participant’s code was broken. All contact  [CONTACT_799723], and the code-breaking CRF is 
to be completed. 
The Institutional Review Board/Independent Ethics Committee (IRB  / IEC) must be notified of 
the code-breaking, in accordance with local regulations. All documentation pertaining to the event 
must be retained in the site’s study records and in [COMPANY_011] Pasteur ’s files. Any intentional or 
unintentional code-breaking must be reported, documented, and explained, and the name o f the 
person who requested it must be provided to the Sponsor. 
A request for the code to be broken may also be made by [CONTACT_29519] (GPV) 
Department through an internal system for reporting to Health Authorities in the case of an SAE , 
as described in International Council for Harmonisation (ICH) E2A
a. In this case, the code will be 
broken only for the participant(s) in question. The information resulting from code-breaking (ie, the participant’s vaccine or group assignment) will not be communicated to either the Investigator or the immediate team working on the study, except for the GPV representative. The code-breaking procedures are described in the Operating Guidelines. 
                                                 
 
a All unexpected and related SAEs submitted to European Union competent authorities must be unblinded.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 52 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page [ADDRESS_1103119] (with access to study 
intervention assignments  [for the S entinel Safety Cohort participants only ] to a limited number of 
Sponsor Study Staff members comprising the Core Safety Management Team ) and at the time  of 
the first interim analysis after the first database lock. However, participant -level data will be 
maintained blinded on site until the end of the study/until the interim Clinical Study Report 
approval. 
6.4 Study Intervention Compliance  
The following measur es will ensure that the study interventions are administered as planned and 
that any noncompliance is documented so that it can be accounted for in the data analyses: 
• All vaccinations will be administered by [CONTACT_29521] 
• The person in charge of study intervention management at the site will maintain 
accountability records of study intervention delivery to the study site, study intervention inventory at the site, dose(s) given to each participant, and unused or wasted doses 
6.5 Concomita nt Therapy  
At the time of enrollment, ongoing medications and other therapi[INVESTIGATOR_014] (eg, blood products) should be 
recorded in the source document as well as new medications prescribed for new medical conditions / AEs during study participation. 
Documentation in the CRF of ongoing concomitant medication(s) will be limited to specific 
categories of medication(s) of interest beginning on the day of first vaccination. This may include 
medications of interest that were started prior to the day of vaccination  or stopped prior to 
enrollment. 
Reportable medications will be collected in the CRF from the day of each vaccination to the end 
of the solicited and unsolicited follow-up period after each vaccination, with the exception of 
influenza vaccination which will be coll ected throughout the study.  
Reportable medications include medications that impact or may impact the consistency of the safety 
information collected after any vaccination and/or the immune response to vaccination. Three standard categories of reportable medications are defined:  
• Category 1: medications impacting or that may have an impact on the evaluation of the safety 
(eg, antipyretics, analgesics, and non- steroidal anti-inflammatory drugs [NSAIDs], systemic 
steroids/corticosteroids) 
• Category 2: medicatio ns impacting or that may have an impact on the immune response (eg, 
hydroxychloroquine, other vaccines, blood products, antibiotic classes that may interfere with bioassays used by [CONTACT_644243] [GCI] department or other testing laboratories, systemic steroids/corticosteroids, immune -suppressors, immune -modulators with 
immunosuppressive properties, anti-proliferative drugs such as DNA synthesis inhibitors) 
• Category 3: medications impacting or that may have an impact on both the safety and the immune response (eg, systemic steroids/corticosteroids)  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 53 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 54 of 111 Dosage and administration route, homeopathic medication, topi[INVESTIGATOR_211251], as well as 
topi[INVESTIGATOR_12969] , ophthalmic and ear treatments will not be recorded. Topi[INVESTIGATOR_34499] s should 
not be applied at the site of vaccination; however, if they are applied inadvertently to the vaccination site, they should be recorded as a Category 1 medication in this specific instance.  
Medications given in response to an AE will be captured in the “Action Taken” section of the AE CRF only. No details will be recorded in the concomitant medication CRF unless  the medication(s) 
received belongs to one of the pre- listed categories. Medicatio ns will not be coded. 
6.5.1 Rescue Medicine  
Appropriate medical equipment and emergency medications, including epi[INVESTIGATOR_238] (1:1000), must be available on site in the event of an anaphylactic, vasovagal, or other immediate allergic reaction.  
6.6 Dose Modification  
Not applicable. 
6.7 Intervention After the End of the Study  
In the event that one of the vaccines formulations evaluated in this study is demonstrated safe and efficacious and is authorized/approved by [CONTACT_1622], such vaccine formulation(s) may be offered 
as soon as possible to participants in this study who received placebo or different formulations, if 
permitted by [CONTACT_427] . 
7 Discontinuation of Study Intervention and Participant 
Discontinuation/Withdrawal 
7.[ADDRESS_1103120] still be within the 
timeframe for vaccination indicated in the SoA.  
TCI01:  Febrile illness (temperature ≥ 38.0°C [≥ 100.4°F]) or moderate or severe acute illness / infection on the day of vaccination, according to Investigator judgment  
TCI02:  Receipt of any vaccine (other than the study vaccine[s]) in the [ADDRESS_1103121] 2 weeks before and a minimum of 2 weeks after study vaccines. This 
exception includes monovalent pandemic influenza vaccines and multivalent influenza vaccines.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 54 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 55 of 111 7.1.2 Definitive Contraindications  
Participants will permanently discontinue (definitive discontinuation) study intervention for the 
reasons listed below. These participants must not receive any additional dose of study intervention 
but should continue to be followed for safety . Additional unscheduled visits may be performed for 
safety  reasons and information will be reported in the source documents. 
Should a participant experience 1 of the conditions listed below, the Investigator will discontinue vaccination:  
DCI01:  Pregnancy, as indicated by a positive urine test 
DCI02:  An anaphylactic or other significant allergic reaction to the previous dose of vaccine 
DCI03:  SAE assessed as related to the study vaccine following the previous dose of vaccine, based on Investigator’s judgment 
DCI04:  Grade [ADDRESS_1103122] the participant at unreasonable or significant risk of injury or illness following repeat exposure to study vaccine 
In the event of a local or national immunization program with a SARS -CoV-2 or a COVID-19 
pandemic vaccine, participants who receive SARS -CoV-2 or a COVID-19 pandemic vaccine at 
any time during the study will not be withdrawn from the study. As efficacy has not been 
demonstrated for any of the investigational formulations under evaluation in the current study, it is 
not required to unblind participants to the VAT00001 study assignment prior to administration of an authorized COVID- 19 vaccine.  
If the participant receives an authorized approved COVID-19 vaccine, this information would be 
collected and the participant’s data  up to the point of receipt of authorized/approved vaccine will 
be included in the primary analysis for immunogenicity and safety. Participants will continue to be followed for the duration of the study as per scheduled visits and procedures. 
7.2 Participant D iscontinuation/Withdrawal from the Study  
• A participant may withdraw from the study at any time at his/her own request or may be 
withdrawn at any time at the discretion of the Investigator for safety, behavioral, compliance, 
or administrative reasons. This is expected to be uncommon.  
• The reason for withdrawal should be clearly documented in the source documents and in the CRF : AE, Lost to Follow- up, Protocol Deviation, or Withdrawal by [CONTACT_25302].  
• The participant will be permanently discontinued both from the study intervention and from the study at that time.  
• If the participant withdraws consent for disclosure of future information, the Sponsor may retain and continue to use any data collected before such a withdrawal of consent. 
• If a participant withdraws consent, he/she may request destruction of any samples taken and 
not tested, and the Investigator must document this in the site study records.  
• Withdrawn participants will not be replaced.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 55 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page [ADDRESS_1103123] to follow -up, the site will not 
attempt to obtain further safety information. See Section  7.3 for  definition of “lost to follow-up”. 
7.[ADDRESS_1103124] be taken if a participant fails to return to the s ite for a required study 
visit or cannot be contact[CONTACT_29525]: 
• The site must attempt to contact [CONTACT_799724] t 
schedule and ascertain whether or not the participant wishes to and/or should continue in the study. 
• Before a participant is deemed lost to follow -up, the Investigator or designee must make every 
effort to regain contact [CONTACT_6635] (where possible, 3 telephone calls and, if necessary, a certified letter to the participant’s last known mailing address or local equivalent methods), or at least to determine his/he r health status while fully respecting his/her rights. 
These contact [CONTACT_13140]’s source documents . 
• Should the participant continue to be unreachable, he/she will be considered discontinued from the study with lost to follow- up as reason for discontinuation . 
Discontinuation of specific sites or of the study as a whole are handled as part of Appendix 10.1. 
8 Study Assessments and Procedures 
• Study procedures and their timing are summarized in the SoA. Protocol waivers or exemptions are not allowed. 
• Immediate safety concerns should be discussed with the Sponsor immediately upon occurrence or awareness to determine if the participant should continue or discontinue study 
intervention. 
• Adherence to the study design requirements, including those specified in the SoA, is essential and required for study conduct. 
• All screening evaluations must be completed and reviewed to confirm that poten tial 
participants meet all eligibility criteria. The Investigator will maintain a screening log to record details of all participants screened and to confirm eligibility or record reasons for screening failure, as applicable.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 56 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 57 of 111 Urine, blood, respi[INVESTIGATOR_799678] s (Section  1.3). 
The maximum amount of blood collected from each participant over the duration of the study, 
including any extra assessments that may be required, is not planned to exceed 340 mL 
(cumulative total) (see Table  8.1). Repeat  or unscheduled samples may be taken for safety reasons 
or for technical issues with the samples.   
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 57 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 58 of 111 Table  8.1: Blood sampling per visit 
N=440 D1 D09 D22 D30 D36 D113/D134 D181/D202 D366/D387 
Vaccination  X  X*     
 
Safety Labs  Cohorts 1 and 2 Cohort 1 only   Cohort 2 only      
Sera (N=440)  BL0001  BL0002  BL0003 BL0004 BL0005 BL0006 
SARS CoV2 Microneut  X  X  X  
X X 
Anti -S IgG ELISA  X  X  X  
X X 
Anti -N IgG ELISA  X  X  X X X X 
Anti -PanCoV IgG ELISA  X   
    
 
PBMC/CMI (N=87)  MC0001*  MC0002*  MC0003*   
 
Whole Blood  (N=87)  WB0001*  WB0002*  WB0003*    
COVID PCR on 
respi[INVESTIGATOR_152922] †  Illness visit 
POC Rapid Test ‡  X   
    
 
* Cohort 2 only  
† 1 swab per illness visit; until day 366/387  
‡ Test at site  
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 58 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 59 of 111 Guidance and information for the sample collection, preparation, storage, and shipment are 
provided in the Operating Guidelines. 
8.1 Baseline Screening for SARS -CoV -2 antibodies  
A blood sample will be obtained before study enrollment to exclude from participation individuals with evidence of SARS- CoV-2 antibodies by a lateral flow immunoassay. 
8.2 Efficacy and Immunoge nicity Assessments 
8.2.1 Immunogenicity Assessments  
[IP_ADDRESS] SARS -CoV -2 Neutralizing Antibody Assessment  
SARS -CoV-2 neutralizing antibodies will be measured using a neutralization assay.  
Serum samples are mixed with constant concentration of the SARS -CoV2 virus. A reduc tion in 
virus infectivity (viral antigen production) due to neutralization by [CONTACT_799725]. After washing and fixation, SARS-CoV-2 antigen production in cells can be detected by [CONTACT_603581] -SARS -CoV-2-specific antibody, 
horseradish peroxide ( HRP ) Immunoglobulin G ( IgG) conjugate, and a chromogenic substrate. 
The resulting optical density  (OD)  is measured using a microplate reader. The reduction in SARS-
CoV-2 infectivity as compared to tha t in the virus control wells constitutes a positive 
neutralization reaction indicating the presence of neutralizing antibodies in the serum sample.  
[IP_ADDRESS] SARS -CoV -[ADDRESS_1103125] curve, which w ill be  included on each assay plate within the run. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 59 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 60 of 111 [IP_ADDRESS] Cellular -Mediated Immunity (using whole blood) 
Cytokines will be measured in whole blood following stimulation with full-length S protein and/or 
pools of S-antigen peptides. 
8.2.2 Efficacy Assessments  
[IP_ADDRESS] Definitions  
COVID-19- like illness  
Symptoms of COVID -19-like illness are as listed below, along with an accompanying tabulation 
of terms used in the CRFs versus diary cards / memory aids ( Table  8.2). 
Any ONE of the following (that persist for a period of at least 12 hours or reoccur within a 
12-hour period): 
• Cough (dry or productive) 
• Fever  
• Anosmia 
• Ageusia 
• Chillblains (COVID- toes)  
• Difficulty breathing or shortness of breath 
• Clinical or radiographic evidence of pneumonia  
• Any hospi[INVESTIGATOR_799679]:  
• Stroke, myocarditis, myocardial infarction 
• Thromboembolic event (blood clots [eg, pulmonary embolism, deep vein thrombosis, 
stroke]) 
• Purpura fulminans  
OR  
Any TWO of the following (that persist for a period of at least 12 hours or reoccur within a 
12-hour period): 
• Pharyngitis 
• Chills  
• Myalgia  
• Headache  
• Rhinorrhea 
• Abdominal pain  
• At least one of nausea, diarrhea, vomiting 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 60 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 61 of 111 Table  8.2: COVID-19- like illness symptoms: CRF and Diary Card / Memory Aid terms  
CRF term  Diary Card / Memory Aid term  
Cough  Cough  
Fever  Temperature measured as 100.4ºF or higher  
Anosmia  Loss of smell  
Ageusia  Loss of taste  
Chillblains  Pain, redness, sores in your fingers and toes 
exposed to cold  
Difficulty breathing  Difficulty breathing  
Shortness of breath  Feeling short winded  
Pneumonia  Infection of the lungs  
Stroke  Stroke  
Myocarditis  Heart inflammation  
Myocardial infarction  Heart attack  
Throm boembolic event  Blood clots  
Purpura fulminans  A type of purplish skin rash  
Pharyngitis  Sore Throat  
Chills  Chills  
Myalgia  Muscle aches and pains  
Headache  Headache  
Rhinorrhea  Runny nose  
Abdominal Pain  Belly pain  
Nausea  Feeling queasy  
Diarrhea  Loose stools  
Vomiting  Throwing up  
 
Virologically -confirmed COVID -[ADDRESS_1103126] (NAAT) on a respi[INVESTIGATOR_799680] a 
COVID-19- like illness.  
Serologic ally-confirmed  SARS -CoV-2 infection  
Serologic ally-confirmed SARS -CoV -2 infection is defined as a positive result in serum for 
presence of antibodies specific to non-Spi[INVESTIGATOR_119901]- CoV-2 detected by [CONTACT_6428]. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 61 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 62 of 111 [IP_ADDRESS] COVID-19- like Illness Surveillance 
Passive Surveillance  
Following randomization and vaccination all participants will be instructed to contact [CONTACT_799726] a COVID-19- like illness at any time during the study. 
Active Surveillance  
Following randomization and vaccination, active surveillance will be used to identify potential COVID- 19 clinical illness cases.  
All participants will be contact[CONTACT_799727] c all center D57 ([ADDRESS_1103127]) after vaccination and continuing until D181 (Cohort 1) or D202 (Cohort 2). The 
frequency of contacts will be once every 2 weeks. Prior to these specified time- points, active 
surveillance will still occur during th e established contacts (phone calls and visits) as described in 
the SoA. After active surveillance has ended at D181 (Cohort 1) or D202 (Cohort 2), passive surveillance will continue through the end of the study as previously stated above. 
Collection of respi[INVESTIGATOR_799681], the site will arrange for a respi[INVESTIGATOR_799682] -19-like illness  (see Section  [IP_ADDRESS]) . The respi[INVESTIGATOR_799683]-19- like illness . 
Reporting of events temporally associated with a COVID -19-like illness  
In addition to obtaining a respi[INVESTIGATOR_152922], the site will collect detailed information about the symptoms, severity and duration of illness, as well as information on healthcare utilization events (hospi[INVESTIGATOR_602], emergency room visits, and non-routine office visits [including urgent care visits]) and medication use (eg, antibiotics, antivirals).  
In the event of hospi[INVESTIGATOR_799684], detailed information on the course of 
the illness including duration of symptoms, oxygen requirements, laboratory tests, imaging investigations (including computerized tomography), use of mechanical ventilation and other respi[INVESTIGATOR_799685], and outcome will be collected . 
In the event that a respi[INVESTIGATOR_603462], the research site will still obtain 
the above information. All participants reporting a COVID -19-like illness will have a 30 -day 
follow-up telephone call. 
[IP_ADDRESS] SARS -CoV -[ADDRESS_1103128] plate.   
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 62 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page [ADDRESS_1103129] curve, which w ill be  included on each assay plate within the run. 
[IP_ADDRESS] Nucleic Acid Amplification Test (NAAT)  for COVID -19 Case Detection  
In the assay , respi[INVESTIGATOR_799686] , and the RNA is extracted. The purified 
template is then evaluated by [CONTACT_799728]- CoV- 2 specific primers to specifically 
amplify SARS- CoV-2 targets.  
8.3 Safety Assessments  
This section presents safety assessments other than AEs which are presented in Section  8.4. 
Planned time points for all safety assessments are provided in the SoA ( Section  1.3). 
8.3.[ADDRESS_1103130] and ongoing. Any such conditions will be documented in the source document. Significant 
(clinically relevant) medical history (reported as diagnosis) including conditions/illnesses for which the participant is or has been followed by a physician or conditions/illnesses that could resume during the course of the study or lea d to an SAE or to a repetitive outpatient care will be 
collected in the CRF . 
8.3.2 Physical Examinations  
At designated visits, the Investigator or a delegate will perform a targeted physical examination based on the participant’s medical history and the examiner ’s medical judgment. Information will 
be recorded in the source document. 
8.3.[ADDRESS_1103131] not 
be used. 
8.3.4 Clinical Safety Laboratory Assessments  
Urine pregnancy testing will be performed in women of childbearing potential before each 
vaccination. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 63 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 64 of 111 • See Appendix 10.[ADDRESS_1103132] of clinical laboratory tests to be performed and to the SoA for 
the timing and frequency. 
• The Investigator must review the laboratory report, document this review, and record any 
clinically relevant changes occurring during the study in the AE section of the CRF . The 
laboratory reports must be filed with the source documents. Clinically significant abnormal 
laboratory findings are those which are not associated with the underlying disease, unless judged by [CONTACT_78782]'s condition. 
• All laboratory tests with values considered clinically significantly abnormal during participation in the study or after the last injection of study intervention should be repeated 
until the values return to normal or baseline or are no longer considered clinically significant by [CONTACT_113543].  
• If such values do not return to normal/baseline within a period of time judged reasonable by [CONTACT_737], the etiology should be identified and the Sponsor notified. 
• All protocol -required laboratory assessments, as defined in Appendix 10.2, must be 
conducted in accordance with the laboratory manual/operating guidelines and the SoA.  
• If laboratory values from non-protocol specified laboratory assessments performed at the institution’s local laboratory of choice require a change in participant management or are considered clinically significant by [CONTACT_737] (eg, SAE or AE), then the results must be recorded in the CRF . 
8.4 Adverse Events and Serious Adverse Events  
Safety will be described in all study participants.  
The definitions of an AE, SAE, and the different categories of AEs can be found in 
Appendix 10.3. 
AEs will be reported by [CONTACT_29528], then by [CONTACT_941] I nvestigator to the 
Sponsor. The Investigator and any qualified designees are responsible for detecting, documenting, and 
recording events that meet the definition of an AE or SAE and remain responsible for following 
up AEs that are serious, considered related to the study intervention or study procedures, or that caused the participant to discontinue the study (see Section  7). 
An ESDR  will be performed for Sentinel Safety Cohort participants. The goal of ESDR is to allow 
the preliminary safety assessment for a cautious, step -wise approach to vaccine administration, 
starting with participants aged 18 -49 years, as there  is no previous human data for the CoV2 preS 
dTM  candidate vaccine.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 64 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 65 of 111 Sentinel Safety Cohort  
The participants’ enrollment will include the following sequential steps:  
• Step 1 :  
• Thirty participants aged 18-49 years from Cohort 1 will be enrolled in the Sentinel Safety 
Cohort, whereafter enrollment will be paused.  
• Six participants will be randomly assigned to each of the 5 dosing groups defined in Cohort 1: 5 µg and 15 µg AF03-adjuvanted groups, 5 µg and 15 µg AS03 -adjuvanted 
groups, and placebo.  
• Early safety data collection is planned 8 days after the completion of the vaccination (D09, including safety laboratory data); and ESDR is to be planned as soon as possible. Limited 
members of the Sponsor Study Team ( RMO, Biostatistician and Programmer, 
Pharmacovigilance Science Expert, and Global Safety Officer ) will review unblinded 
safety data and will provide their recommendation to continue the recruitment.   
• Step 2: If there is no safety signal after the ESDR after the completion of the vaccination in 
Sentinel Safety Cohort, recruitment will reopen to all dosing groups and both age strata.  
ESDR  
The safety data collected for ESDR  for Sentinel Safety Cohort will be reviewed by [CONTACT_3786]. The intensity of non- serious AEs/adverse reactions (ARs) will be assessed using the 
[COMPANY_011] Pasteur scale.  
The following safety parameters will be assessed as part of the early safety data review  for the 
Sentinel Safety Cohort participants after the first injection of CoV2 preS dTM candidate vaccin e: 
• Immediate reactions  
• Solicited injection site and systemic reactions  
• Laboratory abnormalities (including hematology, chemistry, coagulation time, and urinalysis) 
• Unsolicited AEs reported as vaccine related by [CONTACT_737] 
• SAEs and AESIs   
If any of the below criteria are met, the data on the particular alert threshold event will be 
reviewed by [CONTACT_118085] a decision will be made as to whether subsequent vaccinations in the study will be allowed to resume. Enrollment will be paused during the ESDR, and the following safety parameters will be examined:  
• ≥ 2 participants per dosing group (n=6) experiencing Grade 3 systemic reaction (without 
concurrent infectious disease)  
• ≥ 2 participants per dosing group (n=6) experiencing Grade 3 solicited injection site  pain 
• ≥ 2 participants per dosing group (n=6) experiencing Grade 3 unsolicited non serious reactions (reactions not explained by [CONTACT_603596])  
• ≥ 2 participants with Grade 3 laboratory AE (Grade 3 abnormality if Grade 1 or 2 at baseline) of the same type (reactions not explained by [CONTACT_603596]) 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 65 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 66 of 111 • ≥ 2 participants with Grade 2 laboratory AE (Grade 2 abnormality if normal at baseline) of the 
same type (reactions not explained by [CONTACT_603596]) and judged by [CONTACT_799729] 
• Any related SAEs  
Following the ESDR and resumption of enrollment and dosing, occurrence of any one of these 
criteria will result in a pause in enrollment and vaccination pending Sponsor decision. The study status and fin al Sponsor decision will be submitted for notification to the IRB/IEC. 
Halting Rules  throughout the Study  
Blinded s afety data will be reviewed  by [CONTACT_799715] ( RMO, 
Biostatistician and Programmer , Pharmacovigilance Science Expert, and Global Safety Officer) at 
regular intervals to identify any new safety signals or safety concerns during the conduct of the study. A pause might be recommended in both recruitment and/or further vaccination while it 
investigates any potential signal or concern.  
Enrollment will be paused during the review and the data will be examined if:  
• Any of the following events, assessed as related to the vaccine by [CONTACT_81920], are reported in the study: 
• SAE   
• New Onset of Potential imm une-mediated diseases (pI[INVESTIGATOR_159170])  
• Ulceration, abscess or necrosis at the injection site  
• Four or more participants across treatment groups experience the same Grade 3 AE of the 
same type in the absence of any other etiology 
• Two or more participants across trea tment groups experience the same Grade 3 laboratory 
abnormality assessed by [CONTACT_142922] 
• Any of the following events, suggestive of vaccine associated enhanced disease, are detected 
in the study including: 
• Any death due to SARS -CoV-2 infection 
• ˃ 10% of the study population is hospi[INVESTIGATOR_603463]- CoV-2 infection 
• ≥ 4 ICU admissions among participants ≥ 50 years due to SARS- CoV- 2 infection  
• ≥ [ADDRESS_1103133] -vaccination observation should be documented in the source document. 
Reactogenicity  
Solicited injection site reactions will be collected from D01 to D 08 after each  vaccination. 
Solicited systemic reactions will  be collected from D01 to D08 after each  vaccination. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 66 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 67 of 111 The solicited injection site reactions and systemic reactions that are pre -listed in the diary cards 
and CRF , together with the intensity scales, are presented in  Appendix [IP_ADDRESS].1. 
Unsolicited Adverse Events 
Unsolicited AEs include unsolicited non- serious AEs and SAEs . The intensity grading scale for 
unsolicited non- serious AEs is presented in  Appendix [IP_ADDRESS].2. 
Unsolicited non- serious AEs will be collected from D01 to D [ADDRESS_1103134] vaccination  (up to D366 for Cohort 1 and up to D387 for Cohort 2). However, before the first 
study intervention administration, only SAEs related to study procedures are to be collected (eg, 
SAEs related to blood sampling). 
Medical occurrences that begin before the start of study intervention but after obtaining informed 
consent will not be recorded on the AE section of the CRF. 
All SAEs will be recorded and reported to the Sponsor or designee immediately and under no 
circumstance should this exceed 24 hours, as indicated in  Appendix 10.3. The Investigator will 
submit any updated SAE data to the Sponsor within 24 hours of it being available. 
Investigators are not obligated to actively seek AE or SAE after conclusion of the study 
participation . However, if the Investigator learns of any SAE, including a death, at any time after 
a participant has been discharged fro m the study, and he/she considers the event to be reasonably 
related to the study intervention or study participation, the I nvestigator must promptly notify the 
Sponsor.  
Medically Attended Adverse Events (MAAEs)  
MAAEs will be collected at any time during the study. 
Adverse Events of Special Interest (AESIs)  
AESIs will be collected at any time during the study. 
See Section  8.4.[ADDRESS_1103135] be captured in the source document and then reported electronicall y. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 67 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 68 of 111 The 12-month (post- last injection) follow-up will be done by [CONTACT_799730] a visit or over the telephone using a questionnaire to capture SAEs and AESIs, if 
applicable. 
The method of recording, evaluating, and assessing causal relationship of AE and SAE and the 
procedures for completing and transmitting SAE reports are provided in Appendix 10.3. 
Care will be taken not to introduce bias when detecting AEs and/or SAEs. Open-ended and 
non-leading verbal questioning of the participant is the preferred method to inquire about AE occurrences.  
8.4.[ADDRESS_1103136], each participant who experiences an AE (whether serious or non-serious) during the study must be followed until the condition resolves, becomes stable, or becomes chronic (even af ter the end of the participant’s participation in the study) if 
either  of the following is true: 
• The AE is considered by [CONTACT_29531] 
• The AE caused the discontinuation of the participant from the study or from vaccination 
The Investigator will inform the Sponsor of the date of final disappearance of the event or the date 
of “chronicity” establishment.  
8.4.4 Regulatory Reporting Requirements for SAEs 
• Prompt notification by [CONTACT_46352] a SAE is essential so that legal 
obligations and ethical responsibilities towards the safety of participants and the safety of a study intervention under clinical investigation are met.  
• The Sponsor has a legal responsibility to notify both the local regulatory authority and other regulatory agencies about the safety of a study intervention under clinical investigation. The Sponsor will comply with country- specific regulatory requirements relating to safety reporting 
to the regulatory authority, IRB / IEC , and investigators. 
• For all studies except those investigating medical devices investigator safety reports must be prepared for suspected unexpected serious adverse reactions (S[LOCATION_003]R) according to local regulatory requirements and Sponsor policy and forwarded to investigators as necessary.  
• An investigator who receives an investigator safety report describing a SAE or other specific safety information (eg, summary or listing of SAEs) from the Sponsor will review and then file it and will notify the IRB/IEC, if appropriate according to local requirements.  
8.4.5 Pregnancy  
Pregnancy is an exclusion criterion for enrollment in this study, but a participant could potentially 
become pregnant during her participation.  
• Details of all pregnancies in female participants will be collected after the start of study 
intervention and until delivery by [CONTACT_799731]. Any 
data collected after CRF  lock will be transmitted to the pharmacovigilance department on the 
paper form. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 68 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 69 of 111 • The collection period of pregnancy information will correspond at least to the period during 
which the participant is requested to be under contraception. (according to protocol: effective 
method of contraception or abstinence from at least [ADDRESS_1103137] vaccination). If there are any pregnancies during this period, 
follow-up should be conducted up to delivery: this will be covered by [CONTACT_941] 12-month surveillance of the study.   
• If a pregnancy is r eported, the Investigator should inform the Sponsor within 1 month of 
learning of the pregnancy and should follow the procedures outlined in Appendix 10.4. 
• Abnormal pregnancy outcomes (eg, spontaneous abortion, fetal death, stillbirth, congenital anomalies, ectopic pregnancy) are considered SAEs.  
8.4.[ADDRESS_1103138]  
AESIs will include:  
• Anaphylactic reactions, Generalized convulsion, Thrombocytopenia, L acrimal and salivary 
disorders (tearing, dry mouth, dry eyes). 
• New-onset chronic medical conditions (NOCMCs) and pI[INVESTIGATOR_159170]  (see Appendix 10.5). 
8.4.7 Medically Attended Adverse Events  
MAAEs will be collected using the same process as other AEs. See Appendix 10.3.1 for  definition 
of MAAEs.  
8.5 Treatment of Overdose  
Since the study intervention is administered by a health care professional, it is unlikely that 
overdose by [CONTACT_29534]. 
However, in the event of an overdose, the Investigator should:  
1) Contact [CONTACT_211276].  
2) Closely monitor the participant for any AE/SAE.  
3) Document the quantity of the excess of the overdose in the source documents. 
8.[ADDRESS_1103139] the antigens contained in the vaccine. Therefore, the pharmacodynamic profile of the investigational study intervention is defined by [CONTACT_799732]. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 69 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 70 of 111 8.8 Genetics 
Genetics are not evaluated in this study.  
8.9 Biomarkers  
Besides the biomarkers described in the immunogenicity and efficacy assessments section s 
(Section  8.2.1 and Section  8.2.2, respectively ), other emerging biomarkers may be evaluated in 
this study which may be relevant for evaluating scientific aspects of COVID -[ADDRESS_1103140] modification, correlates of risk/protection , 
or participants’ baseline characteristics.  
8.10 Immunogenicity Assessments  
See Section  8.2.1. 
8.11 Medical Resource Utilization and Health Economics  
Medical Resource Utilization will be collected as part of COVID -illness in this study (see 
Section  8.1), as well as for SAE narrative and categorization. 
9 Statistical Considerations  
9.1 Statistical Hypotheses 
All analyses will be descriptive; no hypotheses are planned to be tested.  
9.[ADDRESS_1103141]- in-human trials.  
Vaccine arms will be aggregated to perform complementary assessments on the following main effects: age [(18 -49 years [N=240], ≥ 50 years [N=120]), dose (low [N=180], high [N= 180]), 
injection schedule (1 -injection [N= 120], 2 -injection [N=240]), adjuvant type (AS03 [N=240], 
AF03 [N= 120]), overall adjuvant (high-dose with adjuvants [N=180], high-dose without adjuvants 
[N=20]), and dose- sparing adjuvant (low -dose with adjuvants [N=180], high-dose without 
adjuvants [N=20]).   
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 70 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 71 of 111 9.3 Populations for Analyses 
The following populations are defined: 
Population  Description  
Randomized  All participants with a randomized group that has been allocated by 
[CONTACT_799733] (SafAS)  Subset of randomized participants who have received at least one 
injection of study intervention. Participants will have their safety 
analyzed according to the study intervention they actually received.  
Safety data recorded for a vaccine received out of the protocol design 
will be excluded from the analysis (and listed separately).  
Full analysis set (FAS)  Subset of randomized participants who received at least 1 injection  of 
the study intervention. Participants will be analyzed according to the 
study intervention group to whic h they were randomized.  
Per-protocol analysis set 
(PPAS) Subset of the FAS. Participants presenting with at least one of the 
following relevant conditions  will be excluded from the PPAS:  
• Participant did not meet all protocol-specified inclusion criteria o r 
met at least one of the protocol -specified exclusion criteria  
• Participant did not complete the protocol -defined vaccination 
schedule 
• Participant received a study intervention other than the one that he 
/ she was randomized to receive  
• Preparation and / or administration of study intervention was not 
done as per-protocol  
• Participant did not receive study intervention  in the proper time 
window  
• Participant received a Category 2 or Category 3 therapy / 
medication / as stated in Section 6.5 
• Participant with positive test results in the ELISA and/or 
neutralization test at baseline 
• Additional conditions for exclusion may be identified during the 
review of protocol deviations; such conditions will be documented in the Statistical Analysis Plan ( SAP) 
Per-protocol analysis set for 
immunogenicity (PPAS -IAS ) Subset of PPAS excluding participants who provided all post -dose 
serology samples outside the proper time window or no post -dose 
serology sample was drawn . 
Per-protocol analysis set for 
CMI (PPAS -CMI) Subset of PPAS excluding participants who provided all post -dose 
CMI samples outside the proper time window or no post -dose CMI 
sample was drawn . 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 71 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 72 of 111 9.4 Statistical Analyses  
The SAP will be finalized prior to database lock and it will include a more technical and detailed 
description of the statistical analyses described in this section. This section is a summary of the planned statistical analyses of the critical  endpoints including but not limited to  primary and 
secondary endpoints.  
All statistical analyses will be performed under the responsibility of the Sponsor’s Biostatistics Platform using the SAS
® software, Version 9.4 or above (SAS Institute, Cary, North Carolina, 
[LOCATION_003]) . 
9.4.1 General Considerations 
All analyses will be descriptive. Summaries will be provided for main effects (see Section  9.2) as 
well as individual study arms.  Details will be provided in the SAP. 
9.4.2 Primary Endpoints  
[IP_ADDRESS] Immunogenicity  
The primary endpoints for the evaluation of immunogenicity are based on neutralizing antibody titers , which will be measured with the neutralization assay. The statistical analyses that will be 
performed for the following  primary endpoints are as presented in  Table  3.1. 
Pre-vaccination titers at < LLOQ will be converted to half LLOQ.  
The 95% CIs for the GMTs/GMCs and GMT ratios will be calculated using normal approximation of log-transformed titers. The 95% CIs for the proportions will be based on the Clopper-Pearson method. The ratios of GMTs will be obtained between groups with the 95% CIs calculated using normal approximation of log- transformed titers. The differences in the 
seroconversion rates between groups will be computed along with the 2 sided 95% CIs by [CONTACT_35311] -Score method without continuity correction. Additional parameters may be displayed as 
appropriate.  
Additionally, to evaluate independent determinants of primary immunogenicity endpoints, 
regression models may be constructed for GMT titers and  occurrence of neutralizing antibody 
seroconversion. When the outcome/dependent variable is a continuous numerical variable, linear 
models may be utilized; when the outcome/dependent variable is a categorical variable, logistic regression models may be utili zed. Explanatory/independent variables inserted in these models 
would include age group (18-49 years, ≥ 50 years), antigen dose level (low or high), and adjuvant (none, AS03, AF03). Models evaluating antibody titers or rates at D36 as the outcome variable would include also an explanatory variable corresponding to the injection schedule (1- injection , 
2-injections). Multiplicative interaction terms will be included in expanded models to assess for evidence of effect modification. Non- significant interaction terms can be removed from the 
models. 
Immunogenicity analyses will be performed on PPAS- IAS, unless otherwise specified . 
[IP_ADDRESS] Safety  
The primary endpoints for the evaluation of safety are as presented in  Table  3.1. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 72 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 73 of 111 Primary safety endpoints will be summarized by [CONTACT_29299], as well as aggregate groups 
specified in the SAP . The 95% CIs will be calculated using the Clopper -Pearson method.  
The SafAS will be used for the safety analyses.  
9.4.3 Secondary Endpoints  
[IP_ADDRESS] Immunogenicity  
The secondary endpoints for the evaluation of immunogenicity are as presented in  Table  3.1. 
The 95% CIs for the anti- S antibody concentration and anti- S antibody concentration ratio will be 
calculated using normal approximation of log-transformed titers. The 95% CIs for the proportions 
will be based on the Clopper- Pearson method. The ratios of anti- S antibody concentration will be 
obtained between groups with the 95% CIs calculated using normal approximation of log-transformed titers. The differences in the seroconversion rates between groups will be computed along with the 2-sided 95% CIs by [CONTACT_35311]-Score method without continuity correction. Additional parameters may be displayed as appropriate.  
Regression models may be utilized for further assessment of secondary immunogenicity endpoints, as described in Section  [IP_ADDRESS]. 
Immunogenicity analyses will be performed on PPAS-I AS, unless otherwise specified.  
[IP_ADDRESS] Efficacy  
Virologically -confirmed COVID- 19 illness  is defined by [CONTACT_172719] a COVID-19 illness as 
described in  Section  [IP_ADDRESS] associated with a positive NAAT  for SARS -CoV- 2 in a respi[INVESTIGATOR_365077].  
Serologically -confirmed SARS- CoV -2 infection is defined as a change from negative to positive 
(see Section  [IP_ADDRESS]) in the non- S ELISA assay from any post-baseline sampling time point 
compared to the baseline value, as measured in a SARS -CoV-2 non- S ELISA . 
Correlates of risk  / protection analys is will be  performed  based on antibody responses to SARS-
CoV- 2 as evaluated using virus neutralization  and binding antibody (ELISA) , considering cases of 
virologically -confirmed COVID-19 and/or serologically-confirmed SARS- CoV- [ADDRESS_1103142] atistical methods will be described in an  SAP.  
Efficacy analyses will be performed on FAS  and PPAS- IAS, unless otherwise specified.  
9.4.4 Exploratory Endpoint  
[IP_ADDRESS] Immunogenicity  
Th1 and Th2 cytokines will be measured and summarized for individual and aggregate study arms.  
Detailed CMI analyses will be defined in the SAP.  The CMI analysis will be based on PPAS -CMI 
set. 
The ratio between binding antibody (ELISA) concentration and neutralizing antibody titer will be summarized for individual and aggregate study arms. The ratio (neutralizing antibody / binding 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 73 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 74 of 111 antibody ) will be calculated as difference in log 10 scale and  with the 95% CIs calculated using 
normal approximation will be provided . The analyses will be performed on PPAS -IAS, unless 
otherwise specified.  
9.[ADDRESS_1103143] been 
collected and the final database lock has occurred . 
The SAP will d escribe the planned interim analyses in greater detail . 
Participant safety will be continuously monitored by [CONTACT_1034]’s internal safety review 
committee which includes safety signal detection at any time during the study (see also Section  8.4 for halting rules). 
9.6 Data Monitoring Committee (DMC) 
Not applicable.  
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 74 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 75 of 111 10 Supporting Documentation and Operational Considerations  
10.1 Appendix: Regulatory, Ethical, and Study Oversight Considerations  
Note: The term “participant” is used throughout this protocol. However, the term “subject” will be 
used in the CRF  in order to comply with the Clinical Data Interchange Standards Consortium 
(CDISC) requirements.  
10.1.1 Regulatory and Ethical Considerations 
• This study will be conducted in accordance with the protocol and with the following: 
• Consensus ethical principles derived from international guidelines including the 
Declaration of Helsinki and Council for International Organizations of Medical Sciences 
(CIOMS) International Ethical Guidelines  
• Applicable ICH Good Clinical Practice (GCP) Guidelines  
• Applicable laws and regulations 
• The protocol, protocol amendments, ICF, Investigator Brochure (IB), and other relevant 
documents (eg, advertisements) must be submitted to an IRB/IEC by [CONTACT_223493] (according to local regulations) and reviewed and approved by [CONTACT_1201]/IEC before 
the study is initiated  
• Any amendments to the protocol will require IRB/IEC approval before implementation of changes made to the study design, except for changes necessary to eliminate an immediate hazard to study participants 
• The Investigator or the Sponsor (according to local regulations) will be responsible for the 
following: 
• Providing written summaries of the status of the study to the IRB/IEC annually or more 
frequently in accordance with the requirements, policies, and procedures established by 
[CONTACT_1201]/IEC  
• Notifying the IRB/IEC of SAEs or other significant s afety findings as required by 
[CONTACT_1744]/IEC procedures  
• The Investigator will be responsible for providing oversight of the conduct of the study at the 
site and adherence to requirements of 21 CFR, ICH guidelines, the IRB/IEC, European 
regulation 536/2014 for cli nical studies (if applicable), and all other applicable local 
regulations 
10.1.2 Financial Disclosure  
Information related to financial disclosure is described in the Investigator’s contract.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 75 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 76 of 111 10.1.3 Informed Consent Process  
• The Investigator or his/her representative will explain the nature of the study to the participant 
and answer all questions regarding the study. 
• Participants must be informed that their participation is voluntary. Participants will be 
required to sign a statement of informed consent that meets the requirements of [ADDRESS_1103144] (HIPAA) requirements, where applicable, and the IRB/IEC or study center.  
• The medical record must include a statement that written informed consent  was obtained 
before the participant was enrolled in the study and the date the written consent was obtained. The authorized person obtaining the informed consent must also sign the ICF. 
• The actual ICF used at each center may differ, depending on local regulations and IEC / IRB requirements. However, all versions must contain the standard information found in the sample ICF provided by [CONTACT_1034]. Any change to the content of the ICF must be approved by [CONTACT_29540] / IRB prior to the form being used. 
• If new information becomes available that may be relevant to the participant’s willingness to continue participation in the study, this will be communicated to him / her in a timely manner. Such information will be provided via a revised ICF or an addendum to the original ICF. 
• Participants must be re-consented to the most current version of the ICF during their participation in the study.  
• A copy of the ICF must be provided to the participant. 
• The ICF will contain a specific section that addresses the use of remaining mandatory samples for optional exploratory research. The Investigator or authorized designee will explain to each participant the objectives of the exploratory research. Participants will be told that they are free to refuse to participate and may withdraw their consent at any time and for any reason during the storage period. 
Recruitment Procedures  
Before the start of the study , the Investigator or sub- investigator will contact [CONTACT_799734] s and invite them to participate in the study. The site will ensure that any 
advertisements used to recruit participants (eg, letters, pamphlets, posters) are submitted to [COMPANY_011] 
Pasteur prior to submission to the IEC / IRB for approval.  
10.1.4 Data Protection and Future Use of Stored Samples  
• All personal data collected related to participants, Investigators, or any person involved in the study, which may be included in the Sponsor’s databases, shall be treated in compliance with all applicable laws and regulations including the Global Data Protection Regulation (GDPR). Data collected must be adequate, relevant and not excessive, in relation to the purposes for which they are collected. Each category of data must be properly justified and in line with the study objective. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 76 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 77 of 111 • Particip ants race and ethnicity will be collected in this study because these data are required 
by [CONTACT_17513] (41) . 
• Participants will be assigned a unique i dentifier by [CONTACT_1034]. Any participant records or 
datasets that are transferred to the Sponsor will contain the identifier only; participant names 
or any information which would make the participant identifiable will not be transferred to the Sponsor. 
• The participant must be informed that his/her personal study -related data will be used by [CONTACT_19490]. The level of disclosure must also be explained to the participant as described in the informed consent. 
• The p articipant must be informed that his/her medical records may be examined by [CONTACT_19491], by [CONTACT_6667]/IEC members, and by [CONTACT_6668]. 
• When arch iving or processing personal data pertaining to the Investigator and/or to the 
participants, the Sponsor shall take all appropriate measures to safeguard and prevent access to this data by [CONTACT_13159]. 
• Participant data will be used for this study and in support of the whole drug development program for the Investigational Product, including negotiations with payers and publication of results.  
• Any unused part of the serum, respi[INVESTIGATOR_696], or PBMC samples will be securely stored at the 
[COMPANY_011] Pasteur laboratory (GCI) or Contract Research Organization  for up to [ADDRESS_1103145]’s licensure and the potential revalidation of the study results.  
The other biological samples collected to qualify the participant for inclusion in the study or to 
monitor his/her health are dedicated for im mediate use. In case they are not completely used 
up, they will be destroyed at the latest at the end of the study or after the time requested by [CONTACT_1769].  
In addition, participants will be asked to indicate in the ICF whether they will permit the 
future use of any unused stored serum samples for test s not related to the study objectives . If 
they refuse permission, the samples will not be used for any testing other than that directly related to this study. If they agree to this use, they will not be paid for giving permission. Anonymity of samples will be ensured. The aim of any possible future research is unknown today and may not be related to this particular study. It may be to improve the knowledge of vaccines or infectious diseases, or to improve exist ing tests or develop new tests to assess 
vaccines. Human genetic tests will never be performed on these samples without specific individual informed consent. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 77 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 78 of 111 10.1.5 Committees Structure  
Participant safety will be continuously monitored by [CONTACT_1034]’s internal s afety review 
committee which includes safety signal detection at any time during the study. 
10.1.6 Dissemination of Clinical Study Data  
[COMPANY_011] shares information about clinical trials and results on publicly accessible websites, based 
on company commitments, international and local legal and regulatory requirements, and other clinical trial disclosure commitments established by [CONTACT_13174].   These 
websites include clinicaltrials.gov, EU clinicaltrialregister (eu.ctr), and sanofi.com, as we ll as 
some national registries.  
In addition, results from clinical trials in patients are required to be submitted to peer- reviewed 
journals following internal company review for accuracy, fair balance, and intellectual property. For those journals that re quest sharing of the analyzable data sets that are reported in the 
publication, interested researchers are directed to submit their request to clinicalstudydatarequest.com.  
Individual participant data and supporting clinical documents are available for req uest at 
clinicalstudydatarequest.com. While making information available we continue to protect the privacy of participants in our clinical trials. Details on data sharing criteria and process for 
requesting access can be found at this web address: clinicalstudydatarequest.com. 
10.1.7 Data Quality Assurance 
• All participant data relating to the study will be recorded on electronic CRF  unless transmitted 
to the Sponsor or designee electronically (eg, laboratory data). The Investigator is responsible 
for verifying th at data entries are accurate and correct by [CONTACT_29542] . 
• The Investigator must maintain accurate documentation (source data) that supports the 
information entered in the CRF . 
• The Investigator must permit study -related monitoring, audits, IRB/IEC review, and 
regulatory agency inspections and provide direct access to source data documents. 
• Monitoring details describing strategy (eg, risk-based initiatives in operations and quality such 
as Risk Management and Mitigation Strateg ies and Analytical Risk -Based Monitoring), 
methods, responsibilities and requirements, including handling of noncompliance issues and monitoring techniques (central, remote, or on- site monitoring) are provided in the Monitoring 
Plan.  
• The Sponsor or designee is responsible for the data management of this study including quality checking of the data. 
• The Sponsor assumes accountability for actions delegated to other individuals (eg, Contract Research Organizations).  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 78 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 79 of 111 • Study monitors will perform ongoing source data verification to confirm that data entered into 
the CRF  by [CONTACT_1191], complete, and verifiable from source 
documents; that the safety and rights of participants are being protected; and that the study is being conducted in accordance with the currently approved protocol and any other study agreements, ICH GCP, and all applicable regulatory requirements. 
• Records and documents, including signed ICFs, pertaining to the conduct of this study must be retained by [CONTACT_13177] 25 years after the signature [CONTACT_29563] a longer retention period. No records may be destroyed during the retention period without the written approval of the Sponsor. No records may be transferred to another location or party without written notification to the Sponsor. 
10.1.8 Source Documents  
“Source data” are the data contained in source documents. Source documents are original 
documents or certified copi[INVESTIGATOR_014], and include, but are not limited to, diary cards, medical and hospi[INVESTIGATOR_1097], screening logs, informed consent / assent forms, telephone contact [CONTACT_29543], and worksheets.  
• Source documents provide evidence for the existence of the participant and substantiate the 
integrity of the data  collected. Source documents are filed at the Investigator’s site. 
• Data entered in the CRF  that are transcribed from source documents must be consistent with 
the source documents or the discrepancies must be explained. The Investigator may need to 
request previous medical records or transfer records, depending on the study. Also, current 
medical records must be available.  
Detailed guidance and information are provided in the Operating Guidelines. 
10.1.[ADDRESS_1103146] been either destroyed or returned to the Sponsor, all samples are shipped to the appropriate laboratories, the center study -site has all the documents necessary for archiving and a study -site 
closure visit has been performed along with a Site Close Out Form submitted to the IRB,  as 
required. 
The Investigator may initiate study -site closure at any time, provided there is reasonable cause and 
sufficient notice is given in advance of the intended termination. Reasons for the early closure of a study site by [CONTACT_799735]: 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 79 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 80 of 111 • Failure of the Investigator to comply with the protocol, the requirements of the IRB/IEC or 
local health authorities, the Sponsor's procedures, or GCP guidelines 
• Inadequate recruitment of participants by [CONTACT_18613] 
• Discontinuation of further study intervention development 
If the study is prematurely terminated or suspended, the Sponsor shall promptly inform the 
Investigators, the IECs/IRBs, the regulatory authorities, and any contract research organization(s) used in the study of the reason for termination or suspension, as specified by [CONTACT_1214]. The Investigator shall promptly inform the participant and should assure appropriate participant therapy and/or follow- up. 
10.1.10 Publication Polic y 
Information related to publication policy is described in the Investigator’s contract.  
10.2 Appendix: Clinical Laboratory Tests  
A urine human chorionic gonadotropin (hCG) pregnancy test (as needed for women of childbearing potential)
 will be performed before each  vaccination. 
• The tests detailed in  Table  10.1 will be performed by [CONTACT_779] -selected local laboratory. 
• Protocol- specific requirements for inclusion or exclusion of participants are detailed in  
Section  5 of the protocol.  
• Additional tests may be performed at any time during the study as determined necessary by 
[CONTACT_9332].  
• Pregnancy Testing 
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 80 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 81 of 111 Table  10.1: Protocol-r equired safety laboratory assessments  
Laboratory 
Assessments  Time period for 
assessment  Parameters  
Hematology  Cohort 1 : 
D01 and V02 (D09)  
Cohort 2 : D01  and 
V03 (D30)  Platelet Count  White blood cell (WBC) count with Differential:  
Neutrophils  
Lymphocytes  
Monocytes  
Eosinophils  
Basophils  Hemoglobin  
Hematocrit  
Clinical 
Chemistry  Cohort 1 : 
D01 and V02 (D09)  
Cohort 2:  D01 and 
V03 (D30)  Blood urea 
nitrogen 
(BUN)  Potassium  Aspartate 
Aminotransferase (AST)/ Serum Glutamic -
Oxaloacetic 
Transaminase (SGOT)  Total and 
direct bilirubin  
 Creatinine  Sodium  Alanine 
Aminotransferase (ALT)/ Serum Glutamic -
Pyruvic Transaminase 
(SGPT)  Total 
Protein  
 Glucose 
(nonfasting)   Alkaline phosphatase   
Lipase     
Amylase     
Routine 
Urinalysis  Cohort 1 : 
D01 and V02 (D09)  
Cohort 2 : D01 and 
V03 (D30)  • Glucose , protein, blood, leukocyte esterase  by [CONTACT_5230]  
• Microscopic examination (if blood or protein is abnormal)  
Other 
Screening Tests Cohort 1 : pre-injection 
1 at D01  
Cohort 2: pre -
injections 1 and 2 at D01 and V02 (D22), 
respectively  Highly sensitive urine human chorionic gonadotropin (hCG) 
pregnancy test (as needed for women of childbearing potential*)  
D01 Rapid diagnostic testing for SARS -CoV2 antibody screening  
* To be considered of non -childbearing potential, a female must be post -menopausal for at least [ADDRESS_1103147] document their review of each laboratory safety report. 
Participants, outcome assessors, Investigators, laboratory personnel, and the majority of sponsor 
study staff (except those involved in the ESDR and for concerned participants only) will be blinded to vaccine assignment group (formulation and adjuvant); injection schedule will be unblinded; and those preparing/administering the study interventions will be unblinded to vaccine group assignment. 
Laboratory results that could unblind the study will not be reported to investigative sites or other 
blinded personnel until the study has been unblinded. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 81 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 82 of 111 10.3 Appendix: Adverse Events: Definitions and Procedures for Recording, 
Evaluating, Follow -up, and Reporting  
10.3.1 Definition of AE  
AE Definition  
• An AE is any untoward medical occurrence in a patient or clinical study participant, 
temporally associated with the use of study intervention, whether or not considered related 
to the study intervention. 
• NOTE: An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of study intervention. 
 
Events Meeting  the AE Definition  
• Any abnormal laboratory test results (hematology, clinical chemistry, or urinalysis) or other 
safety assessments (eg, ECG, radiological scans, vital signs measurements), including those that worsen from baseline, considered clinically significant in the me dical and scientific 
judgment of the Investigator (ie, not related to progression of underlying disease). 
• Exacerbation of a chronic or intermittent pre -existing condition including either an increase 
in frequency and/or intensity of the condition. 
• New cond itions detected or diagnosed after study intervention administration even though it 
may have been present before the start of the study. 
• Signs, symptoms, or the clinical sequelae of a suspected drug -drug interaction. 
• Signs, symptoms, or the clinical sequel ae of a suspected overdose of either study 
intervention or a concomitant medication. Overdose per se will not be reported as an AE/SAE unless it is an intentional overdose taken with possible suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae.  
 
Events NOT  Meeting the AE Definition  
• Any clinically significant abnormal laboratory findings or other abnormal safety 
assessments which are associated with the underlying disease, unless judged by [CONTACT_78782]’s condition. 
• The disease/disorder being studied or expected progression, signs, or symptoms of the disease/disorder being studied, unless more severe than expected for the participant’s condition. 
• Medical or surgica l procedure (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 82 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 83 of 111 • Situations in which an untoward medical occurrence did not occur (social and/or 
convenience admission to a hospi[INVESTIGATOR_307]). 
• Anticipated day- to-day fluctuations of pre-existing disease(s) or condition(s) present or 
detected at the start of the study that do not worsen. 
 
Other Definitions  
Adverse Reaction:  
All noxious and unintended responses to a study intervention related to any dose should be 
considered adverse reactions (AR).  
(The phrase “responses to a study intervention” means that a causal relationship between a study intervention and an AE is at least a reasonable possibility) 
Immediate Event/Reaction:  
Immediate events are recorded to capture medically relevant unsolicited systemic AEs 
(including those related to the study intervention administered) that occur within the first 30 minutes after vaccination.  
Medically Attended AE (MAAE)   
An MAAE is a new onset or a worsening of a condition that prompts the part icipant to seek 
unplanned medical advice at a physician’s office or Emergency Department. Physician contact [CONTACT_211306] e-mail will be considered a physician office visit for the purpose of MAAE collection. This includes medical advice seekin g during the study visit or routine 
medical care. This definition excludes pediatric check-ups, follow-up visits of chronic 
conditions with an onset prior to entry in the study, and solicited reactions.  
Injection Site Reaction/Administration Site Reaction s: 
An injection/administration site reaction is an AR at and around the injection/administration 
site. Injection/administration site reactions are commonly inflammatory reactions. They are considered to be related to the study intervention administered . 
Systemic AE/AR:  
Systemic AEs are all AEs that are not injection or administration site reactions. They should 
therefore include systemic manifestations such as headache, fever, as well as localized or topi[INVESTIGATOR_799687] v accination or administration site (eg, 
erythema that is localized but that is not occurring at the injection site).  
Systemic AEs assessed as related to study intervention are referred as systemic ARs.  Solicited 
systemic reactions occurring during the specified collection period are always considered related to the study vaccine even if there is evidence or alternative etiology.  
Adverse Event of Special Interest (AESI):  
An adverse event of special interest (serious or non- serious) is one of scientific and medical 
concern specific to the Sponsor’s study intervention or program, for which ongoing monitoring 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 83 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 84 of 111 and rapid communication by [CONTACT_221289]. Such an event 
might warrant further investigation in order to characterize and understand it. Depending on the 
nature of the event, rapid communication by [CONTACT_29546] (eg, regulators) 
might also be warranted.  
New -Onset Chronic Medical Conditions (NOCMCs):  NOCMCs are defined as any n ew 
ICD- 10 diagnosis (10th revision of the International Statistical Classification of Diseases and 
Related Health Problems) that is applied to the participant during the course of the study, after 
receipt of the study agent, that is expected to continue for at least 3 months and requires continued health care intervention.  
Potential Immune -Mediated Disease (p IMDs ): pIM Ds constitute a group of AEs that 
includes diseases which are clearly autoimmune in etiology and other inflammatory and/or neurologic disorders which may or may not have autoimmune etiologies. pIM Ds currently in 
effect are presented in Appendix 10.5: Adverse Events of Special Interest.  
Reactogenicity / Solicited Reactions 
A solicited reaction is an “expected” adverse reaction (sign or symptom) observed and reported under the conditions (nature and onset) pre-listed in the protocol and CRF  (eg, injection site 
pain or headache occurring between the day of vaccination and the next 7 days). 
By [CONTACT_108], solicited reactions are considered as being related to the study intervention 
administered.  
For injectable vaccines, solicited reactions can either be solicited injection/administration site 
reactions or solicited systemic reactions.  
Unsolicited AE/AR  
An unsolicited AE is an observed AE that does not fulfill the conditions of solicited reactions, ie, pre- listed in the CRF  in terms of diagnosis and/or onset window post- vaccination. For 
example, varicella or a solicited term such as headache starting after the solicited observation period (headache starting on Day  [ADDRESS_1103148]-vaccination in the case where headache occurring 
between the day of vaccination and the next 7 days is pre-listed in the protocol and CRF  as a 
solicited reaction).  
An unsolicited AR  is an unsolicited AE that is considered related to study intervention. 
Unsolicited AEs includes both serious (SAEs) and non -serious unsolicited AEs.  
10.3.2 Definition of SAE  
If an event is not an AE per definition above, then it cannot be an SAE even if serious conditions are met (eg, hospi[INVESTIGATOR_1080]/symptoms of the disease under study, death due to progression of disease).  
A SAE is defined as any untoward medical occurrence that, at any dose:  
a. Results in death  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 84 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 85 of 111 b. Is life- threatening  
The term 'life -threatening' in the definition of 'serious' refers to an event in which the participant 
was at risk of death at the time of the event . It does not refer to an event, which hypothetically 
might have caused death, if it were more severe.  
c. Requires inpatient hospi[INVESTIGATOR_1081]  
• In general, hospi[INVESTIGATOR_799688] (usually involving 
at least an overnight stay) at the hospi[INVESTIGATOR_22771]/or 
treatment that would not have been appropriate in the physician’s office or outpatient setting. Complications that occur during hospi[INVESTIGATOR_1084]. If a complication prolongs hospi[INVESTIGATOR_9236], the event is serious. When in doubt as to whether “hospi[INVESTIGATOR_059]” occurred or was necessary, the AE should be considered serious.  
• Hospi[INVESTIGATOR_90562] a pre-existing condition that did not worsen from 
baseline is not considered an AE.  
d. Results in persistent disability/incapacity  
• The term disability means a substantial disruption of a person’s ability to conduct normal life functions.  
• This definition is not intended to include experiences of relatively minor medical 
significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, and accidental trauma (eg, sprained ankle) which may interfere with or prevent everyday life functions but do not constitute a substantial disruption. 
e. Is a congenital anomaly/birth defect 
f. Other important medical event  
• Medical or scientific judgment should be exercised in deciding whether expedited reporting is appropriate in other situations such as important medical events that may not be immediately life -threatening or result in death or hospi[INVESTIGATOR_29481]. These important medical events should also usually be considered serious. 
• Examples of such events are intensive treatment in an emergency room or at home for allergic bronchospasm, blood dyscrasias or convulsions that do not result in hospi[INVESTIGATOR_059], or development of drug dependency or drug abuse, new-onset diabetes or autoimmune disease.
 
Note:  Serious  and severe are not synonymous. The term severe is often used to describe the 
intensity of a specific event as corresponding to Grade 3. This is not the same as serious,  which is 
based on participant / event outcome or action criteria usually associated with events that pose a 
threat to a participant’s  life or functioning. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 85 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 86 of 111 10.3.3 Recording and Follow -Up of AE and/or SAE  
AE and SAE Recording  
• When an AE/SAE occurs, it is the responsibility of the Investigator to review all 
documentation (eg, hospi[INVESTIGATOR_1088], laboratory reports, and diagnostics reports) 
related to the event.  
• The Investigator will then record all relevant AE/SAE information in the CRF . 
• It is not acceptable for the Investigator to send photocopi[INVESTIGATOR_10914]’s medical 
records to the Sponsor in lieu of completion of the CRF  pages.  
• There may be instances when copi[INVESTIGATOR_88650]. In this case, all participant identifiers, with the exception of the participant number, will be redacted on the copi[INVESTIGATOR_799689]. 
• The Investigator will attempt to establish a diagnosis of the event based on signs, 
symptoms, and/or other clinical information. Whenever possible, the diagnosis (not the individual signs/symptoms) will be documented as the AE/SAE. 
 
Assessment of Causal Relationship  
By [CONTACT_559], all AEs reported at the injection site (whether solicited or unsolicited) and all 
solicited systemic AEs are considered to be related to the study intervention and therefore are referred to as reactions and  do not require the Investigator’s opi[INVESTIGATOR_125611]. 
• Causal  relationship of unsolicited systemic AEs and SAEs will be recorded as follows: 
• For non- serious unsolicited systemic AEs (except for non -serious AESIs), relationship 
to study intervention will usually be assessed by [CONTACT_29547].   
• For SAEs and non- serious AESIs, relationship to study intervention will be assessed 
by [CONTACT_29548]. Sponsor assessment is entered in the GPV 
database only.   
• For SAEs only, the causal relationship to study procedures (related/not related to study procedures) will be assessed by [CONTACT_29548]. Sponsor 
assessment is entered in the GPV database only.  
• The Investigator will assess the causal relationship between each unsolicited systemic AE 
and the study intervention administered
a as either not related or related, based on the 
following definitions: 
                                                 
 
a Study intervention  administered can correspond to either the investigational product or other products when no 
investigational product is administered at the visit  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 86 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 87 of 111 • Not related – The AE is clearly / most probably caused by [CONTACT_29549], therapeutic intervention, or concomitant therapy; or the delay 
between vaccination and the onset of the AE is incompatible with a causal 
relationship; or the AE started before the first vaccination (screening phase, if 
applicable) 
• Related – There is a “reasonable possibility” that the AE was caused by [CONTACT_29550], meaning that there is evidence or arguments to suggest a causal relationship  
• The Investigator will use clinical judgment to determine the relationship.  
• Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention administration 
will be considered and investigated.  
• The Investigator will also consult the IB and/or Product Information, for marketed products, 
in his/her assessment.  
• For each AE/SAE, the Investigator must document in the medical notes that he/she has 
reviewed the AE/SAE and has provided an assessment of causal relationship . 
• There may be situations in which an SAE has occurred and the Investigator has minimal 
information to include in the initial report to the Sponsor. However, it is very important that the Investigator always make an assessment of causal relationship  for ever y event before 
the initial transmission of the SAE data to the Sponsor.  
• The Investigator may change his/her opi[INVESTIGATOR_29484]-up 
information and send a SAE follow-up report with the updated causal relationship  
assessment.  
• The causal  relationship assessment is one of the criteria used when determining regulatory 
reporting requirements. 
 
Follow -up of AEs and SAEs  
• The Investigator is obligated to perform or arrange for the conduct of supplemental 
measurements and/or evaluations as medically indicated or as requested by [CONTACT_29551]/or causal relationship  of the AE or SAE as fully as possible. This 
may include additional laboratory tests or investigations, histopathological examinations, or consultation with other health care professionals.  
• If a participant dies during participation in the study or during a recognized follow-up period, when available the Investigator will provide the Sponsor with a copy of any 
post-mortem findings including histopathology. 
• New or updated information will be recorded in the originally completed CRF . 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 87 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 88 of 111 • The Investigator will submit any updated SAE data to the Sponsor within 24 hou rs of 
receipt of the information.  
• Adverse events likely to be related to the study intervention, whether serious or not, that 
persist at the end of the study will be followed up by [CONTACT_799736]’s condition. The Investigator will 
inform the Sponsor of the date of final disappearance of the event or the date of “chronicity” establishment.  
10.3.4 Reporting of SAEs  
SAE Reporting to the Sponsor via an Electronic Data Collection Tool  
• The primary mechanism for reporting an SAE to the Sponsor will be the electronic data 
collection tool.  
• If the electronic system is unavailable, then the site will use the paper SAE data collection tool (see next section) in order to report the event within 24 hours. The site will enter the 
SAE data into the electronic system as soon as it becomes available.  
• After the study is completed at a given site, the electronic data collection tool will be taken off-line to prevent the entry of new data or changes to exis ting data.  
• If a site receives a report of a new SAE from a study participant or receives updated data on a previously reported SAE after the electronic data collection tool has been taken off-line, then the site can report this information on a paper SAE f orm (see next section).  
• Details regarding SAE reporting can be found in the Operating Guidelines. 
 
SAE Reporting to the Sponsor via Paper CRF  
• The SAE paper CRF can be sent to the Sponsor by [CONTACT_29553]:  
• By [CONTACT_6791], to the following number: [PHONE_425] 
• In PDF format to the following e-mail address, using a method of transmission that 
includes password protection: [EMAIL_453] 
• By [CONTACT_29554], to the following address: 
  Global Pharmaco vigilance, [COMPANY_011] Pasteur  
  Discovery Drive 
  Swiftwater, PA [ZIP_CODE] 
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 88 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 89 of 111 Safety Emergency Call  
If, as per the Investigator's judgment, a participant experiences a medical emergency, the 
Investigator may contact [CONTACT_1034]'s RMO for advice on how to address any study- related 
medical question or problem. If the RMO is not available, then the Investigator may contact [CONTACT_29555] —available 24  hours a day, 7 days a week —that will forward all safety emergency 
calls to the appropriate primary or back -up [COMPANY_011] Pasteur contact, as needed. The toll- free 
contact [CONTACT_29556].  
This process does not replace the need to report an SAE. The Investigator is still required to follow the protocol-defined process for reporting SAEs to the GPV Department. 
In case of emergency code-breaking, the Investigator is required to follow the code-breaking 
procedures described in Section  6.3.2 . 
10.3.5 Assessment of Intensity  
The Investigator will make an assessment of intensity for each AE reported during the study. An 
intensity grade will be assigned to each AE. The intensity grading scales used in this study are 
adapted from the “FDA Guidance for Industry: Toxicity Grading Scale for Healthy Adult and Adolescent Volunteers Enrolled in Preventive Vaccine Clinical Trials, September 2007”. 
[IP_ADDRESS] Tables for Clinical Abnormalities  
[IP_ADDRESS].1 Solicited AR Intensity Grading Scale  
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 89 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 90 of 111 Table  10.2: Solicited injection site reactions: terminology, definitions, and intensity scales  
CRF  term 
(MedDRA lowest 
level term [LLT])  Injection site pain  Injection site erythema  Injection site swelling  
Diary card term  Pain Redness  Swelling  
Definition Pain either present spontaneously or when the injection site is touched or injected limb is mobilized
 Presence of a redness including the approximate point of needle entry Swelling at or near the injection site  
Swelling or edema is caused by a f luid 
infiltration in tissue or cavity and, depending on the space available for the 
fluid to disperse, swelling may be either soft 
(typi[INVESTIGATOR_897]) or firm (less typi[INVESTIGATOR_2855]) to touch and thus can be best described by [CONTACT_654771]/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 90 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 91 of 111 Intensity scale*  CRF : 
Grade 1: A type of adverse event that is 
usually transient and may require only 
minimal treatment or therapeutic intervention. The event does not generally interfere with usual activities of daily living.  
Grade 2: A type of adverse event that is 
usually alleviated with additional therapeutic intervention. The event 
interferes with usual activities of daily 
living, causing discomfort but poses no significant or permanent risk of harm to the research participant. 
Grade 3: A type of adverse event that 
interrupts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic intervention.  
Diary card:  
Grade 1: No interference with usual 
activities  
Grade 2: Some interference with usual 
activities  
Grade 3: Significant; prevents usual 
activities  Grade 1: ≥ 25 to ≤  50 mm 
Grade 2: ≥ 51 to ≤  100 mm 
Grade 3: > 100 mm Grade 1: ≥ 25 to ≤  50 mm 
Grade 2: ≥ 51 to ≤  100 mm 
Grade 3: > 100 mm 
MedDRA: Medical Dictionary for Regulatory Activities  
* For the subjective reaction of pain, participants will record the intensity level (Grade  1, 2, or 3) in the diary card. For the measurable reactions of redness and swelling, they will 
record just the size of the reaction, and the classification as Grade 1, 2, or 3 will be as signed at the time of the statistical analysis  
  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 91 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 92 of 111 Table  10.3: Solicited systemic reactions: terminology, definitions, and intensity scales  
CRF  term (MedDRA 
lowest level term 
[LLT])  Fever  Headache  Malaise  Myalgia  
Diary card term  Temperature  Headache  Feeling unwell  Muscle aches and pains  
Definition  Elevation of temperature to ≥°38.0°C (≥ 100.4°F)  Pain or discomfort in the head or scalp. Does not include migraine.  General ill feeling.  
Malaise is a generalized feeling of discomfort, illness, or lack of well-
being that can be associated with a 
disease state. It can be accompanied 
by a sensation of exhaustion or 
inadequate energy to accomplish usual activities.  Muscle aches and pains are common and can involve more than 
one muscle at the same time. Muscle pain can also involve the 
soft tissues that surround muscles. 
These structures, which are often referred to as connective tissues, 
include ligaments, tendons, and 
fascia (thick bands of tendons).  
Does not apply to muscle pain at 
the injection site which should be reported as injection site pain.  
Intensity scale*  Grade  1: ≥ 38.0°C to ≤  38.4°C,  
or ≥ 100.4°F to ≤  101.1°F  CRF : 
Grade  1: A type of adverse event 
that is usually transient and may require only minimal treatment or 
therapeutic intervention. The event 
does not generally interfere with 
usual activities of daily living.  CRF : 
Grade  1: A type of adverse event 
that is usually transient and may require only minimal treatment or therapeutic intervention.  The event 
does not generally interfere with usual activities of daily living.  CRF : 
Grade  1: A type of adverse event 
that is usually transient and may require only minimal treatment or therapeutic intervention. The event 
does not generally interfere with 
usual activities of daily living.  
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 92 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 93 of 111  Grade  2: ≥ 38.5°C to ≤  38.9°C,  
or ≥ 101.2°F to ≤  102.0°F  Grade  2: A type of adverse event 
that is usually alleviated with 
additional therapeutic intervention. 
The event interferes with usual 
activities of daily living, ca using 
discomfort but poses no significant 
or permanent risk of harm to the 
research participant.  Grade  2: A type of adverse event 
that is usually alleviated with additional therapeutic intervention. 
The event interferes with usual 
activities of daily livin g, causing 
discomfort but poses no significant 
or permanent risk of harm to the 
research participant.  Grade  2: A type of adverse event 
that is usually alleviated with additional therapeutic intervention. 
The event interferes with usual 
activities of daily living, causing 
discomfort but poses no significant 
or permanent risk of harm to the 
research participant.  
 Grade  3: ≥ 39.0°C  
or ≥ 102.1°F  Grade  3: A type of adverse event 
that interrupts usual activities of 
daily living, or significantly affects 
clinical  status, or may require 
intensive therapeutic intervention.  
Diary card:  
Grade  1: No interference with usual 
activities  
Grade  2: Some interference with 
usual activities  
Grade  3: Significant; prevents usual 
activities  Grade  3: A type of adverse event 
that interrupts usual activities of 
daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.  
Diary card:  
Grade  1: No interference with usual 
activities  
Grade  2: Some interference with 
usual activities  
Grade  3: Significant; prevents usual 
activities  Grade  3: A type of adverse event 
that interrupts usual activities of 
daily living, or significantly affects 
clinical status, or may require intensive therapeutic intervention.  
Diary card:  
Grade  1: No interference with  usual 
activities  
Grade  2: Some interference with 
usual activities  
Grade  3: Significant; prevents usual 
activities  
MedDRA: Medical Dictionary for Regulatory Activities  
* For all reactions but fever, participants will record the intensity level (Grade  1, 2, or 3) in the diary card. For fever, they will record the body temperature, and the classification as 
Grade  1, 2, or 3 will be assigned at the time of the statistical analysis based on the unit used to measure the temperature and the  intensity scale.  
 
[COMPANY_011] Pasteur  
 
Confidential/Proprietary Information 
                 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 93 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 94 of 111 Important notes for the accurate assessment of temperature:  
Participants are to measure body temperature once per day, preferably always at the same time. 
The optimal time for measurement is the evening, when body tempe rature is the highest. 
Temperature is also to be measured at the time of any apparent fever. The observed daily temperature and the route of measurement are to be recorded in the diary card , and the highest 
temperature will be recorded by [CONTACT_29558]. The preferred route for this study is oral. 
[IP_ADDRESS].[ADDRESS_1103149] of solicited reactions, the corresponding scale for solicited reactions will be used (see Section  [IP_ADDRESS].1).  
All other unsolicited AEs will be classified according to the following intensity scale:  
• Grade 1  
• CRF : A type of adverse event that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally interfere with usual 
activities of daily living.  
• Diary card: No interference with usual activities.  
• Grade 2  
• CRF : A type of adverse event that is usually allevi ated with additional therapeutic 
intervention. The event interferes with usual activities of daily living, causing discomfort 
but poses no significant or permanent risk of harm to the research participant. 
• Diary card: Some interference with usual activitie s. 
• Grade 3  
• CRF : A type of adverse event that interrupts usual activities of daily living, or 
significantly affects clinical status, or may require intensive therapeutic intervention.  
• Diary card: Significant; prevents usual activities.  
[IP_ADDRESS] Tables for Laboratory Abnormalities  
The pre- defined intensity thresholds for laboratories abnormalities are  shown in Table  10.4. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 94 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 95 of 111 Table  10.4: Intensity thresholds for laboratories abnormalities  
Endpoint  Mild  
(Grade 1)  Moderate  
(Grade 2) Severe  
(Grade 3)  
Hemoglobin (Female) – gm/dL  11.0 – 12.0 9.5 – 10.9 ≤ 9.4  
Hemoglobin (Female)  
(Change from baseline value) – gm/dL  Any decrease – 1.5 1.6 – 2.0 ≥ 2.1  
Hemoglobin (Male) – gm/dL  12.5 – 13.5 10.5 – 12.4 ≤ 10.5 
Hemoglobin (Male)  
(Change  from baseline value) – gm/dL  Any decrease – 1.5 1.6 – 2.0 ≥ 2.1  
Above normal WBC – cell/mm3 10,800 – 15,000  15,001 – 20,000  ≥ 20,001  
Below normal WBC – cell/mm3 2,500 – 3,500  1,500 – 2,499  ≤ 1,499  
Absolute Lymphocytes Decreased – 
cell/mm3 750 – 1,000  500 – 749  < 499  
Absolute Neutrophils Decreased – 
cell/mm3 1,500 – 2,000  1,000 – 1,499  < 999  
Absolute Eosinophils – cell/mm3 650 – 1500  1501 - 5000  > 5000  
Platelets Decreased – cell/mm3 125,000 – 140,000 100,000 – 124,000 ≤ 99,000 
Creatinine – mg/dL  1.5 – 1.7 1.8 – 2.0 ≥ 2.1 or requires 
dialysis  
Blood Urea Nitrogen (BUN) – mg/dL  23 – 26  27 – 31  > 31 or require 
dialysis  
Sodium – Hyponatremia – mEq/L  132 – 134  130 – 131  < 130  
Sodium – Hypernatremia – mEq/L  144 – 145  146 – 147  > 148  
Potassium – Hyperkalemia – mEq/L  5.1 – 5.2  5.3 – 5.4  > 5.4  
Potassium – Hypokalemia – mEq/L  3.5 – 3.6  3.3 – 3.4  < 3.3  
Glucose – Hyperglycemia  (fasting) – 
mg/dL  100 - 110 111 - 125 > 125 
Total Protein – Hypoproteinemia  – 
g/dL  5.5 – 6.0 5.0 – 5.4 < 5.0 
Alkaline phosphate  
(Increase by [CONTACT_12245])  1.1 – 2.[ADDRESS_1103150]  2.1 – 3.[ADDRESS_1103151]  ≥ 3.[ADDRESS_1103152] 
LFT (ALT, AST)  
(Increase by [CONTACT_12245])  1.1 – 2.[ADDRESS_1103153]  2.6 – 5.[ADDRESS_1103154]  ≥ 5.[ADDRESS_1103155] 
Bilirubin – with any increase in LFT 
(Increase by [CONTACT_12245])  1.1 – 1.[ADDRESS_1103156] 1.26 – 1.[ADDRESS_1103157]  ≥ 1.[ADDRESS_1103158]  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 95 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 96 of 111 Endpoint  Mild  
(Grade 1)  Moderate  
(Grade 2) Severe  
(Grade 3)  
Bilirubin – with normal LFT  
(Increase by [CONTACT_12245])  1.1 – 1.[ADDRESS_1103159]  1.6 – 2.[ADDRESS_1103160]   ≥ 2.[ADDRESS_1103161]  
Pancreatic enzymes – amylase, lipase  1.1 – 1.[ADDRESS_1103162]  1.6 – 2.[ADDRESS_1103163]  ≥ 2.[ADDRESS_1103164]  
Urine - protein  Trace  1+ 2+ 
Urine - glucose  Trace  1+ 2+ 
Urine – blood (microscopic) - RBCs per 
high power field (rbc/hpf)  1 - 10 11 - 50 > 50 and/or gross 
blood  
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; 
CRP, C- reactive protein; dL, deciliter; gm, gram; LFT, liver function test; mg, milligram; mm3, cubic millimeter; 
RBC, red blood cell; ULN, upper limit of normal; WBC, white blood cell  
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 96 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 97 of 111 10.4 Appendix: Collection of Pregnancy Information  
DEFINITIONS:  
Woman of Childbearing Potential (WOCBP)  
A woman is considered fertile following menarche and until becoming postmenopausal unless 
permanently sterile (see below).  
If fertility is unclear (eg, amenorrhea in adolescents or athletes) and a menstrual cycle cannot be 
confirmed before first dose of study intervention, additional evaluation should be considered. 
Women in the following categories are not considered WOCBP  
1) Premenarchal  
2) Premenopausal female with 1 of the following: 
• Documented hysterectomy  
• Documented bilateral salpi[INVESTIGATOR_1656] 
• Documented bilateral oophorectomy 
For individuals with permanent infertility due to an alternate medical cause other than the 
above, (eg, mullerian agenesis, androgen insensitivity), investigator discretion should be applied to determining study entry. 
Note: Documentation can come from the site personnel’s: review of the participant’s medical 
records, medical examination, or medical history interview.  
3) Postmenopausal female 
• A postmenopausal state is defined as no menses for 12 months without an alternative 
medical cause.  
• A high follicle stimulating hormone (FSH) level in the postmenopausal range may be 
used to confirm a postmenopausal state in women not using hormonal contraception 
or hormonal replacement therapy (HRT). However, in the absence of 12 months of amenorrhea, confirmation with more than one FSH measurement is required. 
• Females on HRT and whose menopausal status is in doubt will be required to use one of 
the non-estrogen hormonal highly effective contraception methods if they wish to continue their HRT during the study. Otherwise, they must discontinue HRT to allow confirmation of postmenopausal status before study enrollment. 
COLLECTION OF PREGNANCY INFORMATION  
The collection period of pregnancy information will correspond at least to the period during which 
the participant is requested to be under contraception. (according to protocol: effective method of contraception or abstinence from at least [ADDRESS_1103165] vaccination). If there are any pregnancy during this period, follow-up should be conducted up to delivery: this will be covered by [CONTACT_941] 12-month surveillance of the study. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 97 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 98 of 111 Female Participants who become pregnant 
• The Investigator will collect pregnancy information on any female participant who becomes 
pregnant while participating in this study. The initial information together with the 
contraceptive method if any will be recorded on the appropriate form and submitted to the 
Sponsor within 1 month of learning of a participant's pregnancy. 
• The participant w ill be followed to determine the outcome of the pregnancy. The Investigator 
will collect follow -up information on the participant and the neonate and the information will 
be forwarded to the Sponsor. Generally, follow-up will not be required for longer than 6 to 
8 weeks beyond the estimated delivery date, but will be in accordance with local regulations. Any termination of pregnancy will be reported, regardless of fetal status (presence or absence of anomalies) or indication for the procedure. 
• While preg nancy itself is not considered to be an AE or SAE, any pregnancy complication or 
elective termination of a pregnancy for medical reasons will be reported as an AE or SAE.  
• A spontaneous abortion (occurring at < 22 weeks gestational age) or still birth (occurring at > 22 weeks gestational age) is always considered to be an SAE and will be reported as such.  
• Any post-study pregnancy related SAE considered reasonably related to the study intervention by [CONTACT_9341]  8.3.4. While the 
Investigator is not obligated to actively seek this information in former study participants, he 
or she may learn of an SAE through spontaneous reporting. 
• In case of pregnancy during the primary series and if at least 1 dose of the study vaccine(s) has been administered, the participant will not be discontinued from the study, but no further vaccination will be administered until after delivery (if applicable and still within the study vaccination window). However, the participant will be followed for safety assessment (and may be followed for immunogenicity assessment, if applicable). 
• If primary series have been completed and the delivery occurs between the primary series and the booster, the booster dose can be administered. However, if vaccination is a contraindication for lactation (ie, live -attenuated vaccine), the participant may not be 
vaccinated with a booster dose. 
 
  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 98 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 99 of 111  
10.5 Appendix: AESIs  
Events potentially associated with coronavirus vaccine  
Anaphylactic reactions 
Generalized convulsion  
Thrombocytopenia  
Events potentially associated with AFO3 adjuvant use 
Dry eyes 
Tearing  
Dry mouth 
 
Events potentially associated with the adjuvants use (AF03 or AS03) and/or coronavirus 
vaccine  
NOCMCs :  
NOCMCs are defined as any new ICD -10 diagnosis (10th revision of the International Statistical 
Classification of Diseases and Related Health Problems) that is applied to the participant during 
the course of the study, after receipt of the study agent, that is expected to continue for at least 3 months and requires continued health care intervention. 
pI[INVESTIGATOR_159170] :  
Potential immune- mediated diseases (pI[INVESTIGATOR_159170]) are a subset of AEs that include autoimmune 
diseases and other inflammatory and/or neurologic disorders of interest which may or may not 
have an autoimmune etiology. AEs that need to be recorded and reported as pI[INVESTIGATOR_799690] i n Table  10.5.  
However, the Investigator will exercise their medical and scientific judgment in deciding whether 
other diseases have an autoimmune origin (that is  pathophysiology involving systemic or organ -
specific pathogenic aut oantibodies) and should also be recorded as a pI[CONTACT_28839]. 
When there is enough evidence to make any of the diagnoses mentioned in Table  10.5, the AE 
must be reported as a pI[CONTACT_28839] . Symptoms, signs or conditions which might (or might not) represent 
the above diagnoses, should be recorded and reported as AEs but not as pI[INVESTIGATOR_494019], and alternative diagnoses have been eliminated or shown to be less likely. 
In order to facilitate the documentation of pI[INVESTIGATOR_159204], a pI[INVESTIGATOR_163511] a list of preferred terms (PTs)  and PT codes corresponding to the above diagnoses will be 
available to investigators at study start.  
Once a pI[INVESTIGATOR_159202] (serious or non-serious) in a study subject, the Investigator (or 
designate) must complete, date and sign an electronic Expedited Adverse Events Report. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 99 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 100  of 111 Table  10.5: List of potential immune -mediated diseases  
Neuroinflammatory disorders  Musculoskeletal disorders  Skin disorders  
• Cranial nerve neuropathy, 
including paralysis and paresis (eg, Bell’s palsy).  
• Optic neuritis.  
• Multiple sclerosis.  
• Transverse myelitis.  
• Guillain -Barré syndrome *, 
including Miller Fisher syndrome and other variants.  
• Acute disseminated encephalomyelitis *, including 
site specific variants, eg, noninfectious encephalitis, encephalomyelitis, myelitis, myeloradiculoneuritis.  
• Myasthenia gravis, including Lambert -Eaton mya sthenic 
syndrome.  
• Demyelinating peripheral neuropathies including:  
- Chronic inflammatory demyelinating polyneuropathy.  
- Multifocal motor neuropathy.  
- Polyneuropathies associated with 
monoclonal gammopathy
. 
• Narcolepsy *. • Systemic lupus erythematosus 
and associated conditions.  
• Systemic scleroderma (systemic sclerosis), including:  
• Diffuse scleroderma.  
• CREST syndrome.  
• Idiopathic inflammatory myopathies, including:  
• Dermatomyositis.  
• Polymyositis.  
• Anti-synthetase syndrome.  
• Rheumatoid arthritis and associated condition s 
including:  
• Juvenile idiopathic arthritis.  
• Still’s disease.  
• Polymyalgia rheumatica.  
• Spondyloarthropathies, including:  
- Ankylosing spondylitis.  
- Reactive arthritis (Reiter’s syndrome). 
- Undifferentiated spondyloarthritis.  
- Psoriatic arthritis.  
- Enteropathic arthritis.  
• Relapsing polychondritis.  
• Mixed connective tissue disorder.  
• Gout. • Psoriasis. 
• Vitiligo.  
• Erythema nodosum.  
• Autoimmune bullous skin diseases (including pemphigus, pemphigoid, and dermatitis herpetiformis).  
• Lichen planus.  
• Sweet’s syndrome.  
• Localized  scleroderma 
(morphea).  
Vasculitis  Blood disorders  Others  
• Large vessels vasculitis * 
including:  
- Giant cell arteritis (temporal arteritis).  
- Takayasu’s arteritis.  
• Medium sized and/or small 
vessels vasculitis * including:  • Autoimmune hemolytic anemia.  
• Autoimmune  
thrombocytopenia.  
• Antiphospholipid syndrome.  
• Pernicious anemia.  
• Autoimmune aplastic anemia.  • Autoimmune glomerulonephritis including:  
- IgA nephropathy.  
- Glomerulonephritis rapi[INVESTIGATOR_10480].  
- Membranous 
glome rulonephritis.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 100 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 101  of 111 - Polyarteritis nodosa.  
- Kawasaki’s disease.  
- Microscopic polyangiitis.  
- Wegener’s granulomatosis 
(granulomatosis with polyangiitis).  
- Churg– Strauss syndrome 
(allergic granulomatous angiitis or eosinophilic granulomatosis with polyangiitis).  
- Buerger’s disease (thromboangiitis obliterans).  
- Necro tizing vasculitis 
(cutaneous or systemic).  
- Antineutrophil cytoplasmic antibody (ANCA) positive vasculitis (type unspecified).  
- Henoch -Schonlein purpura 
(IgA vasculitis).  
- Behcet’s syndrome.  
- Leukocytoclastic 
vasculitis.  • Autoimmune neutropenia.  
• Autoimmune pancytopenia.  - Membranoproliferative glomerulonephritis.  
- Mesangioproliferative glomerulonephritis.  
- Tubulointerstitial nephritis and uveitis syndrome.  
• Ocular autoimmune diseases including:  
• Autoimmune uveitis.  
• Autoimmune retinitis.  
• Autoimmune myocarditis.  
• Sarcoidosis.  
• Stevens -Johnson syndrome.  
• Sjögren’s syndrome.  
• Alopecia areata.  
• Idiopathic pulmonary fibrosis.  
• Goodpasture syndrome.  
• Raynaud’s phenomenon.  
 
Liver disorders  Gastrointestinal disorders  Endocrine disorders  
• Autoimmune hepatitis.  
• Primary biliary cirrhosis.  
• Primary sclerosing cholangitis.  
• Autoimmune cholangitis.  • Inflammatory bowel disease, including:  
- Crohn’s disease.  
- Ulcerative colitis.  
- Microscopic colitis.  
- Ulcerative proctitis.  
• Celiac disease.  
• Autoimmune pancreatitis.  • Autoimmune thyroiditis (Hashimoto thyroiditis).  
• Grave’s or Basedow’s disease.  
• Diabetes mellitus type  1. 
• Addison’s disease.  
• Polyglandular autoimmune syndrome.  
• Autoimmune hypophysitis.  
* Events potentially associated with coronavirus vaccine  
 
  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 101 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 102  of 111 10.6 Appendix: Risk -based Approach  
ICH E6-R2 guideline for GCP is introducing the « risk-based approach » concept which permits 
to focus efforts on what is critical for a study and most specifically on Critical Data and Critical 
Processes. Critical data and processes are defined for the study w ith associated risks in the Study 
Risk Management Plan.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 102 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 103  of 111 10.7 Appendix: Abbreviations  
AE   Adverse Events 
AESI    Adverse events of special interest  
AR   Adverse reactions  
BARDA   Biomedical Advanced Research and Development Authority  
CI   Confidence interval 
CMI    Cellular- mediated Immunity  
CoV2 preS dTM:  SARS -CoV2 prefusion Spi[INVESTIGATOR_799691]  
D   Day 
DMC    Data Monitoring Committee  
ELISA    Enzyme-linked immunosorbent assay 
EMA    European Medicines Agency  
FAS   Full analysis set  
GCI   Global Clinical Immunology 
GCP    Good Clinical Practice  
GMC    Geometric mean concentration  
GMT    Geometric mean titer  
GPV    Global Pharmacovigilance 
[COMPANY_004]    GlaxoSmithKline  
HA   hemagglutinin 
HAI   hemagglutination inhibition 
IDMC   Independent Data and Monitoring Committee 
IB   Investigator’s Brochure 
ICF   Informed Consent Form 
ICH   International Council for Harmoniz ation  
IgG   Immunoglobulin G IDMC   Independent Data Monitoring Committee IEC   Independent Ethics Committees 
IMP   I nvestigational Medicinal Product  
IRB   Institutional Review Boards  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 103 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page [ADDRESS_1103166] 
NOCMC   new-onset chronic medical conditions 
OD   Optical density  
pI[INVESTIGATOR_799692] -mediated disease  
PPAS    Per-protocol analysis set 
PPAS- CMI   Per-protocol analysis set for CMI 
PPAS- IAS  Per-protocol analysis set for immunogenicity 
PT   preferred term  
RBD    receptor binding domain 
RMO    Responsible Medical Officer  
S   Spi[INVESTIGATOR_799693] l analysis plan  
SARS -CoV-2  Severe acute respi[INVESTIGATOR_6507] 2  
SoA   Schedule of Activities 
TBD    to be determined 
TIV   trivalent influenza vaccine 
VAC    Vaccination (as in Vaccination #)  
WOCBP   Woman of Childbearing Potential 
  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 104 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 105  of 111 10.8 Appendix: Protocol Amendment/Update History  
Revisions and rationale for revisions for protocol Version 2.0, Version 3.0, and Version 4.0 are as 
follows. 
Protocol Version 2.0, dated 24 July 2020 (was an update only before study start)) 
The protocol was updated from the Version 1.0 mainly due to CBER feedback from the pre- IND 
submission, along with other feedback from GlaxoSmithKline. 
Revision  Rationale  
Population: No upper limit on age  It is considered of great relevance to generate data in the older 
adult population to inform schedule and formulation selection 
that will serve the general adult population, including those at particular risk of poor outcomes. CBER concurred and agreed to 
no upper age limit.  
Sentinel Safety Cohort and Early Safety 
Data Review added (with halting rules)  As Phase I/II VAT00001 is a relatively large first -in-human study 
of novel antigen and adjuvant combinations, to improve the safety of the protocol, CBER requested a small sentinel cohort made up of participants 18- 49 years of age in Cohort 1 (single 
dose). If safety data and laboratory measures to D09 in Cohort 1 are considered as acceptable based on unblinded data review by 
[CONTACT_799715] (Responsible 
Medical Officer, Study Biostatistician and Programmer, Pharmacovigilance Science Expert, and Global Safety Officer) and do not meet any halting rules, concurrent enrollment and 
vaccinations at all dose levels in both age groups may proceed as 
planned.  
Removed [ADDRESS_1103167] immune responses. The 
choice of antigen dose is also driven by [CONTACT_799737] a pandemic 
response.  
Sample Sizes revised throughout  Due to addition of Sentinel Safety Cohort, removal of 45 µg 
formulation, and increased focus on the AS03 adjuvant.  
Blood Sample 3 (BL0003) (Cohort 1 and 
Cohort 2) and PBMC Sample 3 (MC0003) (Cohort 2) changed from Day (D)43 to D36; D43 Visit replaced by 
[CONTACT_799738]-vaccination 2 samples (BL0003 and MC0003) for Cohort [ADDRESS_1103168] then became a telephone call for safety 
only.  
Blood Draw added at Month 12 resulting 
in a Visit 7 for both Cohorts instead of 
12-month safety fo llow-up call  Per CBER feedback: To further evaluate safety (risk of vaccine -
enhanced disease), monitoring for the occurrence and severity of NAAT - and serologically -confirmed COVID-like illness 
extended to [ADDRESS_1103169] vaccination.  
Additions a nd revisions for text on 
narcolepsy / pI[INVESTIGATOR_799694] -Mediated 
Diseases, it will be included in the risk ‘Potential Immune-
Mediated Diseases’.  
Additions of terms in list of Adverse 
Events of Special Interest ( AESIs)  Following Safety Platform for Emergency Vaccines (SPEAC) 
and Priority List of AESI: COVID -19 dated 25 May 2020 
(Version 2.0), “Generalized convulsion” and 
“Thrombocytopenia” have been added as AESIs.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 105 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 106  of 111 Exclusion Criteria:  
Added footnote to criterion #3: 
"While receipt of any vaccine as listed in 
this criterion is exclusionary for this study, if a COVID- 19 vaccine becomes 
available from a company other than 
[COMPANY_011] Pasteur, then participants are free 
to receive that vaccine. Participants who receive a COVID- 19 vaccine will still be 
followed for safety until the end of the study but will be discontinued from 
study intervention administration 
thereafter (see Section  7.1.2 : Definitive 
Contraindications)."  
Added to Criterion #12 footnote: 
"current vapi[INVESTIGATOR_007]"  
Added new previous vaccination 
criterion:  
- Prior administration of a coronavirus 
vaccine (severe acute respi[INVESTIGATOR_603438] 2 [SARS -
CoV -2], SARS-CoV, Middle East 
Respi[INVESTIGATOR_23223] [MERS -
CoV]) 
Added 3 new criteria for risk -
management: - Residence in a nursing home or long-term care facility  
- Health care workers providing direct patient care for COVID -19 patients  
- Participants with active or prior documented autoimmune disorder (such as potential immune- mediated 
diseases [pI[INVESTIGATOR_159170]])  Revisions made due to CBER/[COMPANY_004] feedback:  
- Per FDA guidance, it needs to be clear that participants may choose to receive an appro ved COVID-19 vaccine if 
available from another company.  
- Previous plan was to exclude former and current smokers. For completeness, criterion is extended to exclude persons who currently vape.  
- Although there are currently no licensed/marketed COVID vaccines  at the moment, participants may have participated in 
another COVID study.  
- Added 3 exclusion criteria for persons at higher risk for severe COVID- 19 disease or at increased risk for exposure to 
SARS- CoV -2. 
 
Protocol Version 3.0 (dated [ADDRESS_1103170]  2020) and Version 4.0 (dated [ADDRESS_1103171] 2020)  
The protocol was updated from Version 2.0 (dated 24 July 2020) to Version 3.0 (dated 
[ADDRESS_1103172] 2020) due to CBER feedback from its review of the IND submission. One day after 
approval of Version 3.[ADDRESS_1103173] 2020, resulting in Version 4.0.  
Version 3.0 was submitted to the IRB; however, since the protocol was pulled less than 1 day 
later, the below revisions section includes changes between Version 2.0 through Version 4.0, inclusive. 
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 106 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 107  of 111 Major revisions between Version 2.0 and Version 3.0  
Revision  Rationale  
Section 8.4: Halting Rules subheading  
Revised pause bullets #4 and #5  Revised per CBER feedback: 
Halting Rules throughout the Study, ≥10% of 
participants equates to at least n=[ADDRESS_1103174] a Grade 3 
AE of the same type before the study is 
halted and ≥5% of participants equates to at least n=[ADDRESS_1103175] Grade 3 laboratory abnormalities 
of the same type before the study is halted. These numbers exce ed the thresholds that we 
recommended in our pre -IND comments and 
could result in an unreasonable risk of injury 
or harm.   
Section 8.4: ESDR subheading  
If any of the below criteria are met, the data on the particular 
alert threshold event will be reviewed by [CONTACT_118085] a decision will be made as to whether subsequent vaccinations in the study will be allowed to resume. Enrollment will be paused during the ESDR, and the following safety parameters will be examined:  
•≥ 2 participants per dosing group (n=6) experiencing  
Grade 3 systemic reaction (without concurrent infectious  
disease)
•≥ 2 participants per dosing group (n=6) experiencing  
Grade 3 solicited injection site pain
•≥ 2 
participants per dosing group (n=6) experiencing  
Grade 3 unsolicited n on serious reactions (reactions not  
explained by a
ny other possible etiology)
•≥ 2
 participants w ith Grade 3 laboratory AE (Grade 3  
abnormality if Grade 1 or 2 at baseline) of the same type  
(reactions not
 explained by [CONTACT_799739])
•≥ 2 participants with Grade 2 laboratory AE (Grade 2  
abnormality
 if normal at baseline) of the same type
(reactions 
not explained by [CONTACT_603596])  
and ju
dged by [CONTACT_799740] #4 to from “3” to “2” to make it consistent with the overall halting rules ([ADDRESS_1103176] than the overall halting rules).  
Major revision between Version 3.0 and Version 4.0  
Revision  Rationale  
For Section  4.2: "Scientific Rationale for Study Design", 
sentence below was removed:  
The adjuvants that will be utilized in this study also have a well- established safety profile”.   Given ongoing concerns for potential immune -mediated adverse events and the 
relatively small clinical trial safety database for AF03, this sentence was requested to be 
deleted by [CONTACT_257736] 27 AUG 2020.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 107 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 108  of 111 11 References 
1. World Health Organization. Virtual press conference on COVID-19 – 11 March 2020 
[homepage on the Internet]. [cited 2020 Mar 28]. Available from: https://www.who.int/docs/default- source/coronaviruse/transcripts/who -audio -emergencies-
coronavirus- press- conference- full-and-final-11mar2020.pdf?sfvrsn=cb432bb3_2. 
2. Johns Hopkins School of Engineering. Coronavirus COVID-19 Global Cases by [CONTACT_799741] (CSSE) at Johns Hopkins School of Engineering. [homepage on the Internet].[Last updated [ADDRESS_1103177] 25. 5:28:05pm] [Cited [ADDRESS_1103178] 25]. Available from: http://www.arcgis.com/apps/opsdashboard/index.html#/bda7594740fd40299423467b48e9ecf6. 
3. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, et al. Clinical Characteristics of 
Coronavirus Disease 2019 in China. N Engl J Med. 2020. 
4. Wrapp D, Wang N, Corbett KS, Goldsmith JA, Hsieh CL, Abiona O, et al. Cryo- EM 
structure of the 2019-nCoV spi[INVESTIGATOR_135904]. Science. 2020;367(6483):1260- 3. 
5. Li F. Structure, Function, and Evolution of Coronavirus Spi[INVESTIGATOR_103184]. Annu Rev Virol. 
2016;3(1):237-61. 
6. Zhou P, Yang XL, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak 
associated with a new coronavirus of probable bat origin. Nature. 2020;579(7798):270-3. 
7. Pallesen J, Wang N, Corbett KS, Wrapp D, Kirchdoerfer RN, Turner HL, et al. 
Immunogenicity and structures of a rationally designed prefusion MERS-CoV spi[INVESTIGATOR_191608]. Proc Natl Acad Sci U S A. 2017;114(35):E7348-E57. 
8. Cox MM, Hashimoto Y. A fast track influenza virus vaccine produce d in insect cells. J 
Invertebr Pathol. 2011;[ADDRESS_1103179]:S31-41. 9. Tseng CT, Sbrana E, Iwata-Yoshikawa N, Newman PC, Garron T, Atmar RL, et al. 
Immunization with SARS coronavirus vaccines leads to pulmonary immunopathology on challenge with the SARS virus. PLoS One. 2012;7(4):e35421. 
10. Del Giudice G, Rappuoli R, Didierlaurent AM. Correlates of adjuvanticity: A review on 
adjuvants in licensed vaccines. Semin Immunol. 2018;39:14- 21. 
11. Garcon N, Vaughn DW, Didierlaurent AM. Development and evaluation of AS03, an Adjuvant System containing alpha-tocopherol and squalene in an oil- in-water emulsion. Expert 
Rev Vaccines. 2012;11(3):349-66. 
12. Cohet C, van der Most R, Bauchau V, Bekkat-Berkani R, Doherty TM, Schuind A, et al. 
Safety of AS03-adjuvanted influenza vaccines: A review of the evidence. Vaccine. 2019;37(23):3006-21. 
13. Cox RJ, Madhun AS, Hauge S, Sjursen H, Major D, Kuhne M, et al. A phase I clinical 
trial of a PER.C6 cell grown influenza H7 virus vaccine. Vaccine. 2009;27(13):1889-97. 
14. Couch RB, Pat el SM, Wade-Bowers CL, Nino D. A randomized clinical trial of an 
inactivated avian influenza A (H7N7) vaccine. PLoS One. 2012;7(12):e49704. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 108 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 109  of 111 15. Klucker MF, Dalencon F, Probeck P, Haensler J. AF03, an alternative squalene emulsion-
based vaccine adjuvant prepared by a phase inversion temperature method. J Pharm Sci. 2012;101(12):4490-500. 
16. Rudicell RS, Garinot M, Kanekiyo M, Kamp HD, Swanson K, Chou TH, et al. 
Comparison of adjuvants to optimize influenza neutralizing antibody responses. Vaccine. 2019;37(42):6208-20. 
17. Ruat C, Caillet C, Bidaut A, Simon J, Osterhaus AD. Vaccination of macaques with 
adjuvanted formalin-inactivated influenza A virus (H5N1) vaccines: protection against H5N1 challenge without disease enhancement. J Virol. 2008;82(5):2565-9. 
18. Smatti MK, Al Thani AA, Yassine HM. Viral -Induced Enhanced Disease Illness. Front 
Microbiol. 2018;9:2991. 19. Yasui F, Kai C, Kitabatake M, Inoue S, Yoneda M, Yokochi S, et al. Prior immunization 
with severe acute respi[INVESTIGATOR_7686] (SARS) -associated coronavirus (SARS- CoV) 
nucleocapsid protein causes severe pneumonia in mice infected with SARS-CoV. J Immunol. 2008;181(9):6337-48. 
20. Czub M, Weingartl H, Czub S, He R, Cao J. Evaluation of modified vaccinia virus Ankara 
based recombinant SARS vaccine in  ferrets. Vaccine. 2005;23(17-18):2273-9. 
21. Levie K, Leroux-Roels I, Hoppenbrouwers K, Kervyn AD, Vandermeulen C, Forgus S, et al. An adjuvanted, low- dose, pandemic influenza A (H5N1) vaccine candidate is safe, 
immunogenic, and induces cross- reactive imm une responses in healthy adults. J Infect Dis. 
2008;198(5):642-9. 
22. Vesikari T, Pepin S, Kusters I, Hoffenbach A, Denis M. Assessment of squalene 
adjuvanted and non-adjuvanted vaccines against pandemic H1N1 influenza in children 6 months 
to 17 years of age. Hum Vaccin Immunother. 2012;8(9):1283-92. 
23. Peeters M, Regner S, Vaman T, Devaster JM, Rombo L. Safety and immunogenicity of an 
AS03 -adjuvanted A(H1N1)pmd09 vaccine administered simultaneously or sequentially with a 
seasonal trivalent vaccine in adul ts 61 years or older: data from two multicentre randomised trials. 
Vaccine. 2012;30(45):6483-91. 
24. McElhaney JE, Beran J, Devaster JM, Esen M, Launay O, Leroux -Roels G, et al. AS03-
adjuvanted versus non- adjuvanted inactivated trivalent influenza vaccine against seasonal 
influenza in elderly people: a phase [ADDRESS_1103180] Dis. 2013;13(6):485-96. 25. Lambert PH, Ambrosino DM, Andersen SR, Baric RS, Black SB, Chen RT, et al. 
Consensus summary report for CEPI/BC March 12-13, 2020 meeting: A ssessment of risk of 
disease enhancement with COVID -19 vaccines. Vaccine. 2020;38(31):4783-91. 
26. Team CC -R. Preliminary Estimates of the Prevalence of Selected Underlying Health 
Conditions Among Patients with Coronavirus Disease 2019 - [LOCATION_002], Feb ruary 12- March 
28, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(13):382-6. 
27. Burny W, Callegaro A, Bechtold V, Clement F, Delhaye S, Fissette L, et al. Different 
Adjuvants Induce Common Innate Pathways That Are Associated with Enhanced Adaptive Responses against a Model Antigen in Humans. Front Immunol. 2017;8:943. 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 109 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 110  of 111 28. Montplaisir J, Petit D, Quinn MJ, Ouakki M, Deceuninck G, Desautels A, et al. Risk of 
narcolepsy associated with inactivated adjuvanted (AS03) A/H1N1 (2009) pandemic influenza vaccine in Quebec. PLoS One. 2014;9(9):e108489. 
29. Cohet C MJ, Petit D, Quinn M-J, Ouakki M, Deceuninck G, et al. Applying the test-
negative design to vaccine safety studies: risk of narcolepsy associated with A/H1N1 (2009) pandemic influenza vaccination in Quebec [abstract 713]. . Pharmacoepi[INVESTIGATOR_603481]. 2015;24:406-7. 
30. Agency EM. Assessment report. Pandemrix. EMA/CHMP/566359/2015. 2016. 31. Friberg H, Martinez LJ, Lin L, Blaylock JM, De La Barrera RA, Rothman AL, et al. Cell-
Mediated Immunity Generated in Response to a Purified Inactivated Vaccine for Dengue Virus 
Type 1. mSphere. 2020;5(1). 
32. Kennedy JS, Frey SE, Yan L, Rothman AL, Cruz J, Newman FK, et al. Induction of 
human T cell -mediated immune responses after primary and secondary smallpox vaccination. J 
Infect Dis. 2004;190(7):1286-94. 
33. Callow KA. Effect of specific humoral immunity and some non- specific factors on 
resistance of volunteers to respi[INVESTIGATOR_129713]. J Hyg (Lond). 1985;95(1):173-89. 34. Reed SE. The behaviour of recent isolates of human respi[INVESTIGATOR_799695]: evidence of heterogeneity among 229E-related strains. J Med Virol. 1984;13(2):179-
92. 
35. Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. 
Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospi[INVESTIGATOR_45086]-19 in the [LOCATION_001] City Area. JAMA. 2020. 
36. Garg S, Kim L, Whitaker M, O'Halloran A, Cummings C, Holstein R, et al. 
Hospi[INVESTIGATOR_799696] o f Patients Hospi[INVESTIGATOR_203692] -Confirmed 
Coronavirus Disease 2019 - COVID-NET, 14 States, March 1-30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(15):458-64. 
37. European Centre for Disease Prevention and Control. Disease background of COVID-19. 
[hom epage on the Internet].[Last updated 2020] [Cited 2020 Apr 21]. Available from: 
https://www.ecdc.europa.eu/en/2019-ncov-background- disease.  
38. Jackson LA, Campbell JD, Frey SE, Edwards KM, Keitel WA, Kotloff KL, et al. Effect of Varying Doses of a Monovalent H7N9 Influenza Vaccine With and Without AS03 and MF59 Adjuvants on Immune Response: A Randomized Clinical Trial. JAMA. 2015;314(3):237-46. 
39. G. G. NVX-CoV2373 Vaccine for COVID-19. World Vaccine Congress webcast. 2020. 
40. Wang H ZY, Huang B, Deng W, Quan Y, Wang W. Development of an inactivated 
vaccine candidate, BBIBP -CorV, with potent protection against SARS- CoV-2. Cell. 2020. 
41. Collection of Race and Ethnicity Data in Clinical Trials – Guidance for Industry and Food 
and Drug Administration Staff . October 2016. [cited 2020 May 08]. [Available from: 
https://www.fda.gov/regulatory- information/search -fda-guidance- documents/collection -race-and-
ethnicity -data-clinical -trials.  
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 110 of 112
[COMPANY_011]  Pasteur VAT00001  
549 – CoV2  preS  dTM  
Confidential/Proprietary Information  
Page 111  of 111  
12 Sponsor Signature [CONTACT_29564]/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page [ADDRESS_1103181] Name
[CONTACT_29565]
-
-
-
Approver Name [CONTACT_1782]
(Universal Time)Reason for Signature
[CONTACT_125642]
-
-
 
[COMPANY_011] Pasteur 
Confidential/Proprietary Information 
VAT00001
Protocol Version 5.0
549 – CoV2 preS dTM
Page 112 of 112
